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Summary 
Prostate cancer has high cancer incidence in males and is the second highest cause of 
male cancer related mortality.  Currently the main stay therapy for localised and 
metastatic  disease  is  maximum  androgen  blockade  (MAB).  This  aims  to  inhibit 
androgen  production  or  action,  thereby  reducing  stimulation  of  the  androgen 
receptor  (AR).  This  in  turn  prevents  the  activation  of  androgen regulated  genes, 
which  normally  result  in  on going  growth  and  survival.  Inhibition  of  testicular 
androgen  production  may  be  achieved  surgically  (bilateral  orchidectomy)  or 
chemically,  using  gonadotropin releasing  hormone  (GnRH)  agonists.  The  latter 
induces castrate levels of testosterone by down regulating pituitary GnRH receptors 
(and therefore gonadotropin hormone production) through constant stimulation. The 
action of androgen may be blocked at a peripheral level using anti androgens, which 
inhibit ligand binding to AR and subsequent activation. Although this approach has 
initial response rates of over 80% the majority of men relapse with castrate resistant 
prostate cancer (CRPC) and this is the cause of significant morbidity and mortality. 
To  overcome  this  and  to  improve  patients  treatment  options  the  mechanisms  of 
castrate resistance need to be addressed. 
The PI3K/Akt cascade regulates several cellular processes such as proliferation and 
apoptosis. Akt activation results in phosphorylation of multiple substrates and has 
been implicated in prostate carcinogenesis and castration resistance. Research has 
suggested that Akt interacts with signallingcascades implemented in carcinogenesis, 
in particular the NFkB cascade and AR signalling. The current study investigated the 
hypothesis that the expression and activation of PI3K/Akt cascade influences the 15 
progression  to  castrate  resistant  disease  using  clinical  prostate  cancer  tumours.  
Fluorescent  insitu  hybridisation  and  Immunohistochemistry  revealed  that  PTEN 
deletion was a common event in castrate resistant prostate cancer and low PTEN 
protein  expression  was  significantly  associated  with  a  poor  outcome.  PTEN 
negatively regulates PI3K signalling. Consequently increased levels of PI3K and 
activated Akt (pAkt ser 
308 and pAkt ser 
473) were significantly associated with a 
shorter time to biochemical relapse and shorter disease specific survival.  Inhibition 
of  PI3K  resulted  in  a  significant  reduction  in  cellular  proliferation  and  Akt 
phosphorylation. 
The  downstream  affects  of  Akt  activation  were  also  investigated.  Akt  has  been 
reported to directly activate the NFkB signallingcascade both directly and indirectly 
but  no  correlations  between  Akt  and  NFkB  were  observed  in  the  current  study. 
Using an immunohistochemical approach NFkB, IкBα and MMP 9 expression were 
observed to be significantly associated with shorter time to death from relapse and 
disease  specific  death.  MMP 9  and  IкBα  expression  were  also  significantly 
associated  with  metastases  at  relapse.  Using  paired  hormone  naive  and  castrate 
resistant LNCaP cells lines allowed the functional consequences of NFkB inhibition 
to  be  investigated.  Reduced  NFkB  activation  significantly  inhibited  cellular 
proliferation and induced apoptosis in both cell lines.  
Having  shown  a  significant  link  between  expression  and  activation  of  the  PI3K 
cascade and progression to castrate resistant disease, the interaction between Akt and 
the  AR  was  investigated  in  both  clinical  prostate  tumours  and  cell  lines.  The 
phosphorylation  of  AR  at  the  Akt  consensus  site  serine  213  (pARser
213)  was 16 
significantly  associated  with  disease  progression.    Patients  with  high  expression 
pARser
213 had a significantly shorter time to death from relapse and disease specific 
survival.  Additionally  42%  of  patients  displayed  an  increase  in  pARser
213 
expression, these patients also had a significantly shorter time to death from relapse 
and disease specific survival. Inhibition of PI3K resulted in a reduction of pARser
213 
expression  in  both  cell  lines  and  using  siRNA  knockdown  to  target  PI3K  p85 
regulatory subunit reduced pARser
213 expression. This research highlights the impact 
of both the PI3K/Akt and NFkB signallingcascades on prostate cancer progression 
and development of castrate resistant disease. In particular this study highlights the 
impact  of  Akt  phosphorylation  in  castrate  resistant  prostate  cancer  patients. 
Therefore phosphorylation of AR at serine 213 may serve as a diagnostic tool to 
predict patient outcome in response to maximum androgen blockade and inhibition 
of AR 213 phosphorylation via the Akt cascade may be an effective therapeutic 
avenue to investigate for treatment of prostate cancer.  
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1.  Introduction  
1.1 Prostate cancer incidence and prevalence 
Cancer  of  the  prostate  is  recognised  as  a  significant  problem  facing  the  male 
population world wide.  It is the most common cancer in men in the UK accounting 
for nearly a quarter of all new male cancer diagnoses (1). In 2006, there were 35,515 
new cases of prostate cancer diagnosed in the UK, which amounts to an incidence of 
97 men each day or one man every 15 minutes being diagnosed with prostate cancer. 
For men in the UK the lifetime risk of being diagnosed with prostate cancer is 1 in 
10 (1).  
As men live longer an increase in both incidence and mortality of prostate cancer is 
observed. Prostate cancer incidence rates increase rapidly with age and the highest 
rates occur in the oldest age groups. The incidence of prostate cancer per 100,000  
men aged 55 59 is 144; ten years later, the rate more than triples to 500 and by 85+ 
the rate is more than five times higher at 789 (1). Results from post mortem data, 
indicate that roughly half of all men in their fifties have histological evidence of 
cancer in the prostate, which rises to 80% by age 80, but only 1 in 26 men (3.8%) 
will  die  from  this  disease  (2;3).  Thus,  men  are  more  likely  to  die  with  prostate 
cancer than from it.  
At  present  little  is  known  about  what  causes  prostate  cancer  but  there  are  some 
factors that are thought to increase a man's chance of developing the disease.   Apart 
from age, the primary risk factor is hereditary. Men who have close male relatives 
who  have  had  prostate  cancer  are  slightly  more  likely  to  develop  the  disease 18 
themselves.  It  is  belived  that  a  man's  risk  of  developing  prostate  cancer  is 
significantly increased if their father or brother developed prostate cancer at or under 
the age of 60, or if more than one man on the same side of the family has had 
prostate cancer. Only a small number of prostate cancers (5–10% or less than one in 
ten cases) are thought to be due to an inherited altered gene running in the family.  
However,  a  major  susceptibility  locus  for  prostate  cancer,  the  “Human  Prostate 
Cancer Gene 1” has been identified on chromosome 1.  This gene locus has been 
implicated in around 30% of hereditary prostate cancers in one study (4).  A strong 
family  history  of  breast  cancer  may  also  increase  the  risk  of  prostate  cancer, 
particularly if a close relative has been diagnosed with breast cancer under the age of 
40.  The BRCA1 and BRCA2 genes associated with a higher risk of breast cancers, 
are also linked to a higher risk of prostate cancer.  Research has shown that carrying 
the BRCA2 gene, increases the  risk of getting prostate cancer before the age of 65 
by seven times, when compared with the average man under 65 (5).  Once over 65, 
the risk is reduced to 4.5 times, when compared to the average man.  
Other risk factors include diet, lifestyle and race. In the USA there are significant 
differences  in  prostate  cancer  incidence  between  racial  groups.  Prostate  cancer 
incidence  rates  for  black  Americans  are  more  than  50%  higher  than  for  white 
Americans  while  rates  for  Asian  Americans  are  40%  lower  than  for  white 
Americans.  In  2001 2005  the  age standardised  (to  the  2000  US  population) 
incidence rate was 249 per 100,000 for black men, 157 per 100,000 for white men 
and 93.8 per 100,000 for Asian men (6). Prostate cancer occurs less frequently in 19 
Asia. However, when Asians leave their homelands to live in the west, the incidence 
rate multiplies by 5 times suggesting the role of diet plays a part. 
 
 
1.2 Prostate cancer pathology 
 
1.2.1 Normal Prostate pathology 
 
The prostate is a small gland about the size of a walnut that sits under the bladder 
and in front of the rectum (Figure 1). The function of the prostate is to store and 
secrete a slightly alkaline (pH 7.29) fluid, which usually constitutes 25 30% of the 
volume of the semen along with spermatozoa and seminal vesicle fluid. The prostate 
gland anatomy is divided into glandular tissue or non glandular tissue. The glandular 
tissue is epithelial and comprises of ducts and glands that secrete fluid and non 
glandular tissue is fibromuscular stroma. The prostate glandular epithelium has three 
types of cells: basal, luminal secretory and neuroendocrine. Basal cells are fewer in 
number  and  their  function  is  not  wholly  understood  although  they  secrete 
components of the basement membrane. It is suggested that a subset of basal cells 
may be epithelial stem cells for the luminal epithelial cells (7). The luminal cells 
secrete components of the Prostatic fluid, express the Androgen receptor (AR) and 
also secrete prostate specific antigen (PSA) in an androgen dependent manner. The 
stroma is composed of fibroblasts, smooth muscles, endothelial cells, dentric cells, 
nerve cells, some inflammatory infiltrates such as mast cells and lymphocytes. Some 
stromal cells are androgen responsive and produce growth factors which act in a 20 
paracrine fashion on the epithelial cells. Homeostasis is therefore modulated in part 
by the stromal epithelial cross talk (8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Prostate location 
The position of the prostate gland and surrounding organs 
 
 
The prostate gland is classified according to the Prostatic capsule and three zones: 
the  transitional,  the  central,  and  the  peripheral  zones  (Figure  1.2).  The  clinical 
significance of the zonal anatomy of the prostate is in understanding which areas of 
the gland are susceptible to benign and malignant disease.   
 
•  Prostatic capsule 
The Prostatic capsule is a fibromuscular layer which encases the prostate. This layer 
is most prominent along the base of the prostate gland.  
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•  Transitional Zone of the Prostate Gland 
The transitional zone is the innermost part of the prostate gland and surrounds the 
urethra where it passes through the prostate. The transition zone, along with the 
central zone, begins to enlarge as men pass the age of 40. Due to the immediate 
proximity  to  the  urethra,  the  enlargement  of  this  part  of  the  gland  can  cause 
bladder  outflow  obstruction.  The  transition  zone  makes  up  about  5%  of  the 
glandular volume and is the site of about 10% of prostate cancers. 
•  The Central Zone of the Prostate Gland 
The central zone also begins to enlarge after men pass the age of 40. The central 
zone  surrounds  the  transitional  zone  and  constitutes  about  25%  of  the  non 
glandular  volume.  About  5%  of  prostate  cancer  cases  originate  in  the  central 
zone. 
•  The Peripheral Zone of the Prostate Gland 
The peripheral zone of the prostate gland is located in the back of the prostate 
gland closest to the rectum. The peripheral zone constitutes about 80% of the 
prostatic volume and is the site of about 80% of prostate cancers. 
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Figure 1.2: Zones of the prostate gland 
The position of the prostate and the three zones 
1.2.2 Prostate Histology  
1.2.2.1 Benign Prostatic hyperplasia (BPH)  
In  this  condition  the  epithelium  and  the  fibrous  tissue  of  the  prostate  undergo 
proliferative  growth,  causing  enlargement  of  the  prostate  gland.  It  is  extremely 
common, being found to some degree in most men beyond middle age. Histological 
BPH  is  characterized  by  the  benign  overgrowth  of  the  transitional  zone  of  the 
prostate which results in the part of the urethra that is surrounded by the prostate 
becoming constricted. This can cause various urinary symptoms, known collectively 
as lower urinary tract symptoms (LUTS) and obstruction to the neck of the bladder 
usually results in; 
•  difficulty in starting 
•  slowing of the urinary stream 
•  dribbling at the end of the stream 23 
•  bladder irritability 
Currently BPH is treated with medical management or surgery.  
1.2.2.2 Prostatic intraepithelial neoplasia (PIN) 
 
Premalignant change in the prostate gland was identified in 1986 (9); McNeal and 
Bostwick identified the existence of dysplastic prostatic lesions which they named 
intraductal dysplasi.  These lesions exhibited many features, including cytological 
atypia  and  nuclear  polymorphism,  which  are  associated  with  other  premalignant 
conditions.    In  1989,  intraductal  dysplasia  was  renamed  prostatic  intraepithelial 
neoplasia or PIN which brought the nomenclature into line with other pre malignant 
conditions such as CIN (cervical intraepithelial neoplasia). The clinical implications 
of PIN are controversial.  PIN has been shown to occur approximately a decade 
before the onset of prostate cancer (2).  Areas of PIN have been shown to be closely 
associated  with  foci  of  prostate  cancer  and  the  distribution  of  clinically  relevant 
prostate cancer and PIN is similar (10).  Although high grade PIN is not a cancerous 
condition it is a recognised risk factor of prostate cancer. There is a high percentage 
(40 to 50%) chance that a person with PIN will go on to develop prostate cancer at 
some stage of his life. Therefore people diagnosed with PIN are usually carefully 
monitored by techniques such as watchful waiting and repeated biopsy tests may be 
taken to monitor any development of the condition. 
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1.2.2.3 Atypical small acinar proliferation (ASAP) 
 
ASAP is another premalignant change that denotes a focus of atypical glands that 
are suspicious for cancer. The histological findings of ASAP are characterized by 
the  presence  of  abnormal  or  atypical  glands  that  have  insufficient  cytological  or 
architectural atypia for a definitive diagnosis of cancer and follow up of the patient 
is warranted. ASAP has been observed in 2% of biopsy specimens, whereas PIN is 
present in 4% to 16% of contemporary needle biopsy specimens, (11 13). These 
findings  can  occur  together  in  specimens  from  the  same  set  of  biopsies  without 
cancer being present.  
1.2.2.4 Cancer of the prostate (CaP) 
The majority of prostate cancers are adenocarcinoma in origin. Adenocarcinoma is 
the term used to describe a cancer that has originated in epithelial cells that line 
certain internal organs and have gland like properties (Figure 1.3). Prostate cancer 
may also have the form of small cell carcinoma and squamous cell carcinoma. Small 
cell carcinoma is made up of small round cells, and typically forms at nerve cells. 
Small  cell  carcinoma  is  very  aggressive  in  nature  and  as  it  does  not  lead  to  an 
increase in PSA, it can be difficult to detect in comparison to adenocarcinoma and 
generally has reached an advanced form upon detection. Squamous cell carcinoma is 
very aggressive in nature and like small cell carcinoma there is no increase in PSA 
when  it  progresses.  There  are  other,  more  rare  forms  of  prostate  cancer,  these 
include sarcomas and transitional cell carcinoma; the latter seldom develops in the 
prostate but derives from primary tumours present in the bladder or urethra. Prostate 25 
cancer is divided into two subgroups: locally confined or latent prostate cancer and 
locally advanced and metastatic prostate cancer. 
      
 
   
 
                       
Figure 1.3: Prostate cancer histology   
Adenocarcinoma (a) and (b) Small cell carcinoma of the prostate gland  
 
•  Locally confined cancer of the prostate 
The development of clinically progressive disease does not always occur within the 
lifetime of every patient with histological evidence of cancer.  As a result, while 
some patients have a high risk of dying of prostate cancer, the remainder lives with 
localised disease, eventually succumbing to death from other causes. Prostate cancer 
is  unique  among  potentially  fatal  human  cancers  in that  a  wide  difference  exists 
between  the  incidence  of  histologically  confirmed  cancer  and  clinical  disease. 
Scardino (14) attempted to estimate the extent of the discrepancy between the high 
prevalence of the disease at autopsy and the low incidence of clinical disease and 
estimated that only 1 in 95 men with cancer were diagnosed with the disease, and 
only 1 in 323 men with prostate cancer died of the disease.  This indicates that the 26 
majority of small prostatic tumours which are detected at autopsy do not progress to 
clinical prostatic disease. It is thought that many of these small, well differentiated 
prostate  cancers  lack  the  ability  to  grow,  differentiate  and  metastasize  within  a 
patient’s lifetime.  At diagnosis, localised or organ confined disease may be treated 
and potentially cured with treatments such as radical surgery or radiotherapy.  
 However  many  patients  present  with  extracapsular  or  advanced  disease;  this  is 
termed  locally  or  regionally  advanced,  or  metastatic  disease.  It  is  this  subset  of 
prostate cancer patients who make up the majority of the 12,000 deaths per year in 
the UK alone, which contributes in making prostate cancer the second most common 
cause of cancer death in men in Europe (15) 
 
•  Locally advanced and metastatic cancer of the prostate  
At diagnosis, approximately ¼ of men present with locally advanced or metastatic 
prostate cancer. This indicates that the cancer has spread beyond the capsule to local 
tissues or to distant lymph nodes and other sites, such as the bones. For patients 
presenting with advanced stage prostate cancer, the prognosis is significantly worse, 
with survival time limited. 
1.3 Predictive and prognostic markers of prostate cancer 
 
1.3.1 Prostate specific Antigen (PSA) 
 
Prostate specific antigen (PSA) is a 32 kilodalton (kD) glycoprotein protease.  It is 
synthesised by the ductal and acinar epithelium of the prostate gland and is secreted 
into the seminal fluid after ejaculation. The basement membrane of the prostatic 27 
epithelium  normally  creates  a  barrier  preventing  the  escape  of  PSA  into  the 
circulation.  Disruption of the basement membranes by disease allows PSA to enter 
the systemic circulation. Serum PSA is measured in nanograms per millilitre (ng/ml) 
quantities  and  is  a  sensitive  marker  for  detecting  prostate  cancer.  After  radical 
surgery, serum measurements should nadir to undetectable levels. The recurrence of 
measurable PSA is the  initial sign of therapeutic failure. However many  disease 
processes within the prostate gland including BPH and Prostitis are associated with 
elevated circulating PSA concentrations. Thus PSA evaluation is not a diagnostic 
test for prostate cancer but is useful in helping to identify men in whom further 
investigations  such  as  a  prostate  biopsy  would  be  appropriate.  The  test  has 
dramatically changed the way that men are evaluated and treated for prostate cancer 
(16). Prior to the PSA evaluation era nearly 70% of men diagnosed with prostate 
cancer had progressed to the locally advanced or metastatic stage. Since the test was 
introduced into clinical practice in 1986, the early diagnosis and management of 
prostate  cancer  has  been  revolutionized  and  much  has  been  learned  about  the 
strengths  and  weaknesses  of  this  assay.  PSA  testing  not  only  helps  in  the  early 
diagnosis but also assists in assessing the response to therapy, determining tumor 
progression, and, in its most controversial role, screening for prostate cancer. 
1.3.2 Prostate specific membrane Antigen (PSMA) 
 
Prostate  specific  membrane  antigen  (PSMA)  is  an  antigenic  marker  to  prostate 
epithelial  cells  which  can  be  detected  in  the  serum.  PSMA  is  a  100 kd  type  II 
membrane protein that is expressed in normal Prostatic epithelial cells, BPH, PIN, 28 
and cancer. PSMA represents an attractive antigen for antibody based diagnostic and 
therapeutic intervention in prostate cancer, as it is highly restricted to the prostate 
and over expressed in all tumour stages. Immunohistochemical studies indicte that 
PSMA  expression  is  increased  in  castrate  resistant  disease  and  also  increased 
concentrations of PSMA are present in the serum of prostate carcinoma patients 
compared  with  healthy  individuals  (17).Additionally,  PSMA  primers  used  in  a 
reverse transcriptase–polymerase chain reaction (RT PCR) study  have been used to 
detect micro metastases in lymph nodes removed during radical prostatectomy (18). 
At present PSMA is being evaluated as a means for therapy. Vaccines including 
dendritic  cell  (DC) based  vaccines  hold  promise  as  a  safe  therapy  for  prostate 
cancer, here dendritic cells are primed with PSMA and infused into the patient. This 
is intended to produce a specific immune response to prostate cells. Using PSMA as 
a guide to identify and target prostate cells, radioactive isotopes and cytotoxic agents 
can be delivered to these cells. These findings have spurred development of PSMA 
targeted  therapies  for  cancer,  and  first generation  products  have  entered  clinical 
testing.  
 
1.3.3 Prostate tumour stage 
Tumour stage is a measure of the tumour size and the extent of disease spread. The 
TNM  (Tumour  Node  Metastasis)  classification  breaks  tumour  stage  into  three 
components; the T component which reflects the extent of disease at the primary site, 
the N component which reflects the presence or absence of nodal metastases and the 
M component which indicates the presence or absence of distant tumour metastases.  29 
The UICC (International union against cancer) 2002 TNM classification is used for 
staging cancer of the prostate (Table 1). 
1.3.4 Grading of prostate cancer  
The  grade  of  a  tumour  depends  on  its  histological  appearance  and  reflects 
differentiation associated neoplasia.  The most commonly used system for grading 
cancer  of  the  prostate  is  the  Gleason  grading  system  (19).  This  classification 
describes tumour growth according to the degree of cellular differentiation, which is 
graded 1 5.  Tumours can be graded as well differentiated, moderately differentiated 
or poorly differentiated based on their microscopic appearance. A Gleason score is 
calculated using combined scores of the two most prominent tumour areas which can 
range  from  2 10.  Gleason  grade  2 4  (well  differentiated),  5 7  (moderately 
differentiated) and 8 10 (poorly differentiated). This score has been shown to provide 
significant prognostic information and also to be readily reproducible (20).   
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T   Primary tumour 
  TX  Primary tumour cannot be assessed 
  T0  No evidence of primary tumour 
 
T1 Clinically unapparent tumour not palpable or visible by imaging 
  T1a  Tumour incidental histological finding in 5% or less of tissue resected 
  T1b  Tumour incidental histological finding in more than 5% of tissue resected 
  T1c  Tumour identified by needle biopsy (e.g., because of elevated prostate 
specific antigen (PSA) level) 
     
T2 Tumour confined within the prostate
1 
  T2a  Tumour involves one half of one lobe or less 
  T2b  Tumour involves more than half of one lobe, but not both lobes 
  T2c  Tumour involves both lobes 
     
T3 Tumour extends through the prostatic capsule
2 
  T3a  Extracapsular extension (unilateral or bilateral) 
  T3b  Tumour invades seminal vesicle(s) 
     
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder 
neck, external sphincter, rectum, levator ani and/or  pelvic wall 
     
N   Regional lymph nodes
3 
  NX  Regional lymph nodes cannot be assessed 
  N0  No regional lymph node metastasis 
  N1  Regional lymph node metastasis 
     
M   Distant metastasis
4 
  MX  Distant metastasis cannot be assessed 
  M0  No distant metastasis 
  M1  Distant metastasis 
  M1a  Non regional lymph node(s) 
  M1b  Bone(s) 
  M1c  Other site(s) 
     
1  Tumour found in one or both lobes by needle biopsy, but not palpable or visible by 
imaging, is classified as T1c  
2  Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is 
not classified as T3, but as T2. 
3  The regional lymph nodes are the nodes of the true pelvis, which are essentially the 
pelvic nodes below the bifurication of the common iliac arteries. Laterality does not 
affect the N classification. 
4  When more than one site of metastasis is present, the most advanced category 
should be used 
Table 1.1 : TNM classification used for prostate cancer staging 31 
1.4 Treatment of prostate cancer 
There are many different ways of treating prostate cancer. The optimal management 
of prostate cancer is determined primarily by tumour stage and grade, patient’s age 
and general health and individual patient preference.   
1.4.1 Watchful Waiting 
The  watchful  waiting  approach  a  standard  treatment  option  applied  in  the 
management of localised prostate cancer. This is based on the knowledge that a large 
proportion of patients with prostate cancer will not die from the disease. Patients 
who are placed on Watchful waiting have well or moderately differentiated tumours 
and a <10  year life expectancy. Watchful waiting allows clinicians to monitor a 
patient’s progress and intervene if the patient develops symptoms or evidence of 
disease progression.  Watchful waiting tends to be offered to elderly men, especially 
those who have other illnesses, such as coronary heart disease or diabetes.  
1.4.2 Radiotherapy 
 
•  External beam  
Radiotherapy kills cancer cells in the treated area. This treatment uses a high dose of 
radiation just to the area of the prostate gland. Radiotherapy is a potentially curative 
treatment  in  patients  with  localised  prostate  cancer.    Radiotherapy  is  generally 
offered to patients whose prostate cancer is between stage T1 and T3 whereby the 
cancer may have spread through the prostate capsule but is still localised. If the 
cancer has spread any further, radiotherapy is not likely to be used as a curative 
option.  It  is  known  that  both  increasing  T stage  and  a  high  Gleason  score 32 
compromise the chance of achieving a cure with radiotherapy (21;22).  However 
radiotherapy is also given to locally advanced prostate cancer that has started to 
spread from the prostate into nearby tissues, with the aim of shrinking the tumour or, 
when the cancer has relapsed after treatment but has not spread to other parts of the 
body. This therapy is also used to treat bone pain due to metastatic disease. 
•  Conformal Beam radiotherapy&  Intensity Modulated Radiotherapy 
(IMRT) 
In conformal radiotherapy a computer is used to shape the radiotherapy beams to a 
more  exact  shape  of  the  patients  prostate.  This  technique  aims  to  cut  down  the 
amount of healthy body tissue that receives radiation and reduce side effects to the 
bladder and the bowel. However, this is still being investigated in clinical trials.  
Intensity  Modulated  Radiotherapy  (IMRT)  is  a  newer  type  of  conformal 
radiotherapy where the radiotherapy beams are shaped with more precision to the 
cancer and vary the dose across the area of the tumour. 
•  Brachytherapy 
 
Brachytherapy  is  another  method  of  delivering  radiation  doses  directly  to  the 
prostate whilst minimising exposure to the surrounding non target tissues. The dose 
rate of brachytherapy refers to the intensity with which the radiation is delivered to 
the surrounding medium and is expressed in Grays per hour (Gy/h). Brachytherapy 
can be given as permanent Lowdose rate (LDR) by implanting radiation sources that 
emit  radiation  at  a  rate  of  up  to  2  Gy.hr 1(23).  This  involves  placing  small 
radioactive pellets (about the size of a grain of rice) in the prostate tumour area and 33 
leaving  them  there  permanently  to  gradually  decay.  Over  a  period  of  weeks  or 
months, the level of radiation emitted by the sources will decline to almost zero. The 
inactive  seeds  then  remain  in  the  treatment  site  with  no  lasting  effect  (22). 
Temporary  high  dose  rate  (HDR)  brachytherapy  is  a  newer  approach  to  treating 
prostate cancer and is currently less common than seed implantation. It is used to 
boost  therapy,  as  an  extra  dose  in  addition  to  external  beam  radiotherapy.  This 
method offers an alternative way to deliver a high dose of radiation therapy that 
conforms to the shape of the tumour within the prostate, while sparing radiation 
exposure to surrounding tissues (24 28).  HDR brachytherapy as a boost for prostate 
cancer allows the external beam radiotherapy course to be shorter than when using 
alone (24;25;28;29). 
1.4.3 Radical prostatectomy 
The  purpose  of  surgery  is  to  remove  disease  and  classify  the  extent  of  disease 
staging.  A  radical  prostatectomy  is  a  surgical  procedure  in  which  the  prostate, 
seminal vesicles and a sample of some nearby lymph nodes are removed.  Radical 
prostatectomy offers the advantage of a single potentially curative intervention in 
patients with localised prostate cancer. This surgery is offered to patients who have 
localised but clinically significant disease in whom life expectancy is estimated to be 
at least 10 years.  In these patients the expected benefits of surgery out weigh the 
risk of morbidity.  
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1.4.4 Chemotherapy 
Chemotherapy  is  used  in  castrate  resistant  prostate  cancer  patients  to  provide 
effective palliation of symptoms. Several chemotherapeutic agents are available to 
treat  prostate  cancer.  The  most  common  ones  are  docetaxel  (Taxotere)  and 
mitoxantrone (Novantrone). Chemotherapy is often given alongside other treatments 
such  as  palliative  radiotherapy,  bisphosphonates  or  pain relieving  drugs.  Steroids 
such  as  prednisolone  may  also  be  given  along  side  chemotherapy  to  make  the 
treatment more effective. Research has shown that using a combination of docetaxel 
(Taxotere) and prednisolone can help to reduce symptoms such as pain, improve 
quality  of  life  and  increase  survival  (30).  The  molecular  basis  for  taxol based 
chemotherapy  is  well  characterised.  Taxanes,  like  other  chemotherapeutic  agents 
such  as  estramustine,  inhibit  microtubule  disassembly  by  binding  to  tubulin  and 
arresting cells at the G2/M phase.  
1.4.5 Bisphosphonates 
Bisphosphonates are drugs which are used to slow down or prevent bone damage. 
These  drugs  target  areas  of  increased  bone  turnover.  The  osteoclast  cells  which 
breakdown old bones absorb the bisphosphonate, which subsequently slows down 
their activity and reduces bone destruction. Cancer cells that have spread to the bone 
release  cytokines  and  growth  factors  that  stimulate  the  osteoclasts  making  them 
overactive and bone is destroyed faster than it is rebuilt. Subsequently, the bones can 
become thinner and weaker, causing bone pain, hypercalcaemia and increased risk 
of  fractures.  Several  types  of  bisphosphonates  are  used  in  cancer  treatment, 
Zoledronic  acid  is  used  in  treating  castrate  resistant  prostate  cancer  with  bone 35 
metastases. Bisphosphonates may benefit men with castrate resistant disease with 
evidence of bone metastases (31;32). They do not actually alter the prognosis but 
they bind to areas of bone metastases where there is a lot of damage and can help to 
relieve  bone  pain.  They  may  also  help  to  prevent  and  slow  down  the  bone 
breakdown (33).  
1.4.6 Cryotherapy 
 
Cryotherapy is a new method of killing cancer cells by freezing them. However it is 
still undergoing clinical trials due to uncertainties surrounding it. It can be used to 
treat men with localised prostate cancer that has not spread beyond their prostate 
gland. Tiny probes (cryoneedles) are inserted into the prostate gland through the 
wall of the rectum. This freezes the prostate gland killing the cancer cells, but some 
normal cells also die. The aim is to kill cancer cells while causing as little damage as 
possible to healthy cells. The main side effects of cryotherapy include impotence, 
urinary symptoms and rectal problems. 
1.4.7 Hormonal therapy/androgen depravation therapy 
Hormone  therapy  controls  prostate  cancer  by  stopping  production  of  the  male 
hormone testosterone. The key treatment for patients with advanced disease is based 
on androgen deprivation therapy, and this approach has remained unchanged ever 
since Huggins and Hodges first demonstrated the hormonal dependence of prostate 
cancer in 1941 (34).  Their work showed the growth suppressive effect of reducing 
endogenous androgen levels, by surgical castration in patients with prostate cancer. 
Androgen deprivation therapy aims to inhibit androgen production or action, thereby 36 
reducing  stimulation  of  the  Androgen  receptor  (AR).  This  in  turn  prevents  the 
activation of androgen regulated genes, which normally result in on going growth, 
survival and inhibition of apoptosis.  
Front line therapy for locally advanced prostate cancer includes therapies that reduce 
the levels of androgen. The European Association of Urology Guidelines currently 
recommends androgen depravation therapy (ADT) as first line management in these 
patients. Response rates are initially high (70 80%) (35) but after 18 24 months (36), 
almost all patients relapse and develop castrate resistant prostate cancer (CRPC).  
•  Luteinizing hormone releasing hormone agonists (LHRH) 
Production  of  testicular  androgen  may  be  inhibited  surgically  by  Orchidectomy, 
which  is  the  removal  of  both  testicles.  Most  men  (more  than  80%)  respond 
positively to this treatment, with the progression of their cancer slowing markedly 
for  around  18  months  or  more.  Testosterone  production  may  also  be  inhibited 
chemically, using Gonadotrophin realising hormone super agonists (GnRH) which 
are generally referred to as Luteinizing hormone releasing hormone agonists. LHRH 
agonists  induce  castrate  levels  of  testosterone  by  down regulating  pituitary 
gonadotropin releasing  hormone  GnRH  receptors  (and  therefore  gonadotropin 
hormone production) through constant stimulation. Goserelin (Zoladex) is a GnRH 
receptor agonists used in the treatment of prostate cancer.  This drug mimics GnRH, 
a hormone produced by the hypothalamus.  This hormone stimulates the release of 
Follicle stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior 
pituitary  gland.  LH  in  turn  stimulates  the  production  of  androgens  in  the  testes.  37 
Administration  of  GnRH  agonists  initially  causes  a  surge  in  circulating 
concentrations  of  testosterone  and  dihydrotestosterone  which  can  lead  to  tumour 
flare.  Eventually these agonists downregulate the hypothalamic pituitary axis and 
consequently inhibit the production of LH and therefore androgen production (37).  
Hormonal therapy is also used in patients who present with metastatic disease. It 
also reduces bone pain, improves obstructive urinary symptoms, reduces prostatic 
bleeding, and decreases circulating PSA concentrations.  
•  Anti androgens  
The action of androgen may be blocked at a peripheral level using anti androgens, 
which prevent testosterone and DHT from binding to the AR. An antiandrogen is 
often used in combination with LHRH therapy to prevent tumour flare seen at the 
beginning of therapy. Antiandrogens can be used along with Orchidectomy and may 
be used 2 months before radiation or from 4 months to 2 years after radiation for 
men with intermediate risk prostate cancer. Bicalutamide (Casodex) was launched in 
1995 as a combination treatment (with surgical or medical castration) for advanced 
prostate  cancer  and  subsequently  launched  as  monotherapy  for  the  treatment  of 
earlier stages of the disease. Other anti androgens include flutamide (Drogenil or 
Chimax) and cyproterone acetate (Cyprostat). Oestrogens that reduce production of 
testosterone include diethylstilboestrol. 
•  Combination treatment 
Different methods of deceasing androgens are often used in the same patient: using 
LHRH  agonists  with  anti androgens  can  achieve  what  is  known  as  a  maximum 38 
androgen blockade (MAB). Hormone therapy can also be used in conjunction with 
other  treatments,  especially  in  the  case  of  advanced  stage  prostate  cancer  being 
treated with radiation therapy. In that case, hormonal therapy is often given before 
the radiation and this is known as neoadjuvant hormonal therapy and also before 
surgery. 
After a while, all prostate cancers will become resistant to hormonal therapy. For 
some this often takes many years and hormonal therapy can buy a lot of time in 
patients with extensive disease or patients who choose not to undergo surgery or 
radiation. However CRPC is a lethal and heterogeneous disease. Despite secondary 
treatment,  median  survival  of  CRPC  patients  ranges  from  only  9     27  months 
(38;39).  The  development  of  castrate  resistance  remains  a  significant  clinical 
problem, as it leads to disease progression and metastasis. 
 
1.5 Androgens and the Androgen receptor (AR) 
1.5.1 Androgen 
Androgens  control  the  development,  differentiation,  and  function  of  male 
reproductive and accessory sex tissues, such as the seminal vesicle, epididymis, and 
prostate. Other organs and tissues, such as skin, skeletal muscle, bone marrow, hair 
follicles, and brain, are also under the influence of androgens. The principal action 
of androgens is to regulate gene expression through the androgen receptor (AR). 
Androgens are the major regulators of prostate growth (40). Their known effects are 
mediated by a cytoplasmic AR that is translocated into the nucleus upon hormone 
binding to positively or negatively modulate the expression of specific genes (41).  39 
Testosterone  is  the  main  circulating  androgen  produced  primarily  by  the  Testes. 
However,  a  smaller  source  is  also  produced  from  the  adrenal  cortex,  by 
adrenocorticotropoic  hormone  (ACTH),  which  releases  androstene  and 
androsteriedione (42).  Testosterone circulates in the blood bound to albumin and 
sex hormone binding globulin (SHBG).  When free testosterone enters prostate cells  
it  is  converted,  by  the  enzyme  5α  reductase,  to  the  more  active  metabolite 
dihydrotestosterone (DHT) in the cell cytoplasm. Testosterone and DHT wield their 
biological effects through binding the AR and inducing transcriptional activity.  
1.5.2. The Androgen Receptor (AR) 
The gene for the androgen receptor is located on the X chromosome at Xq11 12 and 
encodes  a  protein  with  a  molecular  mass  of  approximately  110  kDa.    AR  is  a 
member of the nuclear receptor super family. Nuclear receptors are ligand inducible 
transcription  factors  that  mediate  the  signals  of  a  broad  variety  of  fat soluble 
hormones,  including  steroid  and  vitamin  D3  hormones,  thyroid  hormones  and 
retinoids  (41;43;44).  AR  can  alter  gene  expression  directly  by  interacting  with 
specific  elements  in  the  regulatory  regions  of  target  genes  (45)  or  indirectly  by 
activating various growth factor signallingpathways (46).  
1.5.3 AR Structure   
The androgen receptor gene was cloned in 1988 by Chang and co workers (47) and 
Lubahn et al. (48;49) followed by several others Tilley et al (50) Trapman et al (51), 
Brinkmann et al (52). AR has four major functional regions (Figure. 1.4): the N 
terminal transactivation domain (TAD), a central DNA binding domain (DBD), a C 40 
terminal ligand binding domain (LBD), and a hinge region connecting the DBD and 
LBD  (53).  Two  autonomous  transactivation  functions,  a  constitutively  active 
activation  function  (AF 1)  originating  in  the  N terminal  and  a  ligand dependent 
activation function (AF 2) arising in the LBD, are responsible for the transcriptional 
activity of nuclear receptors (54).  
 
 
Figure 1.4 Functional domains of Androgen receptor 
The Androgen receptor comprises of four functional domains, the diagram shows the 
function of each domain. 
 
•  N terminal transactivation domain  (N terminal) 
The  N terminal  domain  harbors  the  major  transcription  activation  functions  and 
several  structural  subdomains.  Within  its  538  amino  acids,  two  independent 
activation domains have been identified, these are activation function 1 (AF 1) and 
activation function 5 (AF 5) (Figure 1.4). AF 1 is located between residues 101 and 
370 and is essential for transactivity of full length AR. AF 5 is located between 
residues 360 485 and is required for transactivity of a constitutively active androgen 
receptor, which lacks its LBD (55). In addition, the N terminal contains a variable 41 
polyglutamine tract usually located at positions 57 78, which affects AR stability 
and transcriptional activity (56)  
•  DNA binding domain 
The DNA binding domain (DBD) is an independently folded protein domain which 
contains at least one motif that recognizes double  or single stranded  DNA. The 
DBD  of  AR  exhibits  a  high  degree  of  amino  acid  sequence  identity  to  other 
members of the glucocorticoid receptor (GR) subfamily, the progesterone receptor 
(PR),  and  mineralocorticoid  receptor  (MR).  Consequently,  the  four  receptors 
recognize very similar, if not identical, hormone response elements (HREs). Steroid 
receptors  have  long  been  known  to  bind  DNA  elements  that  are  organized  as 
inverted repeats of hexameric binding sites separated by three nucleotide spacers. 
For AR, GR, PR and MR, the consensus reads 5' TGTTCT 3' (57;58). The DNA 
binding domain has a compact, globular structure with two zinc finger motifs with 
four conserved cysteines. The first zinc finger contains a P box (sequence critical for 
DNA DNA recognition and specificity) and is responsible for binding to HRE of 
target genes (59 61). The second zinc finger contains a five amino acid residue long 
D box and controls dimerisation of the receptor on the HREs.  
•  Hinge Domain 
The hinge region connects the DBD with the LBD. It is defined by residues 628 669 
and  is  a  multifunctional  domain  involved  in  DNA  binding  (62 65)  and  nuclear 
translocation  (66).  The  AR  hinge  contains  a  serine  at  position  650  that  can  be 42 
phosphorylated by MEKK kinases and which seems to be involved in the regulation 
of receptor translocation (67;68). A mutation of Serine 650 to Alanine reduced the 
nuclear export of the AR (67). The hormone dependent nuclear translocation of AR 
is mainly mediated through a bipartite nuclear localization signal (NLS) consisting 
of two clusters of basic residues that are located in the DBD and the hinge region 
(66). The AR can also be acetylated in its hinge region at residues K630, K632, and 
K633 (69). Acetylation of these residues has been reported to regulate transcriptional 
activity (69), subcellular distribution and folding of the AR (70), and coactivator and 
corepressor binding (69 71).  
•  Ligand binding domain 
The  ligand  binding  domain  (LBD)  contains  the  ligand  dependent  transactivation 
function 2 (AF 2). This is a highly conserved hydrophobic cleft flanked by opposing 
charge residues (72). This area contains a fold comprised of up to 12 α helices (H12) 
forming a ligand binding pocket (LBP). Ligand binding changes the conformation 
and the H12 serves as a ‘lid’ to close the ligand binding pocket (LBP), whereas in 
the antagonist bound conformation, H12 is positioned in a different orientation, thus 
opening the entrance to the LBP.  
 
1.5.4 Androgen Receptor Isoforms 
Two  isoforms  of  the  androgen  receptor  (A  and  B)  have  been  identified  (73). 
Androgen receptor A (AR A) is approximately 87 kDa. The N terminus is truncated 43 
and lacks the first 187 amino acids. Androgen receptor B (AR B) is the full length 
AR and is approximately 110kDa. 
•  Splice variants 
Novel splice variants have been identified in prostate cancer cell lines designated 
AR v3, ARv 4, ARv 5 and AR v7; these variants lack the LBD (74). AR v3 has 
been shown to be expressed in human prostate cancer tissues and to be constitutively 
active and its transcriptional activity does not appear to be regulated by androgen or 
anti androgens. AR v3 was also significantly up regulated during prostate cancer 
progression and expression levels correlate with the risk of tumour recurrence after 
radical prostatectomy (74).  Hu et al also reported that levels of AR v7 are elevated 
by approximately 20 fold in castrate resistant prostate cancer cell lines derived from 
metastatic prostate cancer specimens failing hormone ablation therapy. In hormone 
naïve  prostate  cancers  which  had  not  undergone  hormone  therapy  a  low  ARv 7 
expression was observed. Interestingly higher ARv 7 expression was observed in 
these patients flowing therapy and this was also predictive of PSA recurrence (75). 
 
1.5.5 Androgen Receptor Cofactors 
The AR interacts with nuclear proteins, which modify its effects on transcription. 
AR co activators participate in DNA modification of target genes, either directly 
through  modification  of  histones  or  indirectly  by  the  recruitment  of  chromatin 
modifying  complexes,  as  well  as  functioning  in  the  recruitment  of  the  basal 
transcriptional machinery (76). 44 
•  Co activators 
To  facilitate  transcription,  nuclear  receptor  proteins  recruit  coactivator  proteins, 
which  increase  the  rate  of  transcription  by  promoting  histone  acetylation  and 
interactions  with  the  basal  transcriptional  machinery  (77).  The  best characterised 
coactivators include Steroid Coactivator 1 (SRC1) and Creb Binding Protein (CBP). 
The p160/SRC family consists of three members: SRC 1 (p160 1, N CoA1), SRC 2 
(TIF 2, GRIP1, NCoA2), and SRC 3 (RAC3, TRAM1, ACTR, ABI1, P/CIP). Most 
nuclear receptors recruit SRCs to their LBD using a leucine rich motif (LXXLL). 
However, the LBD of the AR preferentially recruits its own AF 1 domain via an N 
terminal FXXLF motif, which interacts strongly with the hydrophobic cleft of the 
LBD created by ligand binding (78 81). The subsequent recruitment of coactivators, 
in particular the SRC family, is then mediated primarily by the AF 1 domain rather 
than by the LBD (77;81 84).  
•  Co Repressors 
Co repressors interact with nuclear receptors in the absence of ligand or the presence 
of antagonists, and repress transcription. Nuclear receptor co repressor 1 (N CoR) 
and silencing mediator for retinoid and thyroid hormone receptors (SMRT) are key 
co repressors. Both prevent AR mediated transcription by recruiting proteins that 
have  histone  deacetylases  (HDAC)  to  the  promoter  region  of  the  genes,  which 
maintains chromatin in a condensed state thus inhibiting access of the transcription 
machinery. Prohibitin and Hey 1 have recently been identified as AR corepressors 
(85 87). 45 
1.5.6 Ligand dependent activation of androgen receptor 
Ligand free AR is maintained in a multiprotein inhibitory complex with heat shock 
proteins (HSPs 70 & 90). A vital component of this complex is the co chaperone 
p23. HSPs bind to regions of the receptor required for homodimerisation, nuclear 
localisation and DNA binding. Androgen binding induces a conformational change 
in  the  AR  that  leads  to  dissociation  from  the  HSPs,  homodimerisation,  receptor 
phosphorylation and nuclear translocation (Figure 1.5). Nuclear AR binds directly to 
HRE sequences in the promoter region of androgen regulated genes. This leads to 
the recruitment of co activators, co repressors and transcription machinery to the 
promoter (88). Androgen/AR interaction functions in promoting the survival of the 
secretory epithelia (89), controlling expression of genes that drive cell growth by 
promoting G1 S phase progression and inhibition of  apoptosis. (90).  
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Figure 1.5 Activation of the AR by androgens  
Testosterone enters prostatic epithelial cell and is converted to dihydrotestosterone 
(DHT) by 5α reductase. DHT binds to AR, resulting in dissociation of inhibitory 
heat shock  proteins  (HSPs)  and  transactivation  of  the  AR  involving  AR 
phosphorylation and dimerisation. The AR homo dimer transolcates to the nucleus 
and binds to androgen response elements in the promoter regions of target genes, 
resulting in biological responses such as growth, survival and PSA expression. 
 
1.5.7 Androgen receptor phosphorylation 
Phosphorylation of AR is stimulated in a ligand dependent manner via androgen 
binding  and  also  in  a  ligand  independent  manner  through  signal  transduction 
cascades.  Phosphorylation  of  Serine  and  Tyrosine  residues  on  the  AR  has  been 
identified. Phosphorylation of Serine residues stabilizes the AR and protects it from 
proteolytic  degradation  (91).  Phosphorylated  amino  acids  within  the  AR  include 
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serines (Ser) 16, 81, 94, 256, 308, 424,578 and 650 (Figure 1.6) (92 94) . All of 
these sites show increased phosphorylation in the presence of androgen, with the 
exception  of  Ser 94,  which  is  constitutively  phosphorylated.  In  response  to 
androgen binding,  Ser 81  is  the  most  frequently  phosphorylated  site  on  the  AR, 
giving the highest stoichiometric phosphorylation yield in LNCaP cells treated with 
androgens  (94).    Phosphorylation  of  Ser 81  is  associated  with  AR  stability  and 
transcriptional activity (95). It is also associated with prostate cancer cell growth in 
cell line studies, suggesting some significance of AR Ser 81 phosphorylation in AR 
function (96). AR transcriptional activity can be induced by EGF, this is dependent 
on  AR  phosphorylation  at  serines  515  (MAPK  consensus  site)  and  578  (PKC 
consensus site), which regulates nuclear cytoplasmic shuffling of the AR, through 
interactions  with  the  Ku 70/80  regulatory  subunits  of  DNA dependent  protein 
kinase (97). The AR can be phosphorylated in response to a variety of signals, which 
facilitates  the  recruitment  of  coactivators  or  components  of  the  transcription 
machinery and therefore acts in conjunction with the ligand to enhance transcription 
activation. Phosphorylation of the AR at serine residues 213 and 791 is mediated by 
Akt  which  results  in  increased  AR  transactivation  (98).  Tyrosine  kinases,  Ack1 
(activated cdc42 associated kinase) and Src, phosphorylate and enhance AR activity 
and promote prostate xenograft tumour growth in castrated animals. Ack1 mediates 
heregulin and Gas6 induced AR Tyrosine 267 phosphorylation, and Src mediates 
Tyrosine 534 phosphorylation induced by EGF, IL 6 and bombesin. Dasatinib, a Src 
inhibitor,  inhibits  EGF induced  Tyrosine  534  phosphorylation  and  also  inhibits 
heregulin induced Ack1 phosphorylation of the AR at Tyrosine 267 (99). 48 
 
Figure 1.6 AR serine phosphorylation sites 
Diagram  of  the  AR  displaying  the  serine  residues  that  are  known  to  undergo 
phosphorylation and the kinases reported to mediate this. 
 
1.5.8 Mechanisms of castrate resistance  
Depriving  prostate  cancers  of  androgen  inhibits  cell  proliferation  and  induces 
apoptosis resulting in tumour regression however disease regression is temporary for 
most  and  the  castrate  resistant  phenotype  proceeds.  The  mechanisms  underlying 
both the development of hormone naïve and castrate resistant disease are poorly 
understood however several possible mechanisms are currently being investigated.  
 
1.5.8.1 Genetic modification of the AR 
•  AR gene amplification 
AR expression is observed in hormone naïve and castrate resistant prostate cancers 
despite  low  levels  of  circulating  androgens  during  treatment.  Increased  AR 
abundance is one mechanism that can aid tumour cell proliferation despite the low 
androgen levels. AR gene amplification has been associated with castrate resistance 49 
(100). Approximately 30% of tumours that progress to castrate resistance have AR 
gene amplification, resulting in increased AR protein expression. However studies 
have reported that AR gene amplification was not present in the  hormone naïve 
tumours before the commencement  of hormone therapy (100;101). This suggests 
that  AR  amplification  was  possibly  due  to  clonal  selection  of  cells  that  could 
proliferate in the reduced androgen environment. AR amplification rates have also 
been shown to significantly increase in the transition from hormone naïve to castrate 
resistant  disease  (102;103).  Interestingly,  80%  of  these  patients  displayed  a 
corresponding  increase  in  AR  protein  expression,  indicating  that  AR  gene 
amplification does not always lead to increased AR protein expression. This study 
also observed that 22% of patients exhibited an increase in AR protein expression in 
the  absence  of  AR  amplification  but  it  was  the  patients  who  acquired  AR  gene 
amplification that had a significantly shorter survival time, suggesting that in a sub 
set of prostate cancer patients AR gene amplification is involved in the progression 
to castrate resistant disease. However, this observation does not account for the 70% 
of patients who do not acquire AR gene amplification but progress to a castrate 
resistant disease thus suggesting another method to disease progression. 
 
Animal  models  of  prostate  cancer  have  suggested  that  increased  AR  levels  can 
initiate  prostate  cancer  development  (104)  and  castrate  resistant  xenografts  have 
shown  that  the  AR  exhibits  an  increased  sensitivity  to  reduced  androgen  levels 
(105). Kim et al observed that castrate resistant tumour cells were hypersensitive to 
the  growth  promoting  effects  of  DHT.  These  androgen  independent  cells  were 50 
stimulated by DHT concentration four times lower than that required for androgen 
dependent LNCaP cells. These results therefore, have shown that in some models of 
prostate  cancer  the  AR  is  transcriptionally  active at  the  low  levels  of  androgens 
found to be circulating in castrated patients. 
 
•  AR Mutations 
In untreated prostate cancer the incidence of AR mutations is found to increase with 
cancer stage. AR mutations are found in 0 4% of latent and stage B prostate tumours 
(106 108). However, they are more commonly observed in distant metastasis, AR 
mutations were found in 21 44% of  metastatic tumours sampled before therapy 
(107;109). Therefore the acquisition of mutations within the AR is likely to be a 
mechanism for castrate resistance in some prostate cancer patients. The majority of 
AR  mutations  identified  are  point  mutations  resulting  from  a  single  amino  acid 
substitution. The replacement of threonine 877 with alanine in the AR LBD is a 
frequent mutation in prostate cancer patients and corresponds to the mutation found 
in  LNCaP  cells  (110 113).  In  cells  with  AR  mutations,  androgen  signalling  is 
maintained  by  the  broader  number  of  ligands  that  can  bind  to  and  activate  the 
receptor.  The  T877A  substitution  allows  the  AR  to  be  activated  by  binding  to 
cortisol  and  progesterone  and  other  ligands  that  the  wild  type  receptor  cannot 
accommodate.  This  mutation  allows  antiandrogens  such  as  flutamide  to  bind, 
changing  its  function  from  an  antagonist  to  agonist,  thereby  promoting  prostate 
cancer cell growth (114;115). Additionally several point mutations in and around the 
hinge region have been identified (116 118). Some of these mutations have been 51 
shown to increase the transcriptional response which indicates an inhibitory function 
of the hinge domain. Various other AR mutations have been identified which are 
catalogued in the Androgen Receptor Gene Mutation Database (119). At present it is 
uncertain how many of these other mutations use the same promiscuous receptor 
mechanism that allow prostate cancer cells to become castrate resistant.  
•  CoRegulator alterations 
Modulation of coregulatory proteins and their function is most likely to contribute to 
the progression to castrate resistant disease.  This may be by increasing the AR 
transcriptional  activity  at  low  androgen  concentrations  or  by  altering  the  ligand 
specificity.  In  prostate  cancer  several  coactivators  have  been  shown  to  alter  the 
ligand specificity of the AR, including CBP, β catenin, AR associated protein 55 
(ARA55) and ARA70 (120 122). In addition, the expression of three members of the 
SRC  family,  SRC 1,  TIF 2  and  SRC 3  have  been  shown  to  be  high  in  prostate 
cancer (76;88). SRC 1 has been shown to be  overexpressed in 50% of hormone 
naïve prostate cancers compared to normal and BPH samples. In castrate resistant 
tumours 63% displayed both SRC 1 and TIF 2 overexpression (123). Moreover an 
increase  in  SRC 3  expression  has  been  shown  to  significantly  correlate  with 
increased tumour stage and Gleason grade and decreased disease specific survival 
(124). Another study also highlighted that higher expression of RAC 3 resulted in 
higher PSA levels in the presence and absence of androgen. Here it was observed 
that RAC 3 facilitates RNA polymerase II recruitment to a distant enhancer element 
of  the  PSA  gene,  resulting  in  a  increase  in  PSA  expression  (125).    The  AR 
coactivator  cdc25B  (cdk activating  phosphatase)  has  also  been  associated  with 52 
prostate cancer progression. High expression of cdc25B was observed in late stage 
prostate tumours with a high Gleason grade (126). In the CWR22 prostate xenograft 
and LNCaP cell line the expression and nuclear localisation of AR coactivator Tat 
interactive  protein  60  kDa  (Tip  60)  was  shown  to  increase  upon  androgen 
withdrawal (127). AR co activator overexpression appears to play a role in prostate 
cancer  progression,  which  coactivators  most  significantly  contribute  to  prostate 
cancer progression remains to be determined. 
 
Several mechanisms have been implicated with the development of castrate resistant 
disease. AR mutations have been identified in a small number of prostate cancers 
and mutated AR may cause anti androgens to activate the AR rather than inhibiting 
it.  AR  gene  amplifications  are  present  in  20 30%  of  castrate  resistant  prostate 
cancers.    Amplification  of  the  AR  gene  may  result  in  increase  protein  which  is 
hypothesised to enable low levels of circulating androgens to bind and activate the 
AR even in the presence of anti androgens. However, there remain a large number 
of  cases  that  cannot  be  explained  by  AR  mutations  or  amplifications.  Cell  line 
studies  suggest  that  castrate  resistance  may  be  a  result  of  AR  activation  by 
phosphorylation or may be due to a mechanism completely independent of the AR. 
 
1.5.8.2 Post translational modifications of the AR  
Upon  AR  expression,  post translational  modification  takes  place.  These 
modifications,  which  are  generated  by  signal  transduction  pathways,  include 
acetylation, ubiquitination, sumoylation and phosphorylation (128). The progression 53 
of prostate cancer has been associated with alteration of growth factor or growth 
factor receptor expression by the tumour (129;130). Growth factors and cytokines 
regulate  cellular  responses  through  binding  to  membrane  receptors.  This  binding 
initiates  a  phosphorylation  cascade  that  ultimately  results  in  phosphorylation  of 
transcription factors or transcription factor interacting proteins.  
 
1.6 Cross talk between AR and growth factor receptor pathways 
In prostate cancer a number of signal transduction cascades are known to influence 
AR  transcriptional  activity  by  direct  phosphorylation  of  the  AR  or  by 
phosphorylation of AR coregulators. In vivo, this may allow the AR to be activated 
in the absence of androgens, by other steroids or be sensitised to the low levels of 
circulating  adrenal  androgens  that  remain  present  during  androgen deprivation 
therapy. Several growth factors such as Insulin like growth factor  1 (IGF 1) and 
EGF can activate the AR and induce AR regulated genes in the absence of androgen 
(131). These growth factors are ligands for receptor tyrosine kinases and initiate 
intracellular  signallingcascades.  A  full  description  of  the  signallingcascades 
implicated in castrate resistant disease progression is beyond the scope of this thesis 
however  current  advances  in  signal  transduction  association  will  briefly  be 
discussed. 
The Human Epidermal Growth Factor Receptor (HER) family has been implicated 
in prostate cancer. Increased expressions of the EGFR, HER2, HER3, HER4, and 
EGFRvIII have all been associated in prostate cancer progression (132 136).  AR 
activation  has  been  reported  through  HER2  induced  Mitogen  activated  protein 54 
kinase    (MAPK)  and  Phosphatidylinositol  3  Kinase  (PI3K)  signalling(137).  In 
LNCaP  cells  HER2  mediated  AR  transactivation  is  reduced  by  transfection  of  a 
dominant  negative  mutant  of  Akt  suggesting  Akt  phosphorylation  of  AR  can 
enhance AR transcription at a low level of androgen (98).  
The IL 6/JAK/STAT cascade is thought to play a key role in the progression of 
castrate resistant disease. IL 6 cytokine was originally described as a regulator of the 
immune and inflammatory responses, but is now known to influence tumour cell 
growth in an autocrine/paracrine manner (138).  As prostate cancer progresses from 
hormone naïve to castrate resistant disease, the circulating concentrations of IL 6 in 
the serum of patients increase (139). Functional cell line studies demonstrate that the 
AR/STAT 3 complex can promote androgen regulated gene transcription even in the 
absence of androgens (140). This mechanism is supported by data that demonstrates 
IL 6 can activate the AR in a ligand independent manner (141;142). Evidence in 
clinical tissue to support these in vitro observations are sparse, although it is reported 
that IL 6 receptor (IL 6 R) expression is eightfold higher in prostate cancer tissue 
compared to normal tissue (143). Additionally, IL 6R and pSTAT3
Tyr705 expression 
are associated with reduced time to biochemical relapse and survival in matched 
hormone naïve and castrate resistant tumour samples (144)  
Work carried out in our lab previously using CGH gene array identified that several 
members of key signallingcascades were upregulated in clinical castrate resistant 
prostate cancer samples (145). This study observed that key members of the PI3K 
and MAPK cascade were more commonly amplified in castrate resistant tumours. 
Both of these signallingcascades can be  activated by  growth factors via tyrosine 55 
kinase receptors.  The Ras/Raf/MAP Kinase pathway may increase prostate cancer 
cell  growth  both  via  and  independently  of  the  AR,  further  implicating  it  in  the 
development of castrate resistant disease. Multiple members of this pathway have 
been  implicated  in  prostate  cancer  progression.  In  studies  using  human  prostate 
tumours, phosphorylated MAPK expression increases with tumour stage and grade 
and is over expressed in castrate resistant disease (146). H, K and N RAS genes are 
amplified in approximately 50% of hormone naïve and castrate resistant prostate 
tumours (145) and N Ras expression is associated with the development of castrate 
resistant disease and correlates with MAPK activation (147). Additionally both an 
increase in Raf 1 and MAPKexpression are significantly associated with prostate 
cancer  survival  (148).    Recent  evidence  suggests  that  MAPK  activation  induces 
phosphorylation of AR at Serine 81 to stimulate prostate cancer cell growth and 
induce PSA expression (96). MAPK has been shown to increase transcription of 
androgen dependent genes independently of androgens via phosphorylation of the 
AR  itself  at  serine  515 or  via  phosphorylation  of  AR  co  factors  such  as  SRC 1 
(141;149).  
 
1.7 The PI3K/Akt cascade 
The PI3K cascade has been shown to regulate multiple cellular events in prostate 
cancer.  Activation  of  the  PI3K  cascade  is  initiated  by  receptor  tyrosine  kinases 
(RTKs)  and  non  RTKs.  PI3K  activation  results  in  the  catalytic  conversion  a 
phosphate from ATP to the D 3 position of the inositol ring of phospatidylinositol 
(4, 5) bisphosphate (PIP2) to phospatidylinositol  (3,4,5) triphosphate (PIP3) (150). 56 
These lipids act as secondary messengers and recruit pleckstrin homology (PH) 
domain  containing  proteins  such  as  Akt  to  the  inner  surface  of  the  plasma 
membrane,  driving  their  conformational  change  resulting  in  their  activation. 
Activated Akt translocates to the cytoplasm and nucleus and activates down stream 
targets such as mammalian target of Rapamycin complex 1 (mTOR 1). The PI3K 
cascade is negatively regulated by the tumour suppressor PTEN (phosphatase and 
tensin  homologue  deleted  on  chromosome  10).Activation  of  this  pathway  is 
believed  to  be  a  key  mechanism  driving  castrate  resistant  disease  progression 
(Figure 1.7) 
 
 
Figure 1.7 PI3K cascade 
Schematic representation of the PI3K cascade 57 
1.7.1  PI3K 
 
The oncogenic form of PI3K, v p3k, was first discovered in an avian sarcoma virus 
(151),  here  the  expression  of  v p3k  was  shown  to  induce  tumours  when  the 
transformed cells were injected into chicken.  The PI3K family is composed of three 
Classes; I, II, and III. Class I PI3K is further divided into two groups: PI3K IA and 
PI3K IB  and  activation  is  dependent  upon  the  specific  regulatory  and  catalytic 
isoforms that associate into the heterodimers. Class IA PI3K heterodimers contain 
specific isoforms of the 85 kDa adaptor subunit (p85α, p55α, p50α, p85β, or p55γ) 
that facilitates interaction with receptor tyrosine kinases (RTK) and either an alpha, 
beta  or  delta  p110  catalytic  subunit  (p110α,  p110β,  or  p110γ).  The  preferred 
substrates  of  class  I,  PI3K  are  phosphoinositides  (4,  5)  bisphosphate  (PIP2), 
Phosphorylation  of  PIP2  by  PI3K  generates  PtdIns  (3,  4,  5)  PIP3.  The  class  IA 
PI3Kp110α  is  mutated  in  many    cancers  causing  the  kinase  to  be  more  active 
(152;153). Functional analyses of PIK3CA mutations revealed that they increase its 
enzymatic activity, stimulate Akt signalling, and allow growth factor independent 
growth as well as increasing cell invasion and metastasis (153).  
 
1.7.2  Akt  
Three Akt family members Akt 1, 2 and 3 have become known as critical mediators 
of signal transduction cascades downstream of activated tyrosine kinases and PI3K. 
An  ever  increasing  list  of  Akt  substrates  has  specifically  defined  the  multiple 
functions of this kinase family in normal physiology and disease states. Cellular 
processes  regulated  by  Akt  include  cell  proliferation  and  survival,  cell  size  and 58 
response to nutrient availability, intermediary metabolism, angiogenesis, and tissue 
invasion.  Akt proteins contain a central kinase domain with specificity for serine or 
threonine residues in substrate proteins. They also contain a pleckstrin homology 
(PH) domain, which mediates lipid protein and/or protein protein interactions. Akt1 
has been implicated as a major factor in many types of cancer. Akt2 has shown to be 
an important signallingmolecule in the Insulin signallingpathway and is required to 
induce glucose transport.These separate roles for Akt1 and Akt2 were demonstrated 
in study using mice which had either Akt1 or Akt2 gene deletion.  In Akt 1 null mice 
with normal Akt2, glucose homeostasis is undisrupted however the animals were 
smaller, consistent with a role for Akt1 in growth. In contrast, Akt2 null mice with 
normal Akt1, have mild growth deficiency and display a diabetic phenotype again 
consistent  with  the  idea  that  Akt2  is  more  specific  for  the  insulin  receptor 
signallingpathway  (154).  The  role  of  Akt3  is  less  clear,  though  it  appears  to  be 
predominantly  expressed  in  brain  tissue  (155).  In  unstimulated  cells  Akt  is 
constituatively  phosphorylated  at  serine  124  and  threonine  450.  Once  correctly 
positioned in the cell membrane via binding of PIP3 Akt can then be phosphorylated 
by its activating kinases at two regulatory residues.  Phosphoinositide dependent 
kinase  1  (PDK 1)  phosphorylates  Akt  at  threonine  308,  this  is  essential  for  Akt 
activation as it causes a charge induced conformational change that allows substrate 
binding and an increased rate of catalysis. Without this threonine phosphorylation  
the  hydrophobic  motif  of  Akt  is  more  susceptible  to  the  action  of  phospatases. 
Mammalian target of rapamycin complex 2 (mTORC2) phosphorylates Akt at serine 
473 (156;157). Phosphorylation of Akt at serine 473 increases Akt activity 10 fold 59 
(156;158).  Once  activated  Akt  translocates  from  the  inner  surface  of  the  cell 
membrane to the cytoplasm and nucleus where it phosphorylates proteins in several 
pathways  regulating  aspects  of  metabolism,  proliferation  and  apoptosis.  Akt  also 
plays significant roles in protein translation, particularly by regulating those proteins 
involved in growth and survival. Akt regulates the apoptotic response to a variety of 
stimuli  via  its  ability  to  interact  with  a  number  of  key  players  in  the  apoptotic 
process.  BAD is a pro apoptotic protein of the Bcl 2 family. Akt phosphorylates 
BAD on Serine 136  which makes BAD dissociate from the Bcl 2/Bcl X complex 
and lose the pro apoptotic function (159). Akt has also been shown to regulate cell 
cycle  progression  via  a  pathway  that  ultimately  down  regulates  the  cell  cycle 
inhibitor p27 (160). 
 
1.7.3 mTOR 
Mammalian target of rapamycin (mTOR) is a large protein kinase that exists in two 
distinc complexes within cells, one that contains mTOR, GβL, and raptor (mTOR 
C1) and another containing mTOR, GβL and rictor (mTOR C2). Akt can directly 
phosphorylate and activate mTOR, as well as cause indirect activation of mTOR by 
phosphorylating  and  inactivating  TSC2  (tuberous  sclerosis  complex  2),  which 
normally  inhibits  mTOR  through  the  GTP binding  protein  Rheb  (Ras  homolog 
enriched in brain). When TSC2 is inactivated by phosphorylation, the GTPase Rheb 
is maintained in its GTP bound state, allowing for increased activation of mTOR. In 
the  mTORC1  complex,  mTOR  signals  to  its  downstream  effectors  S6 
kinase/ribosomal protein S6 and Eukaryotic translation initiation factor 4E (4EBP 60 
1/eIF 4E) to control protein translation. Although mTOR is generally considered a 
downstream substrate of Akt, mTOR can also phosphorylate Akt when bound to 
Rictor in TORC2 complexes, this is thought to provide a level of positive feedback 
on the pathway (156). The downstream mTOR effector S6 kinase 1 (S6K1) can also 
regulate the pathway by catalyzing an inhibitory phosphorylation on insulin receptor 
substrate (IRS) proteins. This prevents IRS proteins from activating PI3K, thereby 
inhibiting activation of Akt. Due to its  central position in the PI3K  cascade i.e 
downstream  of  Akt  and  upstream  of  S6K    the  activation  of  mTOR  is  part  of  a 
fundemental step in controlling tumour cell growth. 
1.7.4  PTEN 
PI3K dependent Akt activation can be regulated through the tumor suppressor PTEN 
which works essentially as the opposite of PI3K. The PTEN tumour suppressor gene 
is located on chromosome 10q23, an area known to undergo loss of heterozygosity 
(LOH) in many human cancers. PTEN Mutations and somatic deletions have been 
identified  in  an  array  of  tumours  placing  PTEN  as  one  of  the  most  commonly 
mutated tumour suppressor genes in human cancer (161). PTEN mutants that retain 
protein tyrosine phosphatase activity but loose the ability to dephosphorylate PIP3 
are found in many tumours, indicating that the lipid phosphatase activity is needed 
for tumour suppression (162). PTEN acts as a phosphatase to dephosphorylate PIP3 
back  to  PIP2.  This  removes  the  membrane localization  factor  from  the  Akt 
signallingpathway.  Without  this localization, the  rate  of  Akt  activation  decreases 
significantly,  as  do  the  all  the  downstream  pathways  that  depend  on  Akt  for 61 
activation.  The  ability  of  PTEN  to  inhibit  PI3K/Akt  signallingallows  it  to  block 
nuclear entry of Mdm2. Phosphorylation of Mdm2 at serines 166 and 188 by Akt 
induces  the  translocation  of  Mdm2  to  the  nucleus.  In  the  nucleus  Mdm2  ligates 
ubiquiton to the p53 tumour suppressor thus targeting it for degradation. PTEN also 
negatively  regulates  cell  migration  and  invasion  by  dephosphorylation  of  focal 
adhesion  kinase  (FAK)  and  also  negatively  regulates  growth  factor  receptor 
signallingthrough inhibition of the adaptor protein Shc, (163;164). 
 
 
1.7.5 The PI3K/Akt cascade and prostate cancer 
Several key components of the PI3K/Akt cascade have been implemented in prostate 
carcinogenesis and castration resistance. PI3K inhibition has been studied in vitro 
for some time and evidence of it key role in carcinogenesis continue to emerge. 
Genetic analysis of high Gleason grade prostate cancers revealed 3% of patients had 
PIK3CA mutation and 13% had PIK3CA amplification (165). Up regulation of PI3K 
signallingmay also be due to overexpression of RTKs which have been previously 
reported to be overexpressed in prostate tumours and cell lines (133;134;137). PI3K 
has shown to be an important signallingmolecule and key survival factor involved in 
prostate  cancer  proliferation  and  invasion.  Previous  studies  have  reported  that 
treatment  LNCaP,  PC 3  and  DU145  with  PI3K  pharmacological  inhibitor, 
LY294002, potentially suppressed the invasive properties in each of these cell lines 
and restoration of the PTEN gene to highly invasive prostate cancer PC 3 cells or 
expression  of  a  dominant  negative  version  of  Akt  also  significantly  inhibited 
invasion  and  down  regulated  protein  expression  of  urokinase type  plasminogen 62 
activator (uPA) and matrix metalloproteinase (MMP) 9, markers for cell invasion, 
indicating a central role of the PI3K/Akt cascade in this process. Increased levels of 
PI3K (p110 / ) and regulatory (p85) and Akt were also observed in these cell lines 
(166). 
A somatic mutation in AKT1 (E17K) has been detected in breast, colorectal, lung, 
ovarian and prostate cancers (167;168). In AKT1, the E17K substitution leads to a 
PI3K independent  activation  of  AKT1.  In  prostate  cancer,  AKT1  mutation  was 
reported to have a prevalence of just 1.4% and the mutation seemed to be associated 
with  favourable  clinical  outcome  and  was  not  associated  with  a  specific  tumour 
growth pattern (168). Overexpression of Akt in prostate cancer is hypothesised to be 
due to defective PTEN gene as discussed below. Prostate tumours are reported to 
have significantly higher Akt expression than BPH (169), and only 10% of well 
differentiated prostate tumours strongly express pAkt compared to 92% of poorly 
differentiated tumours (161;170 172). Additionally, in hormone naive tumours Akt1 
and Akt2 expression has been associated with shorter time to biochemical relapse; 
however,  no  association  was  reported  with  the  activated  forms  or  with  survival 
(173). 
 Loss of PTEN has been associated with advanced prostate cancer (174) and loss of 
PTEN expression is associated with increased risk of recurrence in human tumours 
(175 178). Prostate cancer cell lines that have been cultured from metastatic sites 
such  as  the  lymph  nodes  (LNCaP)  or  brain  metastasis (PC3)  have  highly  active 
PI3K/Akt signallingand PTEN deletion (179;180) The magnitude of loss of function 
of  PTEN  is  best  described  in  both  localised  and  metastatic  prostate  cancers  and 63 
includes  homozygous  deletions,  loss  of  heterozygosity  (LOH)  and  inactivating 
mutations (181). The reported frequency and mode of inactivation at different stages 
of prostate cancer vary. Homozygous deletions of PTEN have been detected in up to 
15% of locally confined prostate cancers and up to 30% in metastatic cases (182 
186).  Heterozygous  loss  has  been  reported  in  13%  of  locally  confined  prostate 
cancers and up to 39% in metastatic cases (183 185;187;188). PTEN mutation has 
been associated with 5 27% of localised and 30 60% of metastatic prostate tumours 
(182;189;190)  In  addition,  loss  of  PTEN  expression  is  associated  with  disease 
progression  and  increased  risk  of  recurrence  (175;176;178)  although  substantial 
heterogeneity has been observed between different metastatic sites within the same 
patients (182).  
Many oncoproteins and tumor suppressors intersect in the PI3K cascade, regulating 
cellular  functions  at  the  interface  of  signal  transduction  and  classical  metabolic 
regulation. This careful balance is altered in human cancer by a variety of activating 
and  inactivating  mechanisms  that  target  both  Akt  and  interrelated  proteins. 
Numerous studies have suggested that PI3K signallingenhances its oncogenic signal 
through interaction with other signallingnetworks such as the transcription factor 
Nuclear factor Kappa B (NFқB) (191;192).  Bai et al have recently reported that 
suppression of NFкB activity by IκB superepressor induces a strong and selective 
resistance  to  PI3K  or  Akt  induced  oncogenic  transformation  which  suggests  an 
essential  role  for  NFкB  in  the  transforming  mechanisms  induced  by  this 
signallingcascade  (193).    NFқB  signallinghas  been  reported  to  regulate  various 
genes involved in the invasion, angiogenesis and metastasis of cancer cell (194). 64 
1.8 NFқB cascade 
Aberrant NFқB nuclear activation has been implicated in the pathogenesis of several 
human  malignancies  including  prostate  cancer.  NFқB  has  been  shown  to  play 
important roles in the control of growth, differentiation, and apoptosis (195;196). 
NFκB has been shown to be related to the initiation and progression of many types 
of cancer through its target genes. These target genes include c myc, cyclin D and 
IL 6 which promote cell growth, Bcl 2 which inhibits apoptosis, IL 8 and VEGF 
which promote angiogenesis, and MMP9 which promotes invasion and metastases 
(197;198). Many different stimuli have been reported to cause nuclear localisation 
and transcriptional activation of NFκB via activation of the IKK complex (IKK α, 
IKK β and IKKγ/NEMO), resulting in phosphorylation of IκBα at serine 32 and 
serine 36.   NFκB normally exists in a dormant state bound to IκBα, when IκBα is 
phosphorylated  NFκB  is  released  from  the  complex  and  IκBα is  marked  for 
degradation.    Following  release  NFκB  translocates  from  the  cytoplasm  to  the 
nucleus where it binds to the promoter region of multiple genes (198). 
 
1.8.1 NFқB 
Transcription factor NFκB was first identified by Sen and Baltimore over twenty 
years ago as a B cell  specific nuclear factor that bound to an enhancer element in 
the  immunoglobulin  kappa  (κ)  light  chain  gene.  NFκB  proteins  are  found  in 
essentially all cell types and are involved in the activation of a remarkably large 
number  of  genes  in  response  to  infections,  inflammation,  and  other  stressful 
conditions which call for prompt reprogramming of gene expression. NFκB exists in 65 
the cytoplasm in the majority of cell types as a variety of homo or heterodimeric 
isoforms. Five family members; c Rel, Rel A (p65), Rel B, NF  κB1 (p50/p105), and 
NF   κB2 (p52/p100) have been identified. These proteins share  a high  sequence 
homology within a conserved Rel homology domain (RHD) near the N terminal. 
This area comprises of DNA binding domains, a dimerisation domain, and interacts 
with  the  inhibitory  IκB  proteins.  Additionally  the  RHD  contains  a  nuclear 
localisation  signal  (NLS).  In  the  majority  of  cell  types  the  Rel  A  (p65)/  p50 
heterodimer is most commonly expressed. The c Rel, Rel A and Rel B proteins have 
c terminal transactivation domains responsible for their function as a transcriptional 
activator. Alternately NF  κB1 and NF  κB2 are created as precursor forms p105 
and  p100  respectively  where  a  series  of  ankaryin  repeats  are  present  in  the  c 
terminal  domain  in  place  of  a  transactivation  domain.  These  proteins  undergo 
proteolytic processing removing the c terminal sequences generating the products 
p50 NF  κB1 and p52 NF  κB2 respectively. Due to the lack of the transactivation 
domain,  p50  and  p52  homodimers  are  thought  to  function  as  transcriptional 
repressors while heterodimers of p50 or p52 with transactivation domain  containing 
Rel proteins lead to activation of target genes (194).  
 
1.8.2 NFκB activation 
Activation  of  NFκB  is  stimulated  through  several  mechanisms  including  signal 
transduction  pathways  involving  tyrosine  kinases,  NFкB  inducing  kinase  (NIK), 
IKK and PI3K. At present it appears that all NFκB complexes are regulated in the 
same manner which is through interaction with IκBs. Seven IκB proteins have been 66 
identified IκBα, IκBB, IκBε, p105, p100, BCL 3 and IκBζ. Based on their domain 
organization, selectivity toward specific NFκB dimmers and subcellular location in 
resting cells this family of proteins has three groupings; canonical, NFκB precursor 
and nuclear IκB. IκBs contain five to seven ankaryin repeats of 30 33 amino acids. 
These stacked helical domains bind to the NLS of NFκB proteins, blocking nuclear 
localisation.  Only  Iκβα,   Iκββ,  and  Iκβ ε  contain  N terminal  regulatory  regions 
which  are  necessary  for  stimulus  induced  degradation,  the  crucial  step  in  NFκB 
activation.  IκBα plays  a  central  role  in  termination  of  NFκB  activation.  Newly 
synthesized  IκBα enters  the  nucleus  and  binds  to  NFκB,  thus  enhancing  the 
dissociation from the DNA and causing its re exportation to the cytoplasm by means 
of  a  nuclear  export  sequence  (NES)  present  on  IκBα . Following  cellular 
stimulation,  IκBs  become  phosphorylated  by  the  multisubunit  IκB  kinase  (IKK) 
complex  at  serine  residues  32  and  36.  The  phosphorylated  IκB  is  then 
ubiquitinylated  leading  to  their  proteolysis  by  the  26s  proteosome  in  an  ATP  
dependent manner (199). A key step in NFκB activation is phosphorylation of the 
p65 and p50 subunits. A number of positions of phosphorylation in the p65 subunit 
have been acknowledged and are associated with the action of multiple stimulus 
coupled  kinases  that  act  in  both  the  cytoplasm  and  the  nucleus.  A  key 
phosphorylation event involves serine 536 of the p65 subunit. The phosphorylation 
of this site is catalysed by multiple kinases that are activated by diverse stimuli (200 
202). The involvement of PI3K and Akt in phosphorylation of p65 is controversial. 
Some studies suggest that PI3K/Akt directly phosphyorylates p65 at serine 536 in 
response  to  IL 1  whereas,  other  suggest  it  serves  as  an  intermediate  kinase  that 67 
activates IKKα by phosphorylation at threonine 23  which in turn phosphorylates 
serine 536 (193;203). Other p65 phosphorylation sites have been identified. Casein 
kinase II and protein kinase A have been shown to phosphorylate p65 at serine 529 
and 276 (204;205). GSK 3 β phosphorylates p65 at ser 468; this reduces the basal 
activity of NFκB to basal activity in resting cells (206).  
 
1.8.3 NFκB and prostate cancer 
NFκB has been shown to be constitutively activated in prostate cancer cells, and 
elevated  NFκB  activity  is  also  sustained  in  androgen responsive  human  prostate 
cancer  cells  by  androgen  treatment  (207).  Huang  et  al  have  demonstrated  that 
suppression  of  NFκB  activity  in  human  prostate  cancer  cells  by  IκBα  mutation 
transfection  inhibits  their  tumorigenic  and  metastatic  properties  in  nude  mice  by 
suppressing angiogenesis and invasion. IκBαM transfection blocked NFκB activity 
was associated with down regulation of VEGF, IL 8 and MMP 9 promoter activities 
and decreased expression of these genes in cultured cells and in cells implanted into 
the  prostate  gland  of  nude  mice.  The  decreased  expression  of  VEGF,  IL 8  and 
MMP 9 in vivo directly correlated with decreased neovascularization and production 
of  lymph  node  metastasis.  This  provides  direct  involvement  of  NFκB  in  the 
regulation of angiogenesis and metastasis of prostate cancer cells.  Numerous reports 
have demonstrated that in prostate cancer as well as other tumour types that the 
metastatic potential of tumour cells directly correlates with the expression level of 
several  angiogenic  genes,  including  vascular  endothelial  growth  factor  (VEGF), 
basic  fibroblast  growth  factor  (Bfgf),  interleukin  8  (IL 8)  and  matrix 68 
metalloproteases MMP 2 and MMP 9 (198;208). Expression of MMPs is associated 
with poor prognosis in a variety of cancers including prostate. MMPs are enzymes 
that are capable of degrading the extracellular matrix and basement membrane. An 
increase in MMP 2 and MMP 9 is associated with tumour progression but how the 
constitutive expression of these genes is regulated in prostate cancer is at present 
unclear.  In  addition  NFκB  has  been  associated  with  the  development  of  castrate 
resistant  prostate  cancer.    The  association  between  steroid  hormone  receptor 
expression and NFκB activation has been of substantial interest in both prostate and 
breast cancers. Primary investigations of breast cancer cell lines and also of solid 
tumours  suggest  an  inverse  correlation  between  NFκB  activation  and  oestrogen 
receptor (ER) expression. However this correlation has not been found in all studies. 
Prominent constitutive NFκB has been observed in the prostate cancer cell lines PC 
3 and DU 145 which lack AR expression however, only very low levels of NFκB 
were seen in the AR positive cell line LNCaP (197). This data suggests that either 
the presence of AR actually inhibits NFκB activity in prostate cancer or alternatively 
that constitutive activation of NFκB may correlate with AR loss, which in turn may 
contribute to compensatory cellular changes, allowing cell survival and growth in 
the absence of AR activation. Chen et al, have observed markedly higher NFκB 
activity  in  an  androgen  independent  prostate  cancer  xenograft  model  than  in  its 
androgen  dependent  counterpart  (209).  Here  NFκB  activated  expression  of  AR 
regulated  gene  PSA.  This  suggests  that  NFκB  is  contributing  to  androgen 
independent prostate cancer cell growth in the absence of the AR signallingpathway. 
It  was  suggested  that  the  absence  of  PTEN  might  contribute  to  constitutive 69 
activation of NFκB induced by PI3K/Akt pathway. However no direct correlation 
has been observed in prostate cancer cell lines.  NFκB has been implicated with 
prostate cancer progression via two mechanisms, promotion of metastases via MMP 
9  expression  or  promotion  of  androgen  independence  via  an  as  yet  unknown 
mechanism.   
The signallingcascades described in brief highlight some of the many possibilities of 
the complex intermolecular signallingmechanisms that are believed to contribute to 
the progression of the castrate resistant disease.  As previously mentioned ligand 
independent  phosphorylation  of  the  AR  has  been  reported  to  enhance  AR 
transcription  in  cell  lines  and  there  is  now  unquestionable  evidence  that  AR 
signallingcontinues to play a critical role in many patients with castrate resistant 
disease.  The  PI3K  and  NFκB  cascades  have  both  been  implicated  in  castrate 
resistant disease and PI3K activity has been reported to influence NFκB signalling. 
However the precise role of the interaction of signallingcascades and the AR in the 
development of clinical castrate resistant disease is still poorly understood.  
 
1.9 Statement of research aims 
The research presented in this thesis investigated the role of the PI3K/Akt and NFκB 
cascades in the development and progression of castrate resistant prostate cancer. 
Using prostate tumours consisting of matched histological tissue specimens obtained 
before commencement of androgen deprivation therapy and after the development of 
castrate  resistant  disease,  the  members  of  the  PI3K  signallingcascade  were 
investigated at a genetic and protein expression level. This tested the hypothesis that 70 
genetic  alterations  lead  to  functional  consequences  in  the  terms  of  protein 
expression. It was speculated that increased protein expression of the components of 
this pathway are  linked to clinical parameters such as time to relapse, time to death 
from relapse and overall survival. As Akt is believed to be a key mediator in the 
development  of  castrate  resistance,  via  its  interaction  with  multiple 
signallingcascades,  the  association  between  the  PI3K/Akt  and  NFқB 
signallingcascades were investigated. The expression and activation levels of NFқB 
were determined in the clinical samples and in vitro studies investigated the effects 
of NFқB inhibition on cell proliferation and apoptosis.  
The protein expression of AR and phosphorylated AR at the Akt consensus site was 
also investigated in the clinical samples and correlated with clinical parameters. In 
vitro studies investigated the effect of PI3K inhibition and siRNA silencing on Akt 
and ARexpression in castrate resistant LNCaP cell lines. 
Ultimately  the  goal  of  this  research  was  to  further  our  understanding  of  the 
mechanisms that drive the development of resistance to anti androgen therapy in 
prostate cancer patients.  
 
Research Aims 
•  To determine if members of the PI3K cascade have gene amplifications or 
deletions in prostate cancer patients  
•  To determine the protein expression levels of members of the PI3K cascade 
in prostate cancer patients and to investigate if protein expression is related 
to patient outcome. 71 
•  To determine the protein expression levels of components of NFқB cascade 
in prostate cancer patients and investigate if protein expression is associated 
with patient outcome. 
•  To investigate the effect of NFқB inhibition on prostate cancer proliferation, 
apoptosis using matched hormone naïve and castrate resistant LNCaP cell 
lines. 
•  To determine the expression levels of AR and AR phosphorylated at the Akt 
consensus  site  in  prostate  cancer  patients  and  investigate  if  protein 
expression is associated with patient outcome. 
•  To determine the levels of activated Akt and AR in matched hormone naïve 
and  castrate  resistant  LNCaP  cell  lines  and  determine  if  these  mirror  the 
tissue observations. 
•  To investigate the effect of PI3K siRNA silencing and inhibition on Akt and 
AR expression in matched hormone naïve and castrate resistant LNCaP cell 
lines. 
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2.   Materials and Methods 
2.1. In- vitro studies 
2.1.1 Culturing of Prostate cancer cell lines 
 
Matched hormone sensitive LNCaP (lymph node metastasis) and castrate resistant 
LNCaP CR prostate cancer  cell lines were a kind gift from Professor  C Robson 
(Northern Institute for Cancer Research, Newcastle). LNCaP cells were routinely 
maintained in RPMI 1640 (Invitrogen, UK) containing phenol red and supplemented 
with 10% foetal calf serum (Invitrogen, UK), 2mM L glutamine (Invitrogen, UK), 
and  penicillin/streptomycin  (50  units/ml,  50 g/ml  (Invitrogen,  UK)).  These  cell 
lines  were  selected  because  they  are  androgen  responsive  and  is  an  androgen 
receptor expressing prostate cancer cell line. LNCaP CR cells have been developed 
using  parental  LNCaP  cells  as  a  model  of  hormone  resistant  prostate  cancer  by 
gradual  withdrawal  of  androgens  from  the  medium.  Castrate  resistant  cells  are 
defined  by  their  ability  to  survive  testosterone  depravation  by  castration  and  to 
sustain  androgen  receptor  activation  through  ligand  dependent  and  ligand 
independent  mechanisms.  These  cells  were  routinely  cultured  in  RPMI  1640 
supplemented with 10% charcoal stripped foetal calf serum (Invitrogen, UK) known 
to contain negligible amount of androgens, 2mM L glutamine (Invitrogen, UK), and 
penicillin/streptomycin (50 units/ml, 50 g/ml (Invitrogen, UK).   
Cells were grown in T 75 flasks (Gibco) and maintained in 5% CO2 at 37°C, with 
the medium changed twice weekly, as it is rapidly acidified.  
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2.1.2 Trypsinisation of cells 
 
Sub confluent  cultures  (70 80%)  were  routinely  passaged  1:6  using  trypsin 
(Invitrogen, UK) to prevent the cells becoming confluent and forming clumps. Used 
medium  was  removed  from  the  flasks  and  the  cells  washed  twice  with  warmed 
Phospho Buffered  Saline  (PBS)  (Invitrogen)  to  eliminate  traces  of  serum,  which 
includes  trypsin  inhibitors.  Cells  were  then  incubated  in  3  mls  of  trypsin  for  5 
minutes in 5% CO2, 37°C, in order to detach the cells from the flask. Once cells 
were no longer adherent, 3mls of RPMI was added to inactivate the trypsin. The 
cells were disaggregated from their clusters by gentle pipetting and seeded into new 
T  75 flasks containing 10mls of fresh RPMI. LNCaP cells grow slowly in clusters 
and were left for up to 48 hours to reattach.   
2.1.3 Freezing Cells 
 
Once cells are trypsinised, aliquots of the cells can be stored for future use. The cell 
suspension was transferred from the flask to a 15ml centrifuge tube and cell pellets 
were  collected  by  centrifugation  at  1200rpm  for  5  minutes.  The  medium  was 
removed and the pellet resuspended in 1ml of RPMI (supplemented 10% foetal calf 
serum  (Invitrogen,  UK),  2mM  L glutamine  (Invitrogen,  UK),  and 
penicillin/streptomycin  (50  units/ml,  50 g/ml  (Invitrogen,  UK))  and  10%DMSO 
which  serves  as  a  cyroprotectant.  The  cells  were  immediately  transferred  in  an 
alcohol bath (Mr Frosty, Sigma) to  80°C for 24 hours before being transferred to 
liquid nitrogen ( 180°C) for long term storage.  
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When  cell  aliquots  were  required,  they  were  removed  from  liquid  nitrogen  and 
warmed for 1 minute in a 37°C water bath before being promptly transferred to a 
flask containing 10mls of pre warmed RPMI. It was essential not to leave the cells 
defrosting longer than necessary, as DMSO is toxic.  
. 
2.1.4 Drug Treatments 
 
Extracellular stimulus was used to measure the phosphorylation status of several 
proteins  investigated  throughout  this  study  in  both  hormone  naive  and  castrate 
resistant  LNCaP cell lines. All drugs  were prepared in large enough volumes to 
provide enough for all time points and to ensure experimental equality. Details of all 
the drugs used are listed in Table 2.1 
 
•  Heregulin α ( α ( α ( α (Sigma) 
Heregulin α (HRG) is the ligand for HER3/4. Ligand binding to HER3 results in 
phosphorylation and dimerisation with HER2 and activation of the growth factor 
receptor  cascades.  Cell  lines  were  treated  with  10nM  HRG.  A  stock  solution  of 
1.42 M was made and stored at –20°C. Treatment time with HRG ranged from five 
minutes to three hours. 
 
•  Epidermal Growth Factor (Sigma) 
Binding  of  Epidermal  Growth  Factor  (EGF)  to  its  receptor  (EGFR)  results  in 
phosphorylation and, either homo  or hetero dimerisation, leading to the activation 
of  growth  factor  receptor  signallingcascades.  Cell  lines  were  treated  with  10nM 75 
EGF. A stock solution of 10 g/ml was prepared in PBS. Treatment time with EGF 
ranged from five to thirty minutes. 
 
•  Insulin like Growth factor 1 (Calbiochem) 
Binding of Insulin like growth factor 1 (IGF 1) to its receptor (IGFR 1), activates 
growth factor receptor signallingcascades. Both cell lines were treated with 10ng/ml. 
A stock solution of 10 g/ml was prepared in PBS, 1%BSA. Treatment time with 
IGF 1 ranged from five minutes to three hours. 
 
•  LY 294002 
LY294002 is a cell permeable compound that acts as a potent and selective inhibitor 
of  PI3K.  It  blocks  the  catalytic  activity  of  PI3K  without  affecting  other  kinases 
including  PKC,  PKA,  MAPK,  EGFR  and  Src.  A  stock  solution  of  3.25mM 
LY294002 was prepared in ethanol and treatment concentrations ranged from 10 to 
1000uM for 48 hours. 
 
•  Tumour necrosis factor Alpha (TNFα)  (Sigma)  
In response to inflammatory stimulation, macrophages or monocytes secrete TNFα 
that can induce apoptotic or necrotic cell death of certain tumour cell lines. TNFα is 
also capable of inducing cell proliferation and differentiation in many types of cells 
under  certain  circumstances.  Functional  characteristics  of  TNFα  are  executed 
through specific members of the TNF receptor (TNFR) superfamily. These receptors 
trigger  several  intracellular  signallingpathways,  most  importantly,  the  IKK  and 76 
MAPK  cascades,  which  govern  gene  expression  through  NFkB  and  AP 1 
transcription  factors,  respectively.  A  stock  solution  of  90ng/ml  was  prepared  in 
distilled water and cell lines were treated with 30ng/ml.  
 
•  NFқB inhibitor (2607 and 2070) 
Two NFкB inhibitors were used in this study: 2070 and 2607, and were supplied by 
Caledonian  Biotech.    These  inhibitors  were  designed  to  directly  block 
phosphorylation hence activation of NFқB. A stock solution of 2mg/ml of each was 
prepared in ethanol and treatment concentrations ranged from 0.10 to 100uM.  
 
•  Dihydrotestosterone (DHT) 
DHT binding to the AR results in AR phosphorylation, translocation to the nucleus 
and transcription of AR genes.  Cell lines were treated with 10nM DHT. A stock 
solution of 10 g/ml was prepared in DMSO. Treatment time with DHT ranged from 
five minutes to three hours. 
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Drug 
Molecular 
Weight 
(Daltons) 
Drug 
prepared 
in 
Stock 
Concentration 
Final 
Concentration 
Pre 
treatment 
Heregulin 
(HRG)  7000  PBS  1.42 M  10nM  NO 
Epidermal 
Growth 
Factor 
(EGF) 
6200  PBS  1.61mM  10nM  NO 
Insulin 
growth 
factor 
(IGF) 
7500  PBS  50 M  10ng/ml  NO 
LY 
294002 
 
307.4  Ethanol  3.25mM  20 M  YES 
2607   
500 
 
Ethanol  2mg/ml 
 
100 M 
NO 
 
2070  400  Ethanol  2mg/ml  100 M  NO 
TNFα  25,600  Water  90ng/ml  30ng/ml  NO 
DHT  290.44  DMSO  10nm  10nm  NO 
 
Table 2.1: Drug informations 
Details  of  all  the  drugs  used  throughout  the  course  of  this  study;  pre treatment 
involved exposure to drugs for 30 minutes prior to other treatments. 
 
2.1.5 Time course treatments of LNCaP and LNCaP CR 
 
Cell lines were grown in T 75 flasks until 80% confluent, the medium was removed 
and  the  cells  washed  in  warmed  PBS.  Then,  cells  were  incubated  in  serum  free 
RPMI overnight. The following day, medium was removed and the cells washed in 
warmed PBS in preparation for the appropriate drug treatment. The first time course 
treatment carried out was with 10nM HRG at five different times, 5, 15, 30, 60 and 
180  minutes;  all  treatments  were  performed  identically  and  in  duplicate. 78 
Additionally an untreated control (cells treated with serum free RPMI and PBS) was 
included as was a completely untreated control, LNCaP cells, that received nothing 
but serum free RPMI (without vehicle). Each flask was treated with 3mls of drug or 
control, ensuring that all cells were completely covered, and incubated at 37°C in 
5%  CO2  for  the  required  time.  The  drug  was  removed  from  the  flask  and  cells 
carefully rinsed twice, with ice cold PBS. It was important to remove as much of the 
PBS, using a pipette, as possible, as it can dilute the lysis buffer. Cells were then 
lysed  in  500 l  Phosphosafe  buffer  (Calbiochem)  and  1:100  Protease  inhibitor 
cocktail set 1 (Calbiochem) for 5 minutes on ice, and collected using a cell scraper 
(Gibco). The cell lysates were then transferred to an appropriately labelled 1.5ml 
eppindorff tube (Gibco) and stored on ice until all treatments were completed. All 
samples  were  centrifuged  at  14  000  rpm  at  4°c  for  15  minutes,  the  supernatant 
removed and subsequently stored at  70°C. This experiment was performed twice; 
therefore,  in  total  there  were  four  protein  samples  for  each  treatment  condition 
available for analysis. Time course treatments using EGF, IGF 1 and DHT were 
performed  identical  to  that  described  above.  TNFα  time  course  treatments  were 
carried out as above excluding the 180 minute time point. 
 2.1.6 Inhibition of PI3K using LY294002 
 
Cell lines were grown in T 75 flasks until 80% confluent, the medium was removed 
and the cells washed in warmed PBS. Subsequently, cells were incubated in serum 
free RPMI overnight. The following day, medium was removed and the cells washed 
in warmed PBS. This was followed by incubation in the presence or absence of 20 
uM  LY294002  for  30  minutes,  followed  by  stimulating  with  IGF 1  for  1  hour. 79 
Additionally  cells  were  treated  in  the  presence  or absence  of  IGF 1  for  an  hour 
without any inhibitor. Protein was extracted as previously described in section 2.1.5. 
 2.1.7 Inhibition of NFKB using 2607 and 2070 
 
Cell lines were grown in T 75 flasks until 80% confluent, the medium was removed 
and the cells washed in warmed PBS. Subsequently, cells were incubated in serum 
free RPMI overnight. The following day, medium was removed and the cells washed 
in warmed PBS. This was followed by incubation in the presence or absence of 2607 
or 2070 diluted in culture media at concentrations ranging from 0.1 uM to 100uM 
for 24 hours. Protein was extracted as previously described in section 2.1.5. 
2.1.8 Determination of protein samples 
 
The method used to determine protein concentration of the cell lysates was Bio 
Rad's  protein  assay,  which  was  based  on  the  Bradford  dye binding  procedure 
(Bradford  1976),  and  involves  a  colorimetric  assay  for  measuring  total  protein 
concentration. Protein standards were prepared using Bovine Serum Albumin (BSA) 
(Sigma). The BSA was supplied at a concentration of 2mg/ml, but for the purpose of 
this study it was diluted to 1mg/ml with dH2O. One reference and seven protein 
standards  were  prepared  in  disposable  cuvettes (Gibco)  in  triplicate  as  shown  in 
Table 2.2.   
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Volume of 1mg/ml BSA required (       l)  Volume of dH2O required (       l) 
0 (REFERENCE)  800 
1  799 
5  795 
10  790 
15  785 
20  780 
25  775 
50  750 
 
Table 2.2: Protein standards 
Samples  were  prepared  in  triplicate  for  a  low concentration  assay  in  disposable 
cuvettes (Gibco). 200 l of Bio Rad Protein Assay Reagent (Bio Rad) was added to 
the cuvette, followed by 795 l of dH2O. Then 5 l of protein sample was included to 
the  mix.  The  solution  was  thoroughly  mixed  with  a  pipette  to  ensure  even 
distribution of the protein for an accurate concentration reading. Once prepared the 
reference  and  standards  were  used  to  calibrate  the  spectrophotometer  (Bio Rad) 
Protein 595 assay programme.  
The optical density at 595nm (O.D. 595nm) was measured for the reference and the 
seven protein standards. The O.D 595 was then read for all the samples and the 
concentration of protein present  generated from the standards concentration. The 
spectrophotometer calculated the amount of protein ( g/ml) present, but the theory 
behind  it  involves  plotting  a  graph  of  absorbance  at  595nm  against  protein 
concentration  of  standards.  This  standard  curve  is  then  used  to  determine  the 
concentration of the protein present in the samples from its O.D. 595 value. The 
concentration ( g/ml) was calculated from a diluted protein sample (1:200). From 
this the final concentration in mg/ml was determined as follows: 
Protein reading (       g/ml) x 0.2 = Final protein concentration (mg/ml) 81 
Proteins were aliquotted into (100 l) samples and stored at  80°c until required. For 
western blotting 50 g of protein was used and the volume of sample required was 
calculated from the final concentration.  
 
2.2 Western blotting of protein samples 
Western  blotting  (immunoblotting)  was  used  to  verify  the  specificity  of  all 
antibodies and also to measure the levels of protein in samples obtained from the 
time course and inhibitor treatments. 
 
•  Preparation of SDS PAGE (Sodium Dodecyl Sulphate – PolyAcrylamide 
Gel Electrophoresis) gels 
Western  blots  were  carried  out  using  the  Bio Rad  Mini PROTEAN  3 
Electrophoresis System. For all the proteins analysed it was suitable to use 10% 
resolving gels, which were prepared as follows: 
 
Gels are formed from the polymerisation of the acrylamide and N N methylene bis 
acrylamide (bis). Bis acts as the cross linking agent for the gel, and the TEMED and 
APS are the catalysts for gel polymerisation. The separation of proteins within the 
Reagents  10% Gel 
40% Acrylamide/Bis Acrylamide 
(Sigma) 
12.49ml 
0.5M EDTA  330 l 
2M Tris, pH 8.9  8.35ml 
10% SDS  500 l 
dH2O  28.33ml 
10% APS  300  l 
TEMED  30 l 82 
gel is directed by the size of the pores within the gel, this is determined by the 
amount of acrylamide bis present. As the amount of acrylamide present increases, 
the pore size decreases. In general a higher percentage of resolving gels are used for 
smaller proteins, and lower percentage gels are more effective for separating larger 
proteins.  
A  gels  thickness  of  1.5mm  was  used  throughout  the  various  studies;  these  were 
produced using 1.5mm spacer plate. Once the gel solution was prepared, excluding 
the  TEMED  and  APS,  the  gel  plates  and  gel  casting  apparatus  were  assembled. 
Having correctly  assembled the plates, the TEMED and  APS were added to the 
resolving gel solution, using a plastic pastette the gel mix was poured in between the 
two glass plates, to a level that allowed for the stacking gel and comb to be added. A 
layer of isopropanol was applied to the top of the gel to remove any air bubbles and 
to  flatten  it  out  at  the  top.  The  resolving  gel  was  then  left  to  polymerise  for 
approximately one hour.  
Once set, the isopropanol was removed from the top of the resolving gel. At this 
stage the gel (wrapped in damp tissue and saran wrap) could be stored at 4°C until 
required. 
When required 4.5% stacking gel was prepared as follows: 
Reagents  4.5 % Gel 
40% Acrylamide/Bis Acrylamide  5.63ml 
0.5M EDTA  400 l 
1M Tris, pH 6.8  6.25ml 
10% SDS  500 l 
dH2O  37.22ml 
10% APS  30 l 
TEMED  10 l 
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Again,  the  TEMED  and  APS  were  the  last  two  reagents  to  be  added  to  the  gel 
solution. The stacking gel was then poured onto the resolving gel to fill the plate, the 
gel  comb  (15  well  combs)  was  then  inserted  and  the  gel  left  to  polymerise  for 
approximately 30 minutes.  
 
•  Protein denaturation 
To enable the primary antibody to recognise and bind to its epitope, it was necessary 
to denature the proteins. Denaturing the protein the gives the antibody easier access 
to the epitope and enables them to run more efficiently through the gels. Having 
previously  obtained  the  concentration  of  protein  within  each  sample,  the  50 g 
removed from each sample and transferred to a new Eppendorf tube. This was stored 
on ice, and 2X Laemmli's sample reducing buffer was added to each sample. This 
buffer consisted of: 
1.0ml 0.5M Tris HCl  
0.8ml Glycerol 
1.6ml 10% sodium dodecyl sulphate (SDS) 
0.4ml 2 Mercaptoethanol 
0.2ml Bromophenol Blue (0.05% w/v) 
4.0ml dH2O 
 
The samples were thoroughly mixed and then boiled at 100°C for four minutes. The 
molecular weight marker (Biotinylated Protein Ladder –Cell SignallingTechnology) 
that was used to determine the size of the detected protein was also boiled at 100°C 
for four minutes.  84 
The SDS within the sample buffer is a detergent, with a highly negative charge. It 
has a hydrophobic tail that binds to the proteins, causing them to become negatively 
charged. SDS also disrupts the tertiary structure of the protein, resulting in their 
unfolding. The 2 Mercaptoethanol prevents the reformation of disulphide bonds and 
helps maintain the protein in its denatured state. Boiling the samples also contributed 
to the denaturing of the proteins by unfolding them completely. Once boiled samples 
were immediately stored back on ice.  
•  Gel Electrophoresis 
The principle behind electrophoresis is that an electrical charge moves the proteins 
down the polyacrylamide gel. The proteins are negatively charged, due to the SDS 
and  they  are  attracted  towards  the  positive  anode.  The  pores  produced  by  the 
acrylamide result in smaller protein molecules travelling through the gel at a faster 
rate than the larger molecules; thus, they progress further down the gel. Therefore, 
proteins are separated by gel electrophoresis according to their molecular weight. 
Gels were placed into the electrode assembly in the mini buffer tank and combs were 
removed from gels. The wells were then rinsed and the tank filled with 1X running 
buffer (details in table 2.2). Denatured protein samples (50 g) and ladder (10 l) 
were then carefully loaded into the wells using a fine tipped pipette. It was important 
to prevent overspill between the wells. Once all samples were loaded the gel was run 
at 100V for approximately one hour.  
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•  Protein Transfer 
To allow protein detection by a primary antibody, the protein had to be transferred 
from the polyacrylamide gel to PVDF (polyvinylidene difluoride) membrane. Once 
the proteins had run sufficiently through the gel, proteins were transferred to the 
PVDF membrane (Biorad).  For optimal transfer, PVDF membrane was pre treated 
in  100%  methanol  for  five  minutes  before  being  soaked  in  1X  Transfer  Buffer 
(Details of which can be found in table 2.2.). Fibre pads and 3M Whatman paper 
were also soaked in transfer buffer. The gels were then carefully removed from the 
glass  plates  and  the  stacking  gel  was  discarded,  the  remaining  resolving  gel 
equilibrated, for approximately five minutes in transfer buffer. This step prevented 
the gel from shrinking during the transfer process.  
The transfer sandwich was then assembled. This comprised of a fibre pad, 3 squares 
of 3M Whatmann paper, gel, and PVDF membrane, 3 squares of 3M Whatmann 
paper and finally a fibre pad. This is shown below in Figure 2.1. 
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Figure 2.1: Schematic Representation of Western Blot Transfer Sandwich 
Schematic representation of the assembly of the transfer sandwich on the cassettes, 
the sandwich was comprised of fiber pads, 3M Whatmann paper, gel and PVDF 
membrane, all of which had been equilibrated in transfer buffer. 
 
While building the sandwich, it was important to make sure that there were no air 
bubbles  present;  this  would  prevent  efficient  transfer.  After  each  new  layer  was 
applied, air bubbles were removed by gently rolling a glass rod over the top surface. 
The assembled sandwich was then slotted into the electrode assembly and placed in 
the mini tank, which was filled with transfer buffer. To reduce the temperature of 
the buffer during the transfer process, the Bio Ice cooling unit was used. A magnetic 
stirrer  was  also  added  to  maintain  even  buffer  temperature  and  ion  distribution. 
Proteins  were  transferred  from  the  gel  (negative/cathode)  to  the  membrane 
(positive/anode) at 100 volts for one hour.  
Black side of cassette 
(Negative) 
Fiber Pad 
3 sheets of 3M Whatmann Paper 
Gel 
PVDF Membrane 
3 sheets of 3M Whatmann Paper 
Fiber Pad 
Clear side of cassette 
(Positive) 87 
•  Blocking of Membrane 
To prevent the primary antibodies from binding non specifically to the membrane 
and also to reduce background staining, it was necessary to block the membrane. 
This was achieved by incubating the membrane in 5% Non Fat Dry Milk (Marvel) 
blocking  solution,  prepared  in  TBS Tween  (TTBS)  for  one  hour  at  room 
temperature. This step and all future steps were performed on an orbital shaker. 
Buffer  Reagents 
10X Running Buffer  200mM Tris, 2M Glycine, 1% SDS 
(For 1X dilute in dH2O) 
10X Transfer Buffer  248mM Tris, 1.3M Glycine, 20% 
Methanol 
(For 1X dilute in dH2O) 
10X TBS  0.1M Tris/HCl, 1.5M NaCl, pH = 7.4 
(For 1X dilute in dH2O) 
0.001% TTBS  1000 l of Tween 20 per litre of 1X TBS 
Table 2.3: Buffers used in western blotting 
Details of the buffers and solutions used in western blotting 
 
•  Incubation of membrane with primary antibody 
Having  blocked  the  membrane,  the  following  step  was  incubation  in  primary 
antibody. All antibodies were prepared in 10mls of 5% Non Fat Dry Milk/TTBS 
solution, to further reduce non specific binding. Membranes were incubated with 
primary antibody overnight (approximately 18 hours) at 4°C.  
•  Incubation of membrane with secondary antibody 
Following incubation with primary antibody, the membrane was washed in TBST 
three times for 20 minutes, to remove any excess antibody. Detection of the protein 
of  interest  required  a  secondary  antibody  bound  to  either  biotin  or  an  enzyme 
conjugate, such as horseradish peroxidase (HRP), which was species specific to the 88 
primary antibody. The secondary antibodies used were HRP linked anti mouse IgG 
(Cell SignallingTechnology) anti rabbit IgG (Cell SignallingTechnology) and anti 
goat IgG (Dako). The anti mouse and anti goat antibodies were used at dilution of 
1:10,000 and the anti rabbit was used at a dilution of 1:2000. In addition a secondary 
antibody for the detection of the biotinylated ladder was required. For this the anti 
biotin HRP linked antibody (Cell SignallingTechnology) was used at a dilution of 
1:1000.  The  anti biotin  and  anti mouse/rabbit  /goat  secondaries  were  prepared 
together in 10mls of 5% Non Fat Dry Milk/TTBS solution and were incubated with 
the membranes for one hour at 37°C.  
 
•  Protein visualisation 
The final steps in the western blotting protocol involved detection of the protein of 
interest using a chemiluminescent method. Luminescence is the emission of light 
due to the dissipation of energy from a substance in an excited state. Horse radish 
peroxidase catalyzes oxidation of luminol, a chemiluminescent substrate, in alkaline 
conditions. Oxidation results in the luminol being in an excited state which then 
decays  to  ground  state  via  a  light  emitting  pathway.  For  this  method  ECL  plus 
(Amersham)  was  used.  The  principle  behind  this  is  that  horse radish  peroxidise, 
conjugated  to  the  secondary  antibody,  oxidises  the  ECL  Plus  chemiluminescent 
substrate  Lumigen  PS 3  Acridan,  which  produces  thousands  of  acridinium  ester 
intermediates  per  minute.  These  intermediates  then  react  with  the  peroxide  to 
produce a sustained, high intensity chemiluminescence with a maximum emission at 
430nm. This light is then detected on autoradiography film. Following incubation 
with the secondary antibody, membranes were washed three times in TTBS for 20 89 
minutes. While the membranes were washing, the ECL plus reagents were decanted 
into a universal and warmed to room temperature. Once the reagents had warmed, 
solution A and solution B were mixed in a ratio of 40:1; 3mls of solution was an 
adequate  amount  per  membrane.  When  using  the  ECL  reagents  all  steps  were 
performed in semi darkness. Membranes were placed protein side up on a sheet of 
saran wrap. The ECL solution was pipetted onto the membrane ensuring complete 
coverage.  The  membrane  was  incubated  with  the  reagents  for  five  minutes,  and 
excess solution was then removed and the membrane transferred to a fresh piece of 
saran wrap, which it was then enveloped in. Lastly the membrane was transferred to 
a  film  cassette  where  it  was  exposed  to  autoradiography  film  for  various  times. 
Generally the incubation times were 30 seconds and 1, 5, 15 minutes. The film was 
then developed using a Kodack X OMAT x ray processor and both the marker and 
protein bands visualised. 
•  Stripping Membranes 
To  confirm  equal  sample  loading,  primary  antibody  was  removed  from  probed 
membranes using 10X Stripping buffer (Chemicon). The membrane was washed in 
TBST 3 times for 10 minutes, to remove any excess antibody. Membranes were 
incubated in 20mls of stripping buffer (diluted 1:10 in dH2o) at 37°C for 20 minutes, 
subsequently, membranes were blocked in 5% Non Fat Dry Milk/TTBS and then 
probed with anti αTubulin HRP linked antibody (1:1 000 AbCam) to confirm equal 
protein loading. 
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2. 3 ELISA  
 
2.3.1 pAKT ser 473 ELISA 
 
The phosphoELISA™ kit (Biosource, UK) was used to assess Akt activity in both 
cell lines. This assay is a solid phase Sandwich Enzyme linked Immuno Sorbent 
Assay (ELISA) and begins with a monoclonal antibody specific for Akt (regardless 
of  phosphorylation  state)  coated  onto  the  wells  of  microtitre  strips.  Samples, 
including a standard containing Akt, control specimens, and unknowns, are added to 
these wells. During the first incubation, the protein antigen binds to the immobilized 
(capture)  antibody.  After  washing,  a  rabbit  antibody  specific  for  total  protein  or 
protein phosphorylated at a specific residue is added to the wells. During the second 
incubation,  this  antibody  serves  as  a  detection  antibody  by  binding  to  the 
immobilized protein captured during the first incubation. After removal of excess 
detection antibody, a horseradish peroxidase–labelled anti–rabbit IgG antibody (anti 
rabbit IgG HRP) is added. This binds to the detection antibody to complete the four 
member sandwich. After a third incubation and washing to remove all the excess 
anti rabbit IgG HRP, a substrate solution is added, which is acted upon by the bound 
enzyme  to  produce  colour.  The  intensity  of  this  coloured  product  is  directly 
proportional to the concentration of total or phosphorylated protein present in the 
original specimen.  
 
ELISA was performed  according to the manufacturer’s instructions.  In brief; the 
Protein  standards  were  prepared  by  reconstituting  the  standard  1  with  Standard 91 
diluent  buffer  and  left  at  room  temperature  for  ten  minutes,  this  was  to  ensure 
complete reconstitution. The standards were then set up as follows. 
Standard:  Add  Into 
100 Units/ ml   Prepare as described 
50 Units/ ml  250  l of 100 Units/ml std  250  l of Diluent buffer 
25 Units/ ml   250  l of 50 Units/ml std  250  l of Diluent buffer 
12.5 Units/ ml   250  l of 25 Units/ml std  250  l of Diluent buffer 
6.25 Units/ ml   250  l of 12.5 Units/ml std  250  l of Diluent buffer 
3.12 Units/ ml   250  l of 6.25 Units/ml std  250  l of Diluent buffer 
1.6 Units/ ml   250  l of 3.12 Units/ml std  250  l of Diluent buffer 
0  250  l of Diluent buffer  Empty tube 
 
Firstly, 100  l of the standard diluent buffer was added to the blank wells to zero the 
wells.  EGF  treated  LNCaP  cell  lysates  as  described  in  section  2.1.5  were  then 
diluted 1:10 in standard diluent buffer.100  l of standards and the prepared samples 
were placed in the appropriate wells, this was then incubated for two hours at room 
temperature. The solution was then carefully removed from the wells and washed 
four times with washing buffer. 100  l of anti Akt (detection antibody) solution was 
added into each well (excluding the chromagen blanks). The plate was then tapped 
gently on the side to carefully mix the sample and antibody and incubated for one 
hour at room temperature. The solution was carefully removed and wells washed 
four times with washing buffer. Following this, 100  l anti rabbit IgG HRP working 
solution was added to each well (except the chromagen blanks) and incubated for 
thirty  minutes  at  room  temperature.  The  antibody  was  then  removed  and  wells 
washed  four  times  with  washing  buffer.  Subsequently  100   l  of  Stabilised 
Chromagen was added to each well and the plate incubated for thirty minutes in the 
dark, at room temperature. Then 100  l of Stop Solution was added to each well and 92 
the side of the plate tapped gently to ensure thorough mixing and even distribution 
of the protein for an accurate concentration reading. This solution changes the colour 
from  blue  to  yellow.  The  absorbance  was  measured  using  a  96  well  microplate 
reader at 450 nm having blanked the reader against a chromagen blank composed of 
Stabilised  Chromagen  and  Stop  Solution.    Using  Excel  the  absorbance  of  the 
standard against the standard concentration was plotted. The values obtained for the 
samples were multiplied by the dilution factor (10) to correct for the dilution. 
2.3.2 Histone/DNA ELISA for detection of apoptosis 
The Cell Death Detection ELISA Kit (Roche, USA) was used to detect apoptosis in 
both prostate cancer cell lines treated with increasing concentrations of 2607 and 
2070, diluted in culture media for 24 and 72 hours. This is a one step sandwich 
ELISA for relative quantification of histone complexed DNA fragments (mono  and 
oligonucleosomes)  from  the  cytoplasm  of  cells  after  the  induction  of  apoptosis. 
LNCaP and LNCaP CR cells were seeded 5x10
3 cells (100  l) per well and cultured 
for 24 hours followed by incubation  for either 24 or 72 hours with 1, 10 and 50  M 
of  2607  or  2070,  diluted  in  culture  media.  After  the  incubation,  the  cells  were 
pelleted  by  centrifugation  at  200xg  for  10  minutes  at  room  temperature  and  the 
supernatant was discarded. The cells were then resuspended with 100  l of lysis 
buffer and incubated for thirty minutes at room temperature. After lysis, the cells 
were  collected  by  centrifugation  at  200x  g  and  20   l  of  the  supernatant  was 
transferred to a streptavadin coated microtiter plate.  100  l of Immunoreagent (two 
monoclonal  antibodies,  antihistone  (biotin labeled)  and  anti DNA  (peroxidase 
conjugated)  was  added  to  the  wells  and  incubated  at  room  temperature  for  two 93 
hours. The immunoreagent was  carefully removed and wells washed three times 
with  washing  buffer  to  remove  cell  components  that  were  not  immunoreactive. 
Following this samples were incubated with peroxidase substrate for fifteen minutes 
at room temperature and absorbance of the samples was measured using a 96 well 
microplate reader at 405 nm.  
 
2.4 Cell proliferation assay 
 
 Proliferation  was  assessed  using  the  WST 1  (Water  Soluble  Tetrazolium  Salts) 
assay (Millipore, UK). Proliferation is based on the cleavage of the tetrazolium salt 
WST 1  (water  soluble  tetrazolium  salt,  in  the  presence  of  1 methoxy  PMS)  to 
formazan  by  cellular  mitochondrial  dehydrogenases.  Expansion  of  viable  cell 
numbers results in an increase in activity of the mitochondrial dehydrogenases in the 
sample, corresponding to an increase in formazan dye metabolism. The formazan 
dye produced by the viable cells is measured at an absorbance of 440 nm using a 
standard multiwell spectrophotometer. 
Cells were seeded in 96 well plates at a density 5x103 cells (100  L) per well in 
standard culture media. The assay was performed at 48, 72 and 96 hours by adding 
10  L of WST 1 reagent prior diluted in Electro Coupling Solution (ECS) to each 
well. The optical absorbance level was measured after 2 hours incubation at 370C, 
(this time point was determined in previous studies performed within our group) 
using a 96 well microplate reader at 450 nm with reference wavelength 600 nm. 
Each experiment was repeated three times and each condition was done in triplicate.  
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2.4.1 The effect of PI3K/Akt on proliferation 
To elucidate the role of PI3K/Akt cascade in regulating   proliferation, LNCaP cells 
were seeded in 96 well plates at 5x10
3 cells (100  L) per well and cultured for 24 
hours followed by incubation with 30 uM, 100 uM, 300 uM and 1000 uM of LY 
294002, diluted in culture media for 72 hours. WST assay was performed at 48 and 
72 hours as described in section 2.1.8. 
2.4.2 The effect of NFKB on proliferation 
 
To elucidate the role of NFKB in regulating proliferation, LNCaP cells were seeded 
in  a  96  well  plate,  at  5x10
3  cells  (100   L)  per  well  and  cultured  for  24  hours 
followed by incubation with 1 uM , 10 uM  and 50 uM of 2607 and 2070, diluted in 
culture media for 48 hours. WST assay was performed at 48 hours as described in 
section 2.1.8. 
 
 2.4.3 Statistical analysis for cell line studies 
All statistical analysis was performed using the SPSS version 15 for Windows. To 
assess if the novel NFкB inhibitors were sufficient to inhibit proliferation (WST) 
and  stimulate  apoptosis  (cell  death  ELISA)  the  Dunnets  and  LSD  tests  were 
performed. This compares values of untreated and treated samples. A value of p < 
0.05 was considered statistically significant. 
 
2.5 siRNA Knock down of PI3K 
LNCaP CR cells were transfected with the Cell Line Nucleofector® Kit R, Program 
T 009 as described by manufacturer (Lonza, Cologne, AG). Briefly, 8 well chamber 95 
slides were filled with 0.5mls of RPMI supplemented with heat inactivated foetal 
calf serum (10%) and 2mM L glutamine, (penicillin/streptomycin was omitted to 
allow the cell membrane to recover after transfection). Chamber slides were then 
placed in a humidified 37°C/5% CO2 incubator to equilibrate. 70% confluent cells 
were  harvested  by  trypsinization  (section  2.1.2)  and  cells  were  counted  using  a 
haemocytometer. 1x10
6 cells per sample were centrifuged at 1000xg for 10 minutes 
at room temperature and supernatant completely removed. The cell pellets were then 
resuspended  in  100   l  room temperature  Nucleofector®  Solution  and  combined 
with 300 nM PI3K siRNA SMARTpool or nonspecific siRNA pool (Dharmacon, 
Lafayette,  CO,  USA).  Samples  were  then  transferred to  cuvettes  and  transfected 
using Nucleofector® Program T 009 (Lonza). 400  l of warmed culture medium 
was  added  to  each  cuvette  and  50   l  of  cells  were  gently  transferred  into  the 
prepared 8 well chamber slide to give a final cell number of 5 x10
4 cells per well .  
The cells were allowed to settle for 24 hours before the medium was replaced with 
RPMI  supplemented  with  heat inactivated  foetal  calf  serum  (10%),  2mM  L 
glutamine and penicillin/streptomycin (50 units/ml, 50 g/ml) for another 48 hours. 
The cells were analysed 72 hours post siRNA transfection by Immunofluorescence 
(IF).  
 
2.6 Immunofluoresence (IF) 
Immunofluorescence (IF) is a method that allows the detection of a specific protein 
or antigen in cells or tissue sections by fluorescent visualisation. There are two types 
of IF direct and indirect. Direct IF requires using a primary antibody labelled with 96 
fluorescent  dye,  whereas  the  indirect  approach  involves  the  use  of  a  secondary 
antibody  labelled  with  a  fluorescent  marker  capable  of  binding  to  the  primary 
antibody which is bound to the antigen. The protein of interest is then visualised 
using a fluorescent microscope. The indirect method was used to investigate the 
expression of proteins in prostate cancer cells following PI3K siRNA knockdown as 
described in section 2.5. Following knockdown cells were washed twice with ice 
cold PBS, before being fixed to the culture slides by incubation in ice cold methanol 
(500 l of methanol per well) for three minutes. Excess methanol was removed by 
washing  the  cells  three  times  in  dH20  for  five  minutes.  To  reduce  non specific 
binding of the antibody, cells were incubated in 500 l of 1.5% normal horse serum 
(Vector Laboratories) in antibody diluent (DAKO) for twenty minutes. As of this 
point all steps were performed on an orbital shaker and at room temperature. Cells 
were incubated with the appropriate primary antibody for 1 hour (100 l of antibody 
per well) before being washed three times with TBS for ten minutes. Following this, 
cells  were  incubated  with  either  100 l  biotinylated  mouse  or  rabbit  secondary 
antibody (3 g/ml in antibody diluent) (Vector Laboratories) for thirty minutes. Cells 
were again washed three times with TBS for ten minutes, before being treated with 
100 l of Fluorescein Avidin D (diluted 1:100 in TBS) (Vector Laboratories) for 
thirty minutes. Once the cells were treated with the fluorescent protein, slides were 
covered  in  foil  and  all  future  steps  performed  in  semi darkness,  to  prevent  the 
fluorescence from fading. Finally cells were washed with TBS three times for ten 
minutes.  At  this  stage  culture  slides  were  mounted  onto  coverslips,  using 
Vectashield  mounting  media  with  4' 6 Diamidino 2 phenylindole  (DAPI)  (635 l 97 
mountant media : 65 l mountant media with DAPI )(Vector Laboratories). DAPI 
stains  nuclei  specifically,  with  little  or  no  cytoplasmic  labelling.  The  protein  of 
interest was then visualised using a fluorescent microscope with either a DAPI or 
FITC filter.  
 
2.7 Patients 
 
Sixty eight patients with matched hormone naive and castrate resistant tumour pairs 
were  retrospectively  selected  for  analysis.  All  tumours  had  patient  identification 
removed, including block number and hospital number and were coded to make the 
database anonymous. Ethical approval was obtained from the Multicentre Research 
Ethics Committee for Scotland (MREC/01/0/36) and  Local Research and Ethical 
Committees. Patients were only selected for analysis if they initially responded to 
hormone treatment (in the form of subcapsular bilateral orchidectomy or maximum 
androgen blockade), but subsequently relapsed (two consecutive rises in PSA greater 
than  10%)  and  had  a  pre   and  post  castrate  resistant  tissue  sample  available  for 
analysis.  The  database  used  for  the  study  consisted  of  matched  pairs  of  tissue 
obtained  sequentially  from  patients  before  androgen  deprivation  therapy  and 
following  the  development  of  castrate  resistant  prostate  cancer.  These  sections 
originated  from  either  a  transurethral  resection  of  the  prostate  (TURP)  or  from 
diagnostic transrectal ultrasound (TRUS) biopsies. Following the development of 
biochemical relapse, castrate resistant tissue was obtained from palliative TURP, 
carried out to relieve clinical outflow symptoms.  
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2.8 Fluorescence in situ hybridisation (FISH) 
 
Fluorescence In Situ Hybridisation is a method that uses fluorescently labelled DNA 
probes to visualise chromosomal or genetic abnormalities. FISH probes are single 
stranded  DNA  that  are  able  to  bind  to  the  complimentary  DNA  strand  on  the 
chromosome/gene of interest and consequently allow the fluorescence detection of 
the chromosome/gene. 
Probes  were  provided  by  Dako  A/S  to  investigate  genetic  changes  (gene 
amplifications and deletions) of PIK3CA (p110 catalytic subunit of PI3K), PTEN, 
Akt 1 3 and mTOR.  FISH was performed on 5  m, archival formalin fixed; paraffin 
embedded  prostate  tumour  tissue  arrays  (TMA’s;  4  cores  from  each  patient  for 
prostate carcinomas). The probe mix consisted of a mixture of Texas Red labelled 
DNA cosmid clones covering the sequence of PIK3CA (p110 catalytic subunit of 
PI3K), PTEN, AKT1, AKT2, AKT3 or mTOR genes and a fluorescein isothiocyanate 
(FITC) labelled  chromosome  specific  reference  for  determining  numerical  gene 
aberration.  Specificity of both genetic and reference probes was tested by restriction 
analysis. Localization of the probe mix was validated by hybridisation to metaphase 
spreads of normal cells which showed hybridisation to all associated chromosomes 
(all performed by Dako A/S before sending the probes).  FISH was performed using 
a Histology FISH accessory kit (Dako Denmark A/S, Glostrup, Denmark) according 
to the manufacturer’s instructions but with minor modifications. In brief slides were 
incubated for 1 hour at 56
oC, dewaxed and re hydrated through graded alcohols.  
Slides  were  rinsed  twice  in  wash  buffer  and  then  incubated  for  10  min  in  pre 
treatment buffer at 96
oC, followed by 3 min incubation at room temperature in wash 99 
buffer.  Slides were then incubated in Pepsin for 26 mins at 25
oC, followed by 3 min 
incubation at room temperature in wash buffer and then incubated for 10 minutes in 
10% formalin.  The slides were then washed, dehydrated and air dried. Ten  l probe 
mix was applied, the slide mounted and sealed with rubber cement. The probe and 
target  DNA  were  denatured  at  82°C  for  22  minutes  and  the  tissue  incubated 
overnight  at  45°C  in  a  humidified  hybridizer  (Dako  Denmark  A/S,  Glostrup, 
Denmark). After washing in stringent wash buffer for 10 minutes at 65°C, the tissue 
was dehydrated, air dried and the slide mounted using vectasheild mounting media 
with  0.5   g/ml  4.6 diamindino 2  phenylindole  (DAPI)  (135 l  Vectasheild  with 
DAPI:565 l Vectasheild) (Vector Laboratories). Signals corresponding to both gene 
and chromosome were visualized using a fluorescent microscope. 
 2.8.1 FISH Scoring  
Gene amplification status was determined in 20 nuclei for each TMA core as the 
ratio of total number of red signals for the gene of interest probes over the total 
number  of  green  signals  for  the  chromosome  reference  probes  (chromosome  3 
(PI3KCA), 10 (PTEN), 14 (AKT1), 19 (AKT2), 1 (AKT3) and 1 (mTOR)). A total of 4 
cores from each patient was analysed and the gene/chromosome ratio was calculated 
separately  for  each  core.  A  tumour  was  considered  amplified  if  the 
gene/chromosome  ratio  in  at  least  one  core  was  equal  to  or  more  than  1.5  and 
deleted if the gene/chromosome ratio in at least one core was below 0.8(210). 
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Borderline  cases  (cases  with  gene/chromosome  ratio  between  0.70  and  0.90  and 
between  1.8  and  2.2)  and  10%  of  all  cases  were  scored  independently  by  two 
observers. Gene and chromosome copy number was addressed for each tumour. A 
tumour was defined as disomic when the mean chromosome copy number (MCCN) 
(mean number of chromosome signals per counted cancer cell) was between 1.35 – 
1.85  (211).  When  the  MCCN  was  below  1.35  or  above  1.85  the  tumour  was 
regarded  as  aneusomic  as  previously  defined  (211).  I  am  indebted  to  Dr  Tove 
Kirkegaard who carried out the PI3KCa and Akt 1 3 FISH. 
  
2.9 Immunohistochemistry IHC)  
 
Immunohistochemistry is a method that allows for the detection of a cellular protein 
or other antigen within cells and tissues using an antibody specific for the desired 
antigen. The simplest immunohistochemical methods attach the marker directly to 
the primary antibody.  In general, this direct immunohistochemical method does not 
have  very  high  sensitivity.    An  alternative  more  sensitive  method  is  indirect 
immunohistochemistry.  This  involves  using  a  second  or  “secondary”  antibody, 
labelled with either a visible marker (fluorochrome) or an enzyme that binds to the 
primary  antibody  bound  to  the  antigen.  This  indirect  approach  generates  an 
amplified signal. The method for this study was the Envision system (DAKO) that 
involves dextran polymer technology. Dako Envision detection reagent consists of a 
dextran  backbone  to  which  a  large  number  of  peroxidase  (HRP)  molecules  and 
secondary antibody molecules have been coupled.  A unique chemistry is used for 
the coupling reaction, which permits the binding of up to 100 HRP molecules and up 101 
to  20  antibody  molecules  per  backbone.  The  secondary  antibody  coupled  to  the 
dextran backbone has been raised in goats.  It reacts equally well with rabbit and 
mouse  immunoglobulins.    Following  incubation  with  the  Envision,  the  tissue  is 
incubated  with  a  substrate  solution  that  consists  of  diaminobenzidine  (DAB) 
chromagen and hydrogen peroxide.  The HRP molecules on the Envision interact 
with the substrate solution to produce a crisp brown end product at the site of the 
target  antigen/protein,  which  can  be  viewed  using  a  light  microscope. 
Immunohistochemistry involves the following steps 
 
•  Tissue preparation  
All  IHC  was  performed  on  5 m,  archival  formalin fixed,  paraffin embedded 
prostate  tumour  sections.  Sections  were  dewaxed  in  xylene  (2x4  minutes)  and 
rehydrated through graded alcohol (100 %( 2x2minutes), 90 %( 1x2minutes), 70 %( 
1x2minutes)) washes.  
 
•  Antigen Retrieval  
After formalin fixation and paraffin embedding of tissues, many antibodies react 
only weakly or not at all with their antigen.  This is due to the fact that solvents, heat 
and  fixatives  can  mask  the  antigen  site.  Formation  of  methylene  bridges  during 
fixation, which cross link proteins, mask antigenic sites therefore, it was necessary 
to include an antigen retrieval step, to break the protein cross links and expose the 
antigenic  binding  site,  in  order  to  optimise  immunohistochemical  staining.  Two 
different  heat  mediated  methods  of  antigen  retrieval  were  used  for  the  antigens 
studied. The first involved incubating the tissue sections under pressure in 1L of TE 102 
buffer (1mM EDTA (Sigma), 5mM Tris (VWR), pH 8.0) or 1L Antigen Unmasking 
Solution (pH 6, 1:100 (Vector)) for five minutes. The alternative method incubated 
tissue  sections  for  twenty  minutes  at  96°C  in  a  water  bath  in  100ml  Antigen 
Unmasking Solution (pH 6, 1:100 (Vector)), or Tris EDTA buffer (10mM EDTA 
(Sigma), 0.25mM Tris (VWR)) pH 9. All antigen retrieval steps were followed by a 
twenty minute cool down period. 
 
•  Reduction of background staining:   Blocking steps 
Peroxidase  reacts  with  diaminobenzidine,  therefore  the  presence  of  endogenous 
peroxidase  activity  in  tissues  is  a  common  problem  in  IHC  as  it  is  a  cause  of 
background staining. Endogenous peroxidase activity was blocked by incubating the 
slides in 3% hydrogen peroxide (H2O2) (VWR) for ten minutes, followed by a wash 
in water. A further cause of background staining is the formation of hydrophobic 
bonds between immunoglobulins and tissue proteins that results in the primary and 
secondary antibodies binding non specifically to the tissue section rather than just 
the  target  antigen.  To  reduce  this  non specific  binding,  tissue  sections  were 
incubated in 5% normal horse serum (Vector Laboratories) in TBS buffer (0.1M 
Tris/HCl, 1.5M NaCl, pH 7.4) for twenty minutes. 
 
•  Incubation with Primary Antibody 
Antibody  dilutions,  incubation  times  and  temperature  were  established  for  each 
protein  investigated.  All  antibodies  were  diluted  to  the  desired  concentration  in 
antibody diluent (DAKO). For each, a dilution series was performed, investigating 103 
various  antibody  titrations,  incubation  times  and  temperatures,  to  establish  the 
optimal conditions in which to achieve the highest quality of staining, i.e. strongest 
specific antigen staining with the lowest non specific background. It was crucial to 
have  both  a  positive  and  negative  control  each  time  IHC  was  performed.  The 
positive  control  confirmed  that  the  chosen  IHC  method  was  working  while  the 
negative  control  checked  the  specificity  of  the  antibody  involved.  Tonsil  tissue, 
placenta tissue or prostate tissues previously shown to have strong expression of the 
desired antigen were incubated with the appropriate antibody and used as positive 
controls. The same tissues were used for negative controls by treating them with a 
negative isotype matched control reagent (DAKO).  
 
•  Incubation with Secondary Antibody 
Following incubation with antibody or negative control, the slides were thoroughly 
washed in TBS buffer twice for five minutes. The Envision detection method was 
used for all antigens. The slides were incubated with Envision for thirty minutes then 
washed twice for five minutes in TBS 
 
•  Detection & Visualisation 
The  chromagen  used  for  staining  the  tissue  sections  was  3,3’ diaminobenzidine 
(DAB) –(5ml distilled water (dH2O), 2 drops of buffer solution, 4 drops of DAB 
stock solution, and 2 drops of Hydrogen Peroxidase solution  Vector Laboratories). 
Slides were incubated with DAB for five to ten minutes to allow brown staining to 
develop and were then washed in running water for ten minutes.  
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•  Counterstaining 
Tissue  sections  were  counterstained  with  haematoxylin  and  Scots  Tap  Water 
Substitute (S.T.W.S). Slides were immersed in the haematoxylin for approximately 
thirty seconds, until a red colour was produced in the tissue section. Following this 
slides were then submerged in S.T.W.S for another thirty seconds, to produce a blue 
colour,  in  contrast  to  the  brown  positive  staining of  the  antigen.    The  last  steps 
involved dehydrating the tissues through a series of alcohol washes: (70% (1x1min), 
90% (1x1min), 100 %( 2x1min)) and xylene (2x1min), and then mounting the slides 
onto coverslips using DPX mountant (VWR) (Dibutyl Phtalate containing Xylene).   
 
2.9.1 Histoscore 
Staining was scored blind by two independent  observers  (Myself and  Dr Joanne 
Edwards) using a semi quantitative weighted histoscore method (212) also known as 
the Hscore system (213). Histoscores were calculated using the following formula: 0 
x % negative tumour cells + 1 x the % of cells staining weakly positive + 2x the % 
of cells staining moderately positive + 3 x the % of cells staining strongly positive. 
The histoscore ranged from a minimum of zero to a maximum of 300. Results were 
considered discordant if the histoscores differed by more than 50. These cases were 
re evaluated by both observers. Also, both intra (variation in individual scoring) and 
inter (  variation  between  two  observers)  class  correlation  coefficients  were 
calculated  Agreement was considered excellent if  the ICCC value was > 0.7, an 
ICCC  of  1  indicates  identical  score  (212).  The  mean  of  the  two  observer’s 
histoscores was used for analysis. Changes in protein expression staining between 105 
hormone naive and castrate resistant cases were defined as an increase or decrease 
out with the 95% confidence interval for the difference in inter observer variation 
(i.e.  the  mean  difference  between  the  histoscore  that  each  observer  assigns  for 
protein expression plus or minus 2 standard deviations) (102). 
2.9.2 Statistical Analysis for Immunohistochemistry Studies 
All statistical analysis was performed using the SPSS version 15 for Windows. Basic 
descriptive statistics were performed to calculate the frequencies, mean, median and 
inter quartile ranges for the histoscore for each protein investigated. These values 
were then used to establish appropriate cut off points to define tumours as either low 
or high expressers of the desired protein. 
 Wilcoxon  signed  Rank  tests  were  used  to  compare  protein  expression  between 
hormone  naive  prostate  cancer  and  castrate  resistant  prostate  cancer  tumours. 
Correlations between protein expression levels in various sub cellular compartments 
and associations between the expressions of different proteins were calculated using 
the Spearman’s Rank Correlation Test.  
Kaplan Meier life table analysis and Cox’s multiple regression (multivariate survival 
analysis) were performed to estimate differences in prostate cancer related survival, 
in terms of time to biochemical relapse, time to death from relapse, disease specific 
death and overall survival. Multivariate analysis combined the biological marker of 
interest with tumour grade at diagnosis, tumour grade at relapse (Gleason score), 
PSA at diagnosis, PSA at relapse, presence of metastasis at diagnosis, presence of 
metastasis at relapse and age  to establish if it was independent of these known 
prognostic markers in influencing patient outcome.  106 
For survival analysis patients were split into groups, those whose tumours expressed 
high levels of protein (above the median) and those who expressed low levels of 
protein (below the median). To establish the relative risk of a patient relapsing or 
dying as a result of either high or low levels of a particular protein in their tumour 
hazard ratios (HR) were calculated using Cox regression analysis. A value of p < 
0.05 was considered statistically significant. 
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3.   The role of the PI3K/Akt cascade in the progression to 
CRPC 
 
3.1 Introduction 
Activation of the PI3K/Akt cascade is reported to play a role in the development and 
progression of prostate cancer. In order to investigate the clinical significance of this 
cascade in the progression to castrate resistant disease paired hormone naïve and 
castrate  resistant  tumours  and  cell  lines  were  utilized.  As  deregulation  of  this 
cascade  can occur through  an  array of processes, members of this cascade were 
investigated  at  the  genetic  level  using  FISH  and  protein  expression  levels  were 
determined using IHC. 
  
3.2 Expression and activation of Akt in LNCaP cell lines 
 
To  establish  the  phosphorylation  hence  activation  levels  of  Akt  in  the  matched 
hormone  sensitive  and  castrate  resistant  prostate  cancer  cell  lines  ELISA  and 
western blotting were carried out.  Both cell lines were incubated with or without 
EGF for 15 minutes (Figures 3.1 and Figure 3.2). It is evident that Phosphorylation 
of Akt at serine 473 in LNCaP CR is notably higher in untreated cells as compared 
to LNCaP cells and is also significantly higher when stimulated with EGF for fifteen 
minutes. Phosphorylation of Akt in LNCaP cells increases to a similar level to the 
basal levels in LNCaP CR after fifteen minutes of EGF stimulation (Figure 3.1). 
LNCaP cells that are hormone sensitive still depend on androgens for growth and 
survival, these results are indicative that in the presence of androgen the activity of 108 
the PI3K/Akt is lower than that of castrate resistant LNCaP suggesting androgens 
become less important factors in tumour cell growth in late stage prostate cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Akt expression LNCaP cell lines.  
Western blot analysis of LNCaP and LNCaP CR cells both untreated and treated 
with10nM EGF for fifteen minutes. Tubulin confirms equal loading of samples. 
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Figure 3.2 EGF induced Akt expression in LNCaP cell lines 
ELISA demonstrating Akt phosphorylated at serine 473 is up regulated in castrate 
resistant  LNCaP  prostate  cells  compared  to  the  hormone  naïve  LNCaP  prostate 
cells when untreated or treated with 10nm EGF. 
 
3.2.1 Stimulation of Akt phosphorylation 
Current  models  suggest  that  phosphatydilinositol 3,  4,  5  triphopshates  produced 
upon growth factor stimulation recruit Akt to the plasma membrane by binding to its 
N terminal pleckstrin homology (PH) domain. To reflect the vigorous recruitment 
and  activation  of  PI3K  by  growth  factor  pathways  Hrg  and  IGF 1  time  course 
treatments  were  carried  out.  Treatment  with  10nM  Hrg  appears  to  induce  Akt 
phosphorylation in a time dependent manner (Figure 3.3).  In the hormone naïve 
LNCaP the basal levels of Phosphorylated Akt are notably higher in the untreated 
sample (grown in serum free medium) and expression of phosphorylated Akt serine 
473 appears to be expressed at a lower level up until the three hour time point. This 110 
data  suggests  that  stimulation  with  Hrg  alone  for  a  shorter  time  period  is  not 
sufficient in enhancing PI3K activity in comparison to overnight serum withdrawal 
in hormone sensitive prostate cancer cells.  In the castrate resistant cells however the 
expression of phosphorylated Akt is reduced for a brief period between the five and 
thirty minute time points which further increases as the time progresses to the three 
hour time point.  
 
 
 
 
 
Figure 3.3 Hrg stimulation of Akt phosphorylation 
Western blot was performed on 50ug of extracts from LNCaP and LNCaP CR cells 
treated  or  untreated  with  10nM  HRG  and  probed  for  pAkt  (ser  473)  (60kd) 
expression.  Lane  1  LNCaP  unstimulated,  2  LNCaP CRunstimulated.Lanes3 12 
loaded  LNCaP,  LNCaP CRfor5,15,30  minutes,1,  and  3  hours 
respectively.Tubulin(50kd) was used as a loading control. 
 
IGF 1  stimulation  of  LNCaP  cells  appears  to  have  an  inhibitory  effect  on  the 
phosphorylation  of  Akt  at  serine  473  (Figure  3.4.)    The  basal  levels  of 
phosphorylated  Akt  in  the  serum  starved  extracts  are  notably  higher  and  the 
stimulation with IGF 1 appears to reduce the expression of phosphorylated Akt at 
serine 473 with time. The reasons for these inhibitory effects of growth factors on 
the phosphorylation of Akt are unclear at present. Elevated phosphorylation of Akt 
in LNCaP cells was
 inhibited by treating cells with the PI3K inhibitor LY294002
 for 
thirty minutes (Figure 3.5), indicating that constitutive phosphorylation of Akt
  at 
60kd 
50kd 111 
serine  473  is  dependent  on  constitutive
  production  of  3' phosphoinositides  Also, 
inhibition  of  PI3K  activity  was  sufficient  to  inhibit  phosphorylation  of  Akt 
  in 
LNCaP cells stimulated with IGF I (Figure 3.5). 
 
 
 
 
 
Figure 3.4 IGF stimulation of Akt phosphorylation 
Western  blot  was  performed  on  50ug  of  extracts  from  LNCaP  cells  treated  or 
untreated  (serum  free  medium)  with  10ng  IGF 1  and  probed  for  pAkt  (ser  473) 
(60kd) expression. Lane 1 LNCaP unstimulated, 2 LNCaP unstimulated (vehicles, 
acetic  acid  and  ethanol).Lanes3 7  LNCaP  cell  extracts  stimulated  for  5,  15,  30 
minutes,  1  and  3  hours.  Lane  8  extracts  treated  with  LY294002  20uM  for  30 
minutes, lane 9 extracts treated with LY294002 20uM 30 minutes then stimulated for 
one hour with 10ng IGF 1.Tubulin confirms equal loading of samples 
 
 
 
 
 
 
 
 
 
Figure 3.5 Phosphorylation of Akt was regulated by PI3K in LNCaP cells. 
Lane 1 LNCaP unstimulated 2, LNCaP cell extracts treated with 20uM LY294002,3 
LNCaP cell extracts stimulated for1 hour with10ng IGF 1,4 extracts treated with 
LY294002  20uM  30  minutes  then  stimulated  for  one  hour  with  10ng,  5  LNCaP 
unstimulated(vehicles,  acetic  acid  and  ethanol    .  Tubulin  confirms  equal  protein 
volumes. 
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3.2. Prostate cancer cell proliferation.  
 To determine the proliferation rate of both cell lines, proliferation was assessed 
using the WST assay (Figure 3.6). The data shown indicates that both cell lines 
proliferate at an almost equal rate and have a doubling time of approximately forty 
hours.  
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Figure 3.6 LNCaP and LNCaP CR cell proliferation 
 Proliferation rates in hours of both cell lines studied 
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3.2.2 PI3K regulates prostate cancer cell proliferation 
Reports  suggest  that  PI3K  signallingmay  play  a  critical  role,  allowing  prostate 
cancers cells to maintain continued proliferation in low androgen environments. To 
clarify the role of PI3K/Akt cascade in regulating proliferation, LNCaP cells were 
incubated with increasing concentrations of LY 294002 for 48 hours. This time was 
deemed to be the optimum from the previous proliferation experiment. Treatment of 
LNCaP  cells  with  LY  294002  resulted  in  a  dose dependent  reduction  in 
proliferation,  the  IC50  was  calculated  as  15uM  (Figure  3.7).  This  data  further 
supports the reports that PI3K plays a role in the proliferation of prostate cancer cells 
in the absence of PTEN.  
 
 
 
 
 
 
 
 
Figure 3.7 LY294002 inhibits prostate cancer cell proliferation. 
LNCaP cells were treated with different doses of LY294002 over a 48 hour period 
and the IC50 calculated was 15uM. 
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Using pAkt ser 
473 as a marker for PI3K activation has provided additional evidence 
that the PI3K signallingcascade is upregulated in the transition to castrate resistant 
disease as expression of pAkt ser 
473 is markedly higher in castrate resistant LNCap 
cells in comparison to hormone naïve LNCaP cells. The expression of pAkt ser 
473   
can be reduced by treatment with LY204002 as can cellular proliferation. Therefore 
having observed that the PI3K cascade is upregulated in prostate cancer cell lines it 
was deemed appropriate to investigate this cascade in the clinical samples. 
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3.3 Patients 
A total of 68 prostate cancer patients were included in this study, all were available 
for IHC analysis (136 tumours in total) and approximately 25 matched pairs were 
available for FISH analysis (31 hormone naive and 25 castrate resistant).  Patients in 
this cohort were diagnosed with locally advanced (50) or metastatic prostate cancer 
(18) and subsequently received surgery and androgen deprivation therapy (26 sub 
capsular bilateral orchidectomy, 44 GnRH analogue, 2 had both).  Forty five of the 
68  patients  also  received  anti  androgen  therapy  and  this  included  all  those  who 
received GnRH analogues.  At initial diagnosis the median age was 70 years (66 74) 
and 26% of patients had metastatic disease.  The median time to biochemical relapse 
was 2.32 (1.48 4.00) years and the percentage of patients with metastatic disease had 
increased to 57%.  Sixty one patients (89.7%) died during follow up and median 
survival for these patients was 4.34(2.94 6.63).  Seven patients were alive at last 
follow up;  the  median  time  of  follow up  for  all  68  patients  was  4.34(2.86 6.74) 
years.    
When  serum  PSA  level,  age,  metastasis  and  Gleason  grade  at  diagnosis  were 
analysed by univariate analysis for this patient cohort, PSA at diagnosis (p=0.036) 
and  Gleason  score  at  diagnosis  (p=0.010)  were  associated  with  shorter  time  to 
biochemical relapse. Death from time of biochemical relapse was associated with 
PSA level at relapse (p=0.016). Overall survival was associated with presence of 
metastases at relapse (p=0.0019) and Gleason score at diagnosis (p=0.049).  116 
3.3.1 Genetic changes for members of the PI3K cascade. 
FISH was performed for PIK3CA (p110 catalytic subunit of PI3K), PTEN, AKT1 3 
and mTOR. 
PI3KCA//chromosome 3 ratio was successfully evaluated in 57 cases (22 hormone 
naive and 35 castrate resistant tumours). The remaining cases were excluded from 
the study because of insufficient tumour material in the cores. Gene amplification 
was observed in only 1 (5%) hormone naive tumour, and 1 (3%) in castrate resistant 
tumour,  therefore  no  significant  alteration  was  observed  in  the  transition  form 
hormone  naive  to  castrate  resistant  disease.    No  PI3KCA  gene  deletions  were 
observed  in  this  cohort.      Due  to  the  low  level  of  genetic  changes  observed 
correlations with clinical parameters were not performed. 
PTEN/chromosome 10 was successfully evaluated in 31 cases (17 hormone naive 
and  14  castrate  resistant  tumours),  PTEN  FISH  is  shown  in  Figure  3.8.  The 
remaining  cases  were  excluded  from  the  study  because  of  insufficient  tumour 
material  in  the  cores.  Gene  deletion  was  observed  in  23%  of  hormone  naive 
tumours, this increased significantly to 52% in castrate resistant tumours (p=0.044).  
Loss of one copy of PTEN was commonly observed, and this was heterogeneous in 
nature, being frequently observed in only one area of tumour.   Loss of PTEN was 
correlated with prostate cancer progression; however, no correlation was observed 
between loss of PTEN and Gleason score at diagnosis, loss of PTEN and presence of 
metastasis at diagnosis or loss of PTEN and PSA at diagnosis. When loss of PTEN 
was  correlated  with  survival,  a  trend  between  loss  of  PTEN  and  poorer  disease 117 
specific survival was noted (p=0.086), this was not independently significant by Cox 
regression analysis.   
AKT1  FISH  was  successfully  evaluated  in  38  prostate  carcinomas  (20  hormone 
naive and 18 castrate resistant tumours). One castrate resistant tumour was identified 
with AKT1 whereas no AKT1 deletions were found. Due to the low level of genetic 
changes observed correlations with clinical parameters were not performed. 
AKT2/chromosome 19 ratio was successfully evaluated in 35/38 cases (92.1%). The 
remaining cases were excluded because of insufficient tumour material in the cores. 
Neither  AKT2  gene  amplifications  nor  deletions  were  identified  in  any  of  the 
evaluated tumours.  Due to the low level of genetic changes observed correlations 
with clinical parameters were not performed. 
AKT3/chromosome 1 ratio was successfully evaluated in 34/38 (89.5%) cases. The 
remaining cases were excluded from the study because of lack of tumour material in 
the  cores.    AKT3  was  neither  amplified  nor  deleted  in  any  of  the  analysed 
carcinomas.  Due  to  the  low  level  of  genetic  changes  observed  correlations  with 
clinical parameters were not performed. 
mTOR /chromosome 1 ratio was successfully evaluated in 50 cases (25 hormone 
naive and 25 castrate resistant tumours). The remaining cases were excluded from 
the study because of insufficient tumour material in the cores. Gene amplification or 
deletion  as  identified,  therefore  correlations  with  clinical  parameters  were  not 
performed.  
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Figure 3.8 PTEN FISH 
Fluorescent in situ hybridisation for chromosome 10 (red signal) and PTEN (green 
signal). 
 
 
3.3.2 Protein expression of the PI3K/Akt signallingcascade 
Expression of all proteins was monitored using an immunohistochemical approach. 
All IHC was performed as descrided in materials and methods (Chapter 2.9). Before 
IHC  commenced  antibody  specificity  was  confirmed  by  western  blotting  (Figure 
3.9).  Information  on  all  antibodies  employed  are  displayed  in  Table  3.1  and 
examples of immunohistochemical staining for each are displayed in Figure 3.10. I 
am grateful to Dr Lisa Gemmel for carrying out both the mTOR and phosphorylated 
mTOR IHC. 
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A. Phosphorylated Akt at serine 
308.Western blot analysis of extracts 
from Jurkat cells treated (lane1)or 
untreated (lane2)with calyculin A(Cell 
signallingtechnologies)    
B. Phosphorylated Akt at serine 473. 
Western blot analysis of extracts from 
Jurkat cells treated or untreated with 
calyculin A (lanes 1&2),LNCaP(3&4) and 
LNCaP CR(5&6)cell extracts treated with 
charcol stripped and full medium.  
 
 
 
 
 
 
 
 
 
 
 
C. PI3K.  Western blot analysis of 
extracts from Jurkat cells untreated or 
treated with calyculin A (lanes 1&2.) 
LNCaP (3) and LNCaP CR (4) cell 
extracts grown in standard culture 
media. 
D.PTEN. LNCaP cells do not express 
PTEN  protein,  where  as  DU145  cells  do 
express  PTEN  protein.  LNCaP&LNCaP 
CRcell lysates (lanes1& 2) lane 3 DU145 
cell lysates. 
 
 
 
 
 
 
E.mTOR. Western blot analysis of 
extracts from MCF7 cells untreated 
and treated with 10nm EGF(lanes 
1&2)BT474 (lanes 3&4) ,MDAMB 
231(lanes 5&6),MDAMB 361(lanes 
7&8). 
F. Phosphorylated mTOR at serine 2448. 
Western blot analysis of extracts from 
MCF7 cells untreated and treated with 
10nm EGF(lanes 1&2)BT474 (lanes 3&4) 
,MDAMB 231(lanes 5&6),MDAMB 
361(lanes 7&8). 
Figure 3.9: Specificity of Antibodies 
Western blotting was performed to confirm the specificity of all antibodies used in 
this study. 
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Protein  Antibody  Antigen 
Retrieval 
Antibody 
concentration 
Incubation 
temperature 
and time 
PTEN 
PTEN 
Mouse 
Monoclonal 
Cell Signalling 
Citrate 
Buffer 
1 g/ml  Overnight at 4ºC 
PI3K 
PI3K( p110 
catalytic subunit) 
Rabbit Polyclonal 
Cell Signalling 
Citrate 
Buffer 
1 g/ml  Overnight at 4ºC 
pAkt (ser473) 
pAkt serine 473 
Rabbit Polyclonal 
Biosource  TE Buffer  4 g/ml  Overnight at 4ºC 
pAkt (ser308) 
pAkt (ser308) 
Rabbit polyclonal 
Cell Signalling 
Citrate 
Buffer 
5 g/ml  Overnight at 4ºC 
*mTOR 
mTOR 
Goat Polyclonal 
Santa Cruz 
Biotechnology 
Citrate 
Buffer 
5 g/ml  Overnight at 4ºC 
pmTOR(ser2448) 
pmTOR(ser2448) 
Rabbit polyclonal 
Cell Signalling 
Citrate 
Buffer 
2 g/ml  Overnight at 4ºC 
Akt 1 
Akt 1 
Mouse 
monoclonal 
Santa Cruz 
Biotechnology 
TE Buffer  1 g/ml  Overnight at 4ºC 
Akt 2 
Akt 1 
Mouse 
monoclonal 
Santa Cruz 
Biotechnology 
 
TE Buffer  2 g/ml  Overnight at 4ºC 
Akt 3 
Akt 1 
Mouse 
monoclonal 
Santa Cruz 
Biotechnology 
TE Buffer  2 g/ml  Overnight at 4ºC 
Table 3.1: Antibody Information 
Details  of  the  antibodies  used  to  detect  members  of  the  PI3K/Akt 
cascade.Information regarding the source, antigen retrieval method, concentation 
and incubation are all recorded. *For the mTOR antibody only, incubation with 121 
 PI3K      PTEN      mTOR  
pmTOR ser 2448    Akt 1      Akt2  
Akt 3       pAkt ser 308    pAkt ser 473  
rabbit anti goat antibody (Dako A/S) (1 : 4000) for 1 h at room temperature was 
also required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: PI3K /Akt cascade Immunohistochemistry 
Prostate tumours displaying immunohistochemical staining magnification x400 
 
Akt1, pAkt
473, PTEN and pmTOR
2448 protein expression was observed in the cell 
membrane, cytoplasm or nucleus. mTOR expression was observed at the membrane 
and  cytoplasm,  and  PI3K,  Akt2  and  Akt3  expression  was  observed  only  in  the 
cytoplasm.  All IHC statistical analysis was carried out as previously described in 
(Chapter 2.9.1&2.9.2).  122 
Expression of all proteins investigated was non parametric, median values and inter 
quartile ranges for each protein at each location are provided in Table 3.2 for both 
hormone naive and castrate resistant tumours.   
Protein  HSPC 
(IQR) 
CRPC 
(IQR) 
P value  ICCC  Histoscore 
units 
Fallers  Risers 
PI3Kc  100(58 140)  100(79 134)  0.875  0.85  60  23  23 
Akt1m 
Akt1c 
Akt1n 
0(0 11) 
75(20 100) 
0(0 18) 
0(0 90) 
70(0 90) 
0(0 0) 
0.798 
0.488 
0.110 
0.88 
0.82 
0.95 
30 
55 
21 
14 
20 
19 
13 
13 
9 
Akt2  125(100 185)  120(98 165)  0.551  0.81  61  22  13 
Akt3  50(0 100)  60(0 95)  0.619  0.84  48  20  30 
pAkt
473m 
pAkt
473c 
pAkt
473n 
40(0 90)  
88(54 110)  
0(0 25) 
33(0 90) 
80(40 105) 
0(0 35) 
0.988 
0.671 
0.465 
0.90 
0.89 
0.93 
58 
49 
40 
22 
25 
15 
23 
23 
18 
mTORm 
mTORc 
0(0 20)  
43(15 87) 
0(0 10) 
40(10 62) 
0.134 
0.123 
0.92 
0.83 
47 
31 
10 
35 
3 
23 
pmTOR
2448
m 
pmTOR
2448c 
pmTOR
2448
n 
0(0 22)  
 
61(20 100)  
 
0(0 10) 
0(0 15) 
 
40(8 70) 
 
0(0 0) 
0.330 
 
0.044 
 
0.575 
0.95 
 
0.91 
 
0.90 
33 
 
45 
 
19 
14 
 
33 
 
3 
8 
 
23 
 
6 
PTEN m 
PTEN c 
PTEN n 
0(0 65) 
100(80 150) 
0(0 50) 
0(0 40) 
100(80 105) 
50(0 80) 
0.086 
0.104 
0.588 
0.84 
0.90 
0.82 
27 
37 
30 
33 
33 
28 
15 
23 
25 
Table 3.2: Protein expression patterns  
For each protein, descriptive statistics were performed on the generated histoscores. 
Median  histoscore  and  interquartile  range  (IQR)  for  hormone  naive  tumours 
(HSPC)  and  castrate  resistant  tumours  (CRPC)  and  the  p  value  of  these  values 
compared  using  a  Wilcoxon  sign  rank  test.    ICCC=  interclass  correlation 
coefficient.  The mean difference in observer scores plus 2 standard deviations is 
also shown as the number of histoscore units that is defined as a change in protein 
expression (change).  The percentage of tumours that were defined as having a fall 
or rise in protein expression (calculated using the number of histoscore units that is 
defined as a change in expression) are also shown. m, c and n relates to protein 123 
cellular location, m = membrane, c= cytoplasm and n = nucleus. P before a protein 
indicates that the antibody detects phosphorylated protein and the number following 
the protein represents the site of phosphorylation. 
 The  Wilcoxon  signed rank  test  was  used  to  compare  expression  levels  in  the 
hormone naive tumours compared to castrate resistant tumours. None of the proteins 
studied were shown to have a significant increase with the development of castrate 
resistant disease. 
3.3.3 Factors associated with time to biochemical relapse. 
When  presence  of  metastases  at  diagnosis,  age  at  diagnosis,  Gleason  score  at 
diagnosis and PSA at diagnosis were analysed for this patient cohort only PSA at 
diagnosis (p=0.036) and Gleason score at diagnosis (p=0.038) were associated with 
shorter time to biochemical relapse.  
3.3.4 Protein expression in the hormone naïve cohort  
To  determine  if  protein  expression  was  linked  to  time  to  biochemical  relapse, 
Kaplan Meier graphs were plotted for the hormone naive tumours expressing low 
levels of protein (< median) versus high levels of protein (> median) and compared 
using the log rank test.  Only PTEN was shown to have significant results. The 
patients whose tumours expressed low levels of PTEN in the cytoplasm were shown 
to have relapsed significantly earlier than those patients whose tumours expressed 
high levels of PTEN in the cytoplasm (Figure 3.11(a), p=0.027).  Cox regression 
analysis  indicates  that  cytoplasmic  PTEN  expression  is  independent  of  known 
clinical prognostic factors (p=0.028, hazard ratio 0.51 (95%CI 0.27 0.93).  It was 
noted, however, that the Kaplan Meier curves did not separate until approximately 124 
2.5 years after diagnosis.  Therefore PTEN loss appeared to be influencing relapse in 
those patients who took more than 30 months to relapse.  If patients that relapsed 
within 30 months were excluded from analysis the median time to relapse for those 
with low PTEN expression was 3.9 (IQR 2.98 4.92) years compared to 5.6 (4.36 
6.84) years for those with high PTEN expression (p=0.0035)(Figure 3.11(b)).   
In addition, those patients with high levels of cytoplasmic PTEN expression in their 
hormone naive tumours were observed to have longer median overall survival (6.1 
years (IQR 2.8 9.4)) compared to those with low PTEN expression (4.4 years (IQR 
3.3 5.4)), although this did not reach significance (p=0.072)(Figure 3.12).   Again 
the curves first separate approximately 30 months after diagnosis. Levels of pAkt
473 
expression in tumours that expressed low levels of PTEN were higher compared to 
tumours that expressed high levels of PTEN (p=0.047). 
 
 
 
 
Figure 3.11(a & b) : PTEN cytoplasmic expression 
Kaplan  Meier  Plot  for  high  (above  the  median,  solid  line)  and  low  (below  the 
median,  dotted  line).    The  figure  on  the  left  (a)  shows  the  time  to  biochemical 
relapse with with low cytoplamic PTENexpression(p=0.027),  figure 3.11(b) shows 
the time to biochemical relapse of patients with  low cytoplamic PTENexpression 
that took more than 30 months to relapse (p=0.0035) 125 
The median for both PTEN membrane and nuclear expression in the hormone naive 
tumours was 0; therefore patients were divided into those patients whose tumours 
did not express PTEN at these locations and those that did. Patients with PTEN 
membrane expression in their hormone naive tumour had significantly longer overall 
survival than those patients without (Figure 3.13, p=0.002).  The median time to 
relapse for patients whose tumours did not express PTEN in the membrane was 3.8 
years  (IQR  2.7 4.85)  compared  to  6.5  (IQR  5.8 7.2)  years  for  patients  with 
membrane expression.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: PTEN cytoplasmic expression and disease specific survival  
Kaplan Meier Plot for high (above the median, solid line) and low (below the median, 
dotted line) PTEN cytoplasmic expression and disease specific survival (labeled overall 
survival) (p=0.072). 
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Figure 3.13: PTEN membrane expression 
Kaplan Meier Plot for patients with membrane expression, (solid line) and no 
membrane expression (dotted line) and disease specific survival (labeled overall 
survival) (p=0.002). 
 
 
PTEN nuclear expression was associated with overall survival, those patients whose 
tumours had no nuclear PTEN expression had a significantly shorter overall survival 
compared to those patients with PTEN nuclear expression (Figure 3.14, p=0.003). 
Median overall survival was 3.4 years (IQR2.6 4.2) compared to 6.5 years (IQR 5.1 
7.8), which confers a survival advantage of 3 years for those patients whose tumours 
express  nuclear  PTEN.    Nuclear  PTEN  expression  was  demonstrated  to  be  an 
independent  prognostic  marker  by  Cox  regression  analysis  when  compared  with 
known  clinical  prognostic  parameters  (p=0.031,  hazard  ratio  0.52  (95%CI  0.29 
0.95).   127 
   
 
 
 
 
   
  
 
 
 
 
 
 
 
 
Figure 3.14: Nuclear PTEN expression 
Kaplan Meier plot for patients that have nuclear PTEN express  (solid line) and 
those who do not (dotted line) and disease specific survival. (p=0.003) 
 
As  observed  with  membrane  expression,  pAkt
473  expression  was  lower  in  the 
nucleus of tumours with high levels of nuclear PTEN than those with low levels but 
this did not reach significance (p=0.132).  In contrast, PTEN membrane expression 
correlated strongly with nuclear PTEN expression (p<0.001, Rs 0.66) 
3.3.5 Protein expression in the castrate resistant cohort 
When expression levels of each protein investigated in the castrate resistant tumours 
were divided into to high or low expression (levels above or below the median) none 
of  the  proteins  investigated  were  associated  with  time  to  death  from  relapse  or 
disease specific survival.  128 
When presence of age at diagnosis, Gleason score at diagnosis, metastases at relapse 
and  PSA  at  relapse  were  analysed  for  this  patient  cohort  only  PSA  at  relapse 
(p=0.016)  was  associated  with  disease  specific  death  from  time  of  biochemical 
relapse. 
3.3.6 Changes in protein expression 
Due to the nature of the cohort it is possible to investigate if those patients whose 
tumours  exhibit  an  increase  or  decrease  in  expression  of  members  of  the  PI3K 
cascade in the transition from hormone naive to castrate resistant disease were more 
likely to relapse or die quicker. The cutoff histoscore selected to separate subgroups 
of patients is displayed in Table 3.2. Using this method, an increase in PI3K (Figure 
3.15; P=0.014, HR=2.11 (95% CI: 1.14–3.91)) and pAkt
308 (Figure 3.16, p=0.038, 
HR 2.4 (1.01 5.67)) were associated with quicker time to relapse.  The median time 
to relapse for those patients whose tumours have a decrease or no change in PI3K 
expression was 2.57 (1.74 3.40) years compared to 1.36 (1.20 2.72) years for those 
patients whose tumours had an increase in PI3K expression.  The median time to 
relapse for those patients whose tumours had no change or decrease in pAkt
308 was 
2.36 (1.61 3.11) years compare to 1.14 (0.17 2.63) years for those patients whose 
tumours had an increase in pAkt
308 expression.   
Additionally,  an  increase  in  pAkt
473  (Figure  3.17,  p=0.0019,  HR  2.89(95%  C.I., 
1.43 5.8)) was associated with shorter disease specific survival. The median survival 
from  diagnosis  for  those  patients  whose  tumours  had  no  change  or  decrease  in 
pAkt
473 was 6.68 (IQR, 6.22 7.14) years compared to 4.15 (IQR, 2.65 6.5) years for 
those patients whose tumours had an increase in pAkt
473expression. 129 
 
 
 
 
 
 
 
 
 
Figure 3.15: Increased PI3K expression 
Kaplan Meier plot for patients that have increased PI3K expression (dotted line) and 
those who do not (solid line) and time to relapse (p=0.014) 
 
 
 
 
 
 
 
Figure 3.16 Increased pAkt (ser 308) 
Kaplan Meier plot for patients that have increased pAkt (ser 308) expression (dotted line) 
and those who do not (solid line) and time to relapse (p=0.038). 
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Figure 3.17: Increased pAkt (ser 473) expression 
Kaplan Meier plot demonstrates that those patients whose tumours exhibit an increase in 
pAkt
473 cytoplasmic expression (broken line) have shorter time to disease specific death 
than those patients whose tumours exhibit no change or a decrease in pAkt
473 expression 
(solid line).  
 
When all significant factors associated with disease specific survival were combined in 
multivariate  analysis,  presence  of  metastases  at  relapse,  PTEN  nuclear  expression  in 
hormone  naive  tumours  and  an  increase  in  pAkt
473  expression  were  independently 
significant (Table 3.4). 
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Factor  P value (uni)  P value (multi)  Hazard ratio  95% C.I. 
Metastases at relapse  0.0019  0.043  3.54  1.03 12.07 
PTEN nuclear expression  0.011  0.0054  0.27  0.11 0.68 
Change pAkt
473 expression  0.0019  0.0314  2.74  (1.09 6.88) 
Table 3.4: Multivariate analysis for factors effecting disease specific survival 
Factors  significantly  associated  with  disease  specific  survival  using  Kaplan  Meier 
analysis  and  those  independently  associated  with  disease  specific  survival  using  Cox 
Regression analysis. PTEN nuclear expression represents those patients whose hormone 
naive tumours expressed PTEN in the nucleus compared to those patients whose hormone 
naive  tumours  did  not  express  PTEN  in  the  nucleus.    Change  in  pAkt
473expression 
represents  those  patients  whose  tumours  exhibited  an  increase  in  expression  in  the 
transition from hormone naive disease to castrate resistant disease compared to those 
patients whose tumours had no change or a decrease in expression 
 
3.4 Discussion 
 
Evidence  from  several  groups  indicates  that  the  PI3K  cascade  may  influence  the 
progression to castrate resistant prostate cancer despite only castrate levels of circulating 
androgens.  Indicating  that  this  pathway  could  serve  as  a  novel  target  for  therapeutic 
intervention  in  the  treatment  of  prostate  cancer.    Due  to  the  significance  of  PI3K 
signallingin prosate cancer cell lines this study further examined if the protein expression 
levels  of  several  key  components  of  this  signallingcascade  played  a  role  in  prostate 
cancer relapse to castrate resistant  disease aiming to identify which proteins would make 
the  optimum  targets  for  treatment  and  most  effectively,  identify  patients  suitable  for 
therapy.   
Functional loss of PTEN has been associated with increased Akt phosphorylation, higher 
gleason grade, advanced stage and poor prognosis, predicting disease recurrence after 
primary  treatment  (214).  The  generation  of  transgenic  mouse  models  that  recaptilate 132 
features of the disease has enhanced understanding of the pathway (215) and studies of 
knockout mice with targeted deletion of prostate specific PTEN (PTEN / ) have revealed 
prostate  intraepithelial  neoplasia  formation,  invasive  adenocarcinoma  progressing  to 
metastatic disease, an initial response to androgen ablation therapy, and eventual tumour 
growth  despite  castration  (216).  This  study  presents  data  in  keeping  with  PI3K 
signallinginducing continued prostate cancer growth. 
Akt activity has been shown to increase during androgen ablation to stimulate cell growth 
and survival when androgen reliance is weaker, and therefore promote development of 
CRPC (150;172). LNCaP cells are PTEN deficient, therefore PI3K pathway signallingis 
evident by high levels of phosphorylated Akt..In this study it was established that both 
hormone naïve and castrate resistant LNCaP express phosphorylated Akt during serum 
starvation which indicates PI3K signallingis active at both stages of the disease regardless 
of the growth conditions. Phosphorylated Akt expression was markedly higher in the 
castrate resistant cells than hormone naïve cells (Figure 3.1&3.2) and treatment with EGF 
induces  the  phosphorylation  of  Akt  in  hormone  naïve  cells  to  a  similar  level  of  that 
observed in the untreated castrate resistant cells. Heregulin was shown to induce Akt 
phosphorylation  in  both  cell  lines  but  at  a  quicker  rate  in  the  castrate  resistant  cells 
(Figure 3.3). IGF 1 stimulation did not appear to enhance the phosphorylation of Akt to a 
higher than basal level in the hormone naïve LNCaP cells (Figure 3.4). This observation 
that  Akt  phosphorylation  increases  with  prostate  cancer  progression  is  supported  by 
several  reports  in  the  literature.  Androgen  ablation  in  LNCaP  cells  stimulated  the 
activation of Akt, which eventually resulted in androgen independence of the cell line in 
culture  (180).  The  PI3K  inhibitor  LY294002  was  sufficient  in  blocking  Akt 133 
phosphorylation  in  LNCaP  cells  with  and  without  IGF 1  stimulation  (Figure  3.5). 
LY294002 was also observed to inhibit the proliferation of LNCaP cells. In keeping with 
previous reports this study established that the PI3K cascade is upregulated both hormone 
naïve and castrate resistant prostate cancer cell lines (217). It was therefore fitting to 
investigate the members of the PI3K cascade at the genetic level in matched hormone 
naive and castrate resistant clinical samples. 
One  mechanism  by  which  protein  expression  is  altered  is  by  gene  amplification  or 
deletion, however this study failed to show any link between  gene amplification and 
increased  protein  expression.    Loss  of  PTEN  was  noted  in  23%  hormone  sensitive 
tumours compared to 52% castrate resistant tumours, these rates of loss are similar to 
those previously reported by FISH analysis (185) suggesting that PTEN loss is associated 
with  tumour  progression.  Although  this  was  not  significantly  associated  with  clinical 
outcome measures a trend was observed that demonstrated that those patients with PTEN 
loss had shorter overall survival.  If the FISH studies were expanded to a larger dataset 
these results may have reached significance.    FISH depending on the region that the 
probe binds to does not always detect small deletions and in the case of this study the 
probe  covers  the  whole  of  the  PTEN  gene,  hence  loss  of  the  whole  gene  is  being 
measured.  It was observed that very few tumours had homogeneous PTEN deletion and 
complete  loss  of  PTEN  expression  (2%),  but  almost  all  have  heterogeneous  loss  of 
expression, this is consistent with previous reports (185). In the current study, PTEN loss 
does not correlate with PTEN gene deletion, although all tumours with PTEN deletion 
have low PTEN expression.  An explanation for low PTEN expression in tumours that 
appear not to have PTEN deletion is hypermethylation of the PTEN promoter region. 134 
Evidence for promoter hypermethylation has been reported in prostate cancer xenografts 
(190) and the promoter region of PTEN in the LNCaP cell lines used in this study were 
observed to be methylated (data not shown) additionally western blot analysis confirmed 
that these LNCaP cell lines did not express PTEN (Figure  3.1). Although the mechanism 
of PTEN inactivation is currently controversial and possibly due to different mechanisms 
in different tumours, it is widely accepted that PTEN loss is one of the most common 
events associated with prostate cancer (218). 
Work using human prostate tissue confirms that pAkt
473 is expressed in PIN and invasive 
prostate cancer, and staining intensity positively correlated with PSA levels and Gleason 
grades (172;217).  Additionally, a large study of 640 radical prostatectomy specimens 
demonstrated that high levels of pAkt were predictive of biochemical recurrence (171). 
However, to date this had not been investigated in castrate resistant tumour samples. The 
current study demonstrates for the first time that the PI3K/Akt pathway is up regulated in 
clinical  castrate  resistant  disease  and  that  it is independently  associated  with  reduced 
disease  specific  patient  survival.  An  increase  in  PI3K  expression  and  low  PTEN 
cytoplasmic expression were both associated with shorter time to biochemical relapse.  
The consequence of low PTEN expression displays an increase in Akt activation, in a sub 
cohort  of  the  patients.  It  is  observed  that  those  patients  with  an  increase  in  pAkt
308 
(partially activated)  and
 pAkt
473 expression (fully activated  Akt) have  shorter time to 
relapse and disease specific survival respectively (Figures 3.16 & 3.17).  As expected the 
relationship between disease specific survival and fully activated Akt (pAkt
473) appears to 
be  stronger  than  that  with  partially  activated  Akt (pAkt
308).    The  increase  in  pAkt
473 
expression predicts disease specific survival independent of Gleason score and presence 135 
of  metastasis.  By  investigating  PTEN  protein  expression  as  predicted,  loss  or  low 
cytoplasmic  PTEN  expression  was  independently  associated  with  time to  relapse  and 
linked with increased Akt activation. However this was observed to be a late event with 
curves separating 30 months following diagnosis, suggesting that other factors such as 
PI3K  expression  may  also  contribute  to  Akt  activation  and  disease  progression.    In 
addition to cytoplasmic PTEN expression, nuclear PTEN expression was also observed.   
Unlike  cytoplasmic  PTEN  expression,  loss  of  nuclear  PTEN  expression  was  weakly 
associated  with  time  to  relapse  and  this  did  not  reach  significance.    Nuclear  PTEN 
expression was independently associated with overall survival where the curves on the 
Kaplan Meier plot begun to separate approximately after diagnosis.  These results in 
combination  with  the  lack  of  correlation  with  Akt  activation  suggest  that  the  role  of 
PTEN in the nucleus is independent of cytoplasmic PTEN.   
It is possible that nuclear PTEN is simply a surrogate marker of PTEN activation, as in 
vitro  studies  demonstrate  that  following  phosphorylation,  PTEN  is  released  from  the 
membrane  bound  scaffolding  proteins  and  enters  the  nucleus.    In  support  of  this  a 
correlation between membrane and nuclear PTEN expression was observed (p<0.001, Rs 
0.66) and PTEN membrane expression is also linked to survival.  However, in contrast to 
cytoplasmic  PTEN  expression,  no  correlations  were  observed  between  nuclear  PTEN 
expression  and  Akt  activation,  therefore  the  evidence  to  support  nuclear  PTEN  as  a 
surrogate marker of PTEN cytoplasmic activation is not convincing in the current study. 
In addition, both cytoplasmic and nuclear PTEN are independently associated with good 
outcome measures in hormone sensitive prostate cancer, yet appear to have independent 136 
roles.  Results gained for this study suggest that the increase in Akt activity we observe 
may be due to PTEN loss and/or an increase in PI3K activity. 
The protein mTOR is also downstream of Akt and was also investigated in this study as it 
has previously  been linked to CRPC (219).  In the  current cohort, pAkt
473 expression 
correlates  with  pmTOR
2448  expression,  however,  expression  levels  or  changes  in 
expression  levels  of  pmTOR
2448  do  not  correlate  with  any  clinical  parameters  in  the 
cohort suggesting that mTOR may not be involved in the development of CRPC. This is 
surprising as stimulation of mTOR ultimately results in increase protein synthesis and 
enhances translation of proteins involved in growth control via turning off 4EBP and 
activating  S6Kinase.  Although  Akt  has  been  demonstrated  to  phosphorylate  mTOR 
directly,  the  role  of  these  phosphorylation  sites  remains  unclear.  A  more  appropriate 
marker of mTOR activation could be S6Kinase (220). Apart from activating its substrate 
S6 it is also involved in a negative feedback loop to inactivate Akt (221). Interestingly 
Munders et al have recently demonstrated that VEGF C increased the survival of prostate 
cancer cells during hydrogen peroxide stress by the activation of Akt. This activation was 
mediated by mTORC2 and was not observed in the absence of oxidative stress. It is 
therefore possible that during stress cells prefer to shut off  protein synthesis which is 
energetically expensive and growth and enhance cellular processes that mediate survival. 
Thus the absence of mTOR activity facilitates prolonged activation of  Akt during severe 
stress  providing  suvival  advantage.  Agents  including  radiotherapy,  chemotherapeutic 
drugs  such  as  pacitaxel  and  histone  deacetalase  inhibitors  increase  oxidative  stress 
(222;223). Thus a reccurrence of the tumour after therapy likely results from a subset of 
cells that have developed the ability to overcome oxidative damage (223).  137 
It  has  long  been  hypothesised  that  interaction  with  growth  factor  receptors  and  the 
Androgen receptor drive the development of CRPC. This study presents clinical evidence 
that expression and activation of the components of the PI3K cascade is associated with 
poor clinical outcome. Loss of PTEN expression as prostate cancer progresses results in 
constitutive  activation  of  Akt.  These  prelimanary  results  demonstrate  an  increase  in 
phosphorylated  Akt  (serine  473)  expression  in  the  transition  from  hormone  naïve  to 
castrate resistant disease, suggesting that the PI3K cascade is up regulated in a sub group 
of patients, this was also associated with a reduced survival period from relaspe. Cell line 
arm of this study also indicated tha PI3K cascade was upregulated at castrate levels of 
androgen and that this pathway is involved in prostate cancer cell proliferation. As PI3K 
signallingat  castrate  levels  of  circulating  androgen  appears  to  play  a  role  in  prostate 
cancer progression it was deemed appropriate to investigate the downstream effects of 
Akt  activity.  As  mentioned  earlier  Akt  interacts  with  NFқB  a  transcription  factor 
involved  in  a  vast  many  cellular  processes  and  also  with  the  Androgen  receptor 
phosphorylating it at serine residue 213 and 791.   Accordingly the next two chapters 
shall investigate the effects of Akt on NFқB signallingand interaction with the androgen 
receptor.  
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4.   The role of NFқB signalling in clinical prostate cancer 
progression. 
 
4.1. Introduction 
 
In the previous chapter  the significance of the  PI3K/Akt cascade in the transition for 
hormone naive to castrate resistant disease was highlighted using in vivo and in vitro 
models.  Based  on  these  results  it  was  decided  to  further  investigate  the  activity  and 
expression  levels  of  proteins  down  stream  of  Akt.  Akt  has  been  shown  to  stimulate 
signallingcascades that regulate the activity of the transcription factor NFκB which has 
been proven to be directly involved in a number of human disorders including a variety of 
cancers. 
 
4.2 Patients 
 
A total of 61 prostate cancer patients were included in this study, all were available for 
IHC analysis (132 tumours in total). Clinical data, recorded for each patient included age 
(median 70, inter quartile range 67 74), PSA at diagnosis (median 31 ng/ml, inter quartile 
range 7.8 109), PSA at relapse (median 10 ng/ml, inter quartile range 4 11) and Gleason 
grade at diagnosis (median 8, range 6 9).  All patients under went biochemical relapse 
(median time to relapse 2.48 years, inter quartile range 1.76 4.43 years).  At last follow 
up, 40 patients had died of their disease and 15 patients had died of other causes and 6 
were still living.  The median follow up for those patients still alive was 6.4 years and 
inter  quartile  range  was  3.7 9.2  years.    Following  diagnosis  10  %  patients  received 
surgical orchidectomy and 90% patients received LHRH analogue in combination with 139 
anti  androgen  therapy.    Following  biochemical  relapse  64%  patients  received 
radiotherapy, no patients received taxane therapy.  Clinical parameters associated with 
time to biochemical relapse, time to death from biochemical relapse and disease specific 
survival are shown in table 4.1. 
 
  Time to relapse  Time to death 
from relapse 
Disease specific 
survival 
Age 
(<70/>70/unknown) 
 
0.809 
29/29/3 
 
0.137 
28/29/4 
0.434 
30/29/2 
Gleason 
(<7/=7/>7/unknown) 
0.473 
14/12/28/7 
0.026 
14/12/27/8 
0.013 
14/12/29 
Metastasis at 
diagnosis 
(No/Yes/Unknown) 
0.182 
40/14/7 
0.013 
40/14/7 
0.002 
40/16/unknown 
PSA at diagnosis 
(<4/4 10/>10) 
unknown 
0.063 
9/7/38/7 
0.568 
9/7/37/7 
0.664 
9/7/37/8 
Metastasis at 
relapse 
(No/Yes/Unknown) 
 
  0.001 
10/33/unknown 
0.012 
10/35/unknown 
PSA at relapse    0.933 
39/18/unknown 
0.045 
39/18/unknown 
Table 4.1: Patient characteristics 
An  overview  of  the  cohort’s  characteristics  where  each  clinical  parameter,  were 
appropriate has been correlated with time to relapse, time to death from relapse and 
disease specific survival (p values).  
 
 
4.3 Immunohistochemisrty   
 
Before IHC commenced antibody specificity was confirmed by western blotting (Figure 
4.1). Information on all antibodies employed are displayed in table 3.2 and examples of 
immunohistochemical  staining  for  each  are  displayed  in  figure  3.2.  This  study  was 
carried out to investigate the significance of NFқB activation in clinical prostate cancer 
specimens  using  an  immunohistochemical  approach  therefore  by  investigating  the 140 
expression  of  pIқBα  serine 
32/36  gives  an  indication  of  NFқB  activation  as 
phosphorylation of IқBα at this serine residue leads to the activation of NFқB. 
 
 
 
 
 
 
 
 
A.  pIқBα serine 
32/36 Western blot of 
Hela cells extracts treated 
(lane1)or untreated (lane2)with 
TNFα (Cell 
signallingtechnologies) 
 
B. NFқB p65 Western blot of LNCaP, 
LNCaP CR, PC3 and DU145 cell extracts 
grown in full medium.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. pNFқB p65 serine 
536 Western blot of 
LNCaP, LNCaP CR, PC3 and DU145 cell 
extracts grown in full medium.  
D. NFқB p65 serine
276Western blot of 
LNCaP, LNCaP CR, and PC3 cell extracts 
grown in full medium.  
 
 
 
 
 
E.MMP 9 Western blot of PC3, LNCaP, 
LNCaP CR, and DU145 cell extracts 
grown in full medium.  
 
 
Figure 4.1: Antibody specificity Western blotting was performed to confirm the 
specificity of all antibodies used in this study. 
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Protein  Antibody  Antigen 
Retrieval 
Antibody 
concentration 
Incubation 
temperature 
and time 
NFκB 
NFκBp65 
Mouse Monoclonal 
IgG1 Ab F 
Santa Cruz 
Citrate 
Buffer 
8ug/ml  Two hours at 
25ºC 
NFκB 
NFκB p serine 536 
Rabbit Polyclonal 
Abcam 
Citrate 
Buffer 
2ug/ml  Overnight at 
4ºC 
NFκB 
NFκB p serine 276 
Rabbit Polyclonal 
Cell Signalling 
Citrate 
Buffer 
2ug/ml  Overnight at 
4ºC 
IκBα 
IκBα  p serine 32/36 
Mouse Monoclonal 
Cell Signalling 
Citrate 
Buffer 
2ug/ml  Overnight at 
4ºC 
MMP 9 
MMP 9 
Rabbit Polyclonal 
Millipore 
 
N/A  0.5ug/ml 
Thirty Minutes 
at 25ºC 
Table 4.2: Antibody Information. Details of the antibodies used to detect members of 
the  NFκB  cascade.Information  regarding  the  source;  antigen  retrieval  method, 
concentation and incubation are all recorded.  
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Figure 4.2: Immunohistochemistry 
Prostate tumours displaying immunohistochemical staining, magnification x400 
 
4.3.1Protein expression patterns 
 
NFқB p65, pNFқB p65 serine 
276, pNFқB p65 serine 
536, MMP 9 and pIқBα serine 
32/36  
protein expression was observed in the cell cytoplasm, pNFқB p65 serine 
276, pNFқB p65 
serine 
536 and pIқBα serine 
32/36  expression was also observed in the nucleus. All IHC 
statistical  analysis  was  carried  out  as  previously  described  in  (Chapter  2.9.1&2.9.2). 
Expression  of  all  proteins  investigated  was  non  parametric,  median  values  and  inter 
quartile  ranges  for  each  protein  at  each  location  are  provided  in  Table  3.2  for  both 
hormone naive and castrate resistant tumours.   
 IκBα p ser 
32/36         NFκBp65      NFκB p ser 
536 
 
                NFκB p ser
 276                MMP 9 
   143 
 
 
HSPC 
(IQR) 
CRPC 
(IQR) 
P value  ICCC 
Histoscore 
units 
NFқB p65, c  100 (140 180)  100 (150 180)  P=0.755  0.86  40 
NFқB p65
276,c 
NFқB p65
276,n 
0 (0 41) 
7(50 80) 
0(0 30) 
50(70 92) 
P=0.010
P=0.544 
 
0.77 
 
64 
NFқB p65
536,c 
NFқB p65
536,n 
70(100 120) 
0(20 73) 
42(90 123) 
0(40 80) 
 
P=0.276 
P=0.159 
0.83 
0.85 
80 
55 
pIқBα
32/36 , c 
pIқBα
32/36 , n 
110 (116 196) 
 
133(160 186) 
P=0.392 
P=0.963 
0.80 
0.93 
80 
55 
MMP 9  80(120 170)  90(120 160)  P=0.922  0.83  80 
Table 4.3: Protein expression pattern 
The  median  histoscore  and  interquartile  range  (IQR)  for  hormone  naive  tumours 
(HNPC)  and  castrate  resistant  tumours  (CRPC)  and  the  p  value  of  these  values 
compared using a Wilcoxon sign rank test.  ICCC= interclass correlation coefficient.  
The mean difference in observer scores plus 2 standard deviations is also shown as the 
number of histoscore units that is defined as a change in protein expression (change). c 
and n relates to protein cellular location, c= cytoplasm and n = nucleus. P before a 
protein  indicates  that  the  antibody  detects  phosphorylated  protein  and  the  number 
following the protein represents the site of phosphorylation. 
 
4.3.2 Protein expression in the Hormone Naïve cohort 
To determine if protein expression was linked to time to biochemical relapse, Kaplan 
Meier  graphs  were  plotted  for  the  hormone  naïve  tumours  expressing  low  levels  of 
protein (< median) versus high levels of protein (> median) and compared using the log 
rank  test.    Only  cytoplasmic  p65  ser 
536  was  shown  to  have  significant  results.  The 
patients whose tumours expressed low levels of p65 ser 
536in the cytoplasm were shown 
to have relapsed significantly earlier than those patients whose tumours expressed high 144 
levels of p65 ser 
536 in the cytoplasm p= 0.024 (Figure 4.3), the median time to relapse for 
those with low expression was 2.3 (2.1 2.6) years compared to 3.5 years (1.6 5.4 years) 
for those with high p65 ser 
536  expression indicating that cytoplasmic p65 ser 
536 has a 
protective role in hormone naïve prostate cancer.. 
 
Figure 4.3 High cytoplasmic p65 ser 
536 expression 
Kaplan Meier plot demonstrates that those patients whose tumours express high p65 ser 
536 in the cytoplasm (black line) relapse later than those patients whose tumours exhibit 
low p65 ser 
536 expression (broken line).  
When protein expression patterns were correlated with clinical parameters cytoplasmic 
NFқB p65 expression was significantly associated with PSA at relapse (p=0.02) (Figure 
4.4). The median p65 histoscore value for patients with PSA below 4(ng/ml) was 135 
(80 160) vs. 170(120 200) for patients with a PSA greater than 4 (ng/ml). In addition, 
MMP9 expression was significantly associated with the presence of metastasis at relapse 
(p=0.026), the median histoscore value for patients with no metastasis was 85 (72.5 115) 
vs. 125 (100 200) for those patients with metastasis at relapse (Figure 4.5). 145 
Figure 4.4: p65 expression & PSA at relapse  
p65 expression is significantly associated with higher PSA at relapse (p=0.02). 
 
 
 
 
 
 
 
 
 
Figure  4.5:  MMP 9  expression  &  metastases  at  relapse  MMP 9  expression  is 
significantly higher in patients with metastases at relapse (p=0.026) 
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To  determine  whether  NFқB  ser 
536  phosphorylation  was  influenced  by  the  Akt  a 
correlation between phosphorylated Akt ser 
473 and phosphorylated NFқB ser 
536 was 
carried out. A negative correlation was observed between cytoplasmic Akt ser 473 and 
cytoplasmic p65 ser 536, r2=0.433 p=0.008 (Figure 4.6) 
Figure 4.6: Scatter Graph  
Scatter Graph comparing p65 ser536 cytoplasmic expression and cytoplasmic pAkt ser 
473 expression, P=0.008 
4.3.3 Protein expression in the Castrate resistant cohort 
   
To establish if protein expression was linked to time to death from biochemical relapse, 
Kaplan Meier graphs were plotted for the castrate resistant tumours expressing low levels 147 
of protein (< median) versus high levels of protein (> median) and compared using the 
log rank test.  
The patients whose tumours expressed low levels of nuclear p65ser 
536 were shown  to 
have a significantly shorter time to death from relapse compared to those patients whose 
tumours expressed high levels of nuclear p65 ser 
536 p= 0.028 (Figure 4.7). These patients 
had a shorter time to death from relapse, 1.1 years (0.2 2.1 years) compared to 3years 
(1.2 4.8). Patients expressing a high level of nuclear p IκBα ser 
32/36 had a significantly 
shorter time to death from relapse p=0.029 (Figure 4.8). Here it was observed that the 
patients who expressed a higher level of nuclear p IκBα ser 
32/36  had a median time to 
death from relapse of
 1.9 years (0.9 2.8)
  compared to those patients who expressed 
 levels 
below the median, 4.1 years (0.5 7.9). 
 Additionally high MMP 9 expression resulted in a significantly shorter time to death 
from  relapse  p=0.015,  (Figure  4.9),  these  patients  survived  for  1.3  years  (0.5 2.2) 
compared to 3.6 years (0.6 6.6).  
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Figure 4.7: Nuclear p65ser 
536 expression  
Kaplan Meier plot demonstrates that those patients whose tumours express high p65 ser 
536 in the nucleus (black line) have a longer time to death from relapse than those patients 
whose tumours exhibit low p65 ser 
536 expression (broken line).  
 
 
 
 
 
 
 
 
Figure 4.8: Nuclear Iκ κ κ κBα  α  α  α ser 
32/36 expression  
Kaplan  Meier  plot  demonstrates  that  those  patients  whose  tumours  express  high  p 
IкBαser 
32/36  in the nucleus (broken line) have a longer time to death from relapse than 
those patients whose tumours exhibit low p65 ser 
536 expression (black line).  
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Figure 4.9: MMP 9 expression  
Kaplan Meier plot demonstrates that those patients whose tumours express high MMP 9 
(broken line) have a longer time to death from relapse than those patients whose tumours 
exhibit low MMP 9 expression (black line).  
 
Correlations between clinical parameters and protein expression revealed Gleason grade 
at relapse was significantly associated with nuclear p65 ser 
536 and cytoplasmic p65 ser
276 
expression p=0.001 and p=0.020 respectively and metastasis at relapse was significantly 
associated with nuclear p IκBα ser 
32/36  p=0.003 (Figure 4.10). The median histoscore 
value  for  patients  with  no  metastasis  was  130  (40 161)  vs.  195  (171 213)  for  those 
patients with metastasis at relapse. 
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Figure 4.10: IқBαser 32/36 expression and metastases at relapse  
I Bα ser 
32/36 expression is significantly higher in patients with metastases at relapse 
(p=0.003) 
 
4.3.4 Changes in protein expression 
 
As mentioned in the previous chapter the strength of this patient cohorts is the ability  to 
investigate if those patients whose tumours exhibit an increase or decrease in protein 
expression, in the transition from hormone naïve  to castrate resistant disease are  more 
likely  to  relapse  or  die  quicker.  Table  4.3  provides  the  cutoff  histoscore  selected  to 
separate subgroups of patients and the associations observed between time to biochemical 
relapse and disease specific survival for each protein investigated are shown in table 4.5. 
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Protein  Time to death from 
relapse 
Overall survival 
NFқ B p65  P=0.044  P=0.081 
pNFқ B p65ser 
276, c  P=0.983  P=0.901 
pNFқ B p65
276,n  P=0.428  P=0.839 
pNFқ B p65
536,c  P=0.259  P=0.009 
pNFқ B p65
536,n  P=0.137  P=0.200 
pIқBα
32/36 , c  P=0.399  P=0.172 
pIқBα
32/36 , n  P=0.114  P=0.260 
MMP 9  P=0.129  P=0.022 
Table 4.4: Changes in protein expression and survival 
Kaplan  meier  survival  analysis  was  performed  to  investigate  if  changes  in  protein 
expression were linked to time to death from biochemical relapse, and overall survival. 
 
Nuclear p65 ser 
536 and nuclear p65 ser 
276 significantly increased with the progression to 
castrate resistant disease P=0.021 and P=0.001 respectively. To determine if an increase 
in protein expression was linked to time to death from biochemical relapse, and overall 
survival Kaplan Meier graphs were plotted for the castrate resistant tumours expressing 
increased levels of protein versus decreased/no change of protein and compared using the 
log rank test, (Table 4.). An increase in cytoplasmic p65 expression was significantly 
associated with time to death from relapse p=0.004 (Figure 4.11). Those patients who had 
an increase in p65 expression had a significantly shorter time to death from relapse, 1.9 
years (0.1 3.8) compared to those who displayed a decrease or no change 3.4 years (2.4 
4.3). 152 
 
 
 
 
 
 
 
 
 
 
Figure  4.11  Increased  p65  expression  Kaplan  Meier  plot  demonstrates  that  those 
patients whose tumours express an increase in P65 expression (black line) have shorter 
time  to  death  from  relapse    than  those  patients  whose  tumours  exhibit  decrease/no 
change in  expression (broken line). 
 
 
 
4.4 Cell line 
4.4.1 Activation of p65 
To  establish  the  activation  levels  of  p65  in  the  matched  hormone  naive  and  castrate 
resistant prostate cancer cell lines a TNF α time course treatment was carried out (Figure 
4.12). Phosphorylation of p65 at serine 536 was used as a measure of p65 activation and 
is seen to be rapidly achieved in the presence of TNF α. A higher phosphorylation level is 
evident  the  untreated  LNCaP CR  suggesting  p65  phosphorylation  is  a  more  common 
event in castrate resistant prostate cancer. By stimulating with TNF α both cell lines have 
undergone phosphorylation of the p65 subunit at serine 536 after 15 minutes, and both 
are observed to be markedly higher than in the untreated samples.  Consequently it was 153 
fitting to examine the effect of p65 inhibitors on NFқB activation, downstream protein 
expression, cell proliferation and apoptosis.  
 
Figure 4.12 TNF stimulation of p65  
Western blot was performed on 50ug of extracts from LNCaP& LNCaP CR cells treated 
or  untreated(serum  free  medium)  with  30ng  TNFα  and  probed  for  p65  (ser  536) 
expression.Lane  1LNCaP,  2  LNCaP CR  (unstimulated),  3&4  LNCaP&  LNCaP CR 
unstimulated(vehicle,dh2o).Lanes5 12LNCaP&  LNCaP CR  cell  extracts  stimulated  for 
5,15,30 minutes, and 1 hour. Double bands in lanes 8 and 10 are due to the volume of 
protein required to amount to 50ug. The loading wells in the gels only hold 30ul and for 
these samples extra had to be added as the proteins began to run through the stacking 
gel. Tubulin confirms loading of samples. 
 
4.4.2 NFқB Inhibition 
It  was  observed  that  treatment  of  LNCaP  cells  with  NFқB  inhibitors  2607  and  2070 
resulted in a dose dependent decrease in constitutive expression of p65 ser 
536 (Figure 
4.13a & 4.13 b) while total p65 levels remained unchanged.  To assess the downstream 
effect  of  p65  inhibition  MMP 9  expression  was  examined.  A  reduction  in  MMP 9 
expression is also shown (Figures 4.13 a & 4.13 b), here it is observed that 2607 and to a 154 
lesser  extent  2070  both  inhibit  the  down  stream  activity  of  p65.  The  above  results 
indicate that both inhibitors attenuate constitutive phosphorylation of p65 at ser 
536 which 
in turn inhibit its down stream actions. 
 
 
 
Figure 4.13(a) Effect of 2607 on p65 Inhibition  
Western blot was performed on 50ug of extracts from LNCaP cells and probed for p65, 
p65 (ser 536) and MMP 9 expression. Lane 1&2 LNCaP unstimulated & unstimulated 
(vehicle,  ethanol).Lanes  3 8  LNCaP  cell  extracts  incubated  for  24  hours  in 
0.1,1,3,10,30,100 uM of drug 2607respectively. Tubulin (50kd) was used as a loading 
control. 
 
p65 
Pp65 
MMP 9 
Tubulin 155 
 
Figure 4.13 (b) Effect of 2070 on p65 Inhibition  
Western blot was performed on 50ug of extracts from LNCaP cells and probed for p65, 
p65 (ser 536) and MMP 9 expression. Lane 1&2 LNCaP unstimulated & unstimulated 
(vehicle,  ethanol).Lanes  3 8  LNCaP  cell  extracts  incubated  for  24  hours  in 
0.1,1,3,10,30,100 uM of drug 2070 respectively. Tubulin (50kd) was used as a loading 
control. 
 
To further examine the affect of NFқB inhibition both cell lines were incubated with 
1uM, 10 uM and 50 uM of inhibitors 2607 and 2070 and the proliferation measured at 24 
and  72  hours  by  WST  assay.  Both  cell  lines  showed  a  dose  dependent  inhibition  in 
proliferation after 72 hours, (Figures 4.14(a), 4.14(b) and 4.15). Additonally the effect of 
these inhibitors on apoptosis was also examined. It was observed that 2070 stimulated 
apoptosis during 24 hours in response to all concentrations tested and 2607 stimulated 
apoptosis during 24 hours in response to 50uM only (Figure 4.16 & 4.17).  
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Figure 4.14(a): Drug 2607 inhibits cellular proliferation 
 LNCaP  cells  were  treated  with  1,  10  &50  uM  of  drug  2607  and  proliferation  was 
significantly reduced at 72 hours 
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Figure 4.14(b): Drug 2070 inhibits cellular proliferation 
 LNCaP  cells  were  treated  with  1,  10  &50  uM  of  drug  2070  and  proliferation  was 
significantly reduced at 72 hours. 
 
 
 
 
 
 
 
 
Figure 4.15: Drug 2070 inhibits proliferation in LNCaP CR cells  
LNCaP  cells  were  treated  with  1,  10  &50  uM  of  drug  2070  and  proliferation  was 
significantly reduced at 72 hours. 
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Figure 4.16: Drug 2070 stimulates apoptosis in LNCaP CR cells  
LNCaP CR  cells  were  treated  with  1,  10  &50  uM  of  drug  2070  and  apoptosis  was 
significantly induced at 24 hours. 
 
 
 
 
 
 
 
 
Figure 4.17: Drug 2607 stimulates apoptosis in LNCaP cells 
 LNCaP  cells  were  treated  with  1,  10  &50  uM  of  drug  2607  and  apoptosis  was 
significantly induced at 24 hours 
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4.5 Discussion 
 
The NFқB system is viewed as a hopeful anticancer target due to its role in oncogenesis 
and chemotherapy resistance in many tumour types. As the biological significance of 
constitutive  NFқB  activation  in  prostate  cancer  is  unclear  at  present,  this  study  was 
undertaken to provide further evidence on the expression and role of NFқB in prostate 
cancer progression and aimed to characterise the expression and subcellular location of 
p65 protein and explore the value of p65 in predicting patient outcome. Phosphorylated 
and  total  NFқB  p65  protein  expression  and  localisation  were  determined  in  prostate 
cancer tissue and cell lines.  
In this study it was observed that phosphorylation of p65 at serine residues 276 and 536 
was  a  common  event  in  prostate  cancer  with  all  samples  showing  some  degree  of 
expression of both phosphorylation sites in the nucleus.  Both activation sites were found 
to significantly increase with the progression to castrate resistant disease however neither 
were associated with survival. In the hormone naïve tumours a high expression level 
(above  the  median)  of  cytoplasmic  p65p
536  resulted  in  a  longer  time  to  biochemical 
relapse than those patients who expressed low  levels, (Figure 4.3). This result is not 
unforeseen as it is frequently stated in the literature that p65 subunit of NFқB is further 
activated in the nucleus where it then binds to and activates a wide number of genes. 
Surprisingly a high level of nuclear p65 
536 in castrate resistant tumours was also shown 
to have protective role. Patients whose tumours expressed low levels of nuclear p65 
536 
were observed to have a significantly shorter time to death from relapse (Figure 4.7). 
However when a change in p65 
536 expression from hormone naïve to castrate resistant 
disease was examined it was observed that increased levels of cytoplasmic p65 ser
536 160 
resulted in a shorter overall survival (Table 4.4) however this result was only observed in 
four patients and data was therefore not shown, if the cohort were expanded this may 
have been evident in a larger population of the cohort. Thus these results indicate that the 
activation  of  p65  ser 
536  is  not  playing  a  direct  role  in  the  development  of  castrate 
resistant prostate cancer however, in a sub group of patients increased levels p65 ser
536  is 
seen  to  have  a  negative  effect  on  patient  survival.  We  hypothesis  that  another 
phosphorylation site of p65 is driving this observation or it could simply be that nuclear 
localisation is a more appropriate marker of NFkB and would serve as a more robust 
biomarker/prognostic marker.  The phosphorylation sites chosen in the current study had 
been extensively reported in the literature as being associated with p65 transactivation in 
many cancer types (224 226). 
A review of the literature, demonstrated that Akt can activate NFқB via serval stimuli 
and this in turn functions to prevent apoptosis. In particular, two studies have indicated 
that  Akt,  via  TNFα  signallingor  in  response  to  growth  factor  stimulation,  stimulated 
NFқB nuclear translocation via the IKK complex (192;203). Another study indicated that 
Akt alone could not induce nuclear translocation of NFқB but synergized with PMA to 
induce this response (191). It has been shown that Akt signallinginvolves the stimulation 
of the transcription function of NFқB and that the ability of oncogenic Ras to activate 
NFқB transcriptional activity is dependent on Akt activity (227;228). Madrid et al have 
also observed that the ability of Akt to stimulate the transactivation potential of the p65 
subunit of NFқB actually requires IKK and p38 (229). In this study a negative correlation 
between  activated  Akt  and  p65  ser
536  was  observed  which  corroborates  with  others 
suggesting that Akt does not directly phosphorylate p65 at ser 
536.  161 
Studies showing that NFқB is active (i.e. nuclear) in a number of tumours are consistent 
with a role for NFқB in cancer, although some tumour cell lines exhibit NFқB activity 
without significant nuclear accumulation hence suggesting a cytoplasmic role  for p65 
other than a nuclear transcription factor. In this study it was observed that an increase in 
cytoplasmic p65 expression in the transition from hormone naïve to castrate resistant 
disease was significantly associated with a shorter time to death from relapse (Figure 
4.11) and cytoplasmic p65 expression also correlated with PSA at relapse (Figure 4.5). 
The PSA gene promoter has қB site (230). PSA is involved in prostate epithelial growth 
therefore  suggesting  that  p65  is  involved  in  prostate  cancer  progression.    When 
expression levels of   p65 inhibitor pIқBα
32/36 were  examined it was noted that high 
nuclear levels were significantly associated with a shorter time to death from relapse this 
result  indicates  that  p65  is  active  in  the  cell.  Moreover  metastasis  at  relapse  was 
significantly associated with nuclear p IκBα ser 
32/36 (Figure 4.10), further suggesting a 
role  for  p65  in  prostate  cancer  progression.  As  previously  mentioned  IκBα  is 
phosphorylated at serines 32/36 in by IKKα/β in response to multiple stimuli and marked 
for degradation by the UPS, this is known to occur in the cytoplasm and leads to NFκB 
activation  and  nuclear  translocation.  Newly  synthesized  IκBα  shuttles  in  and  out  the 
nucleus  controlling  NFκB  activity  however  evidence  now  indicates  that  proteasomes 
occur in the
 cytoplasm and the cell nucleus (231 233) (234;235). Additionally, IKKα has 
recently  been  reported  to  have  a  nuclear  role  (236).  In  prostate  cancers  infiltrating 
immune cells which express RANKL (Receptor activator of NFκB) have been shown to 
bind to its receptor, RANK which induces activation and nuclear translocation of IKKα. 162 
IKKα  then  interacts  with  the  Maspin  gene  promoter  silencing  its  expression,  in  turn 
promoting prostate cancer metastases (237).  
NFκB has been shown to be constitutively activated in prostate cancer cells, and elevated 
NFκB activity is also sustained in androgen responsive human prostate cancer cells by 
androgen treatment. Huang et al have demonstrated that suppression of NFκB activity in 
human  prostate  cancer  cells  by  IκBα  mutation  transfection  inhibits  their  metastatic 
properties  in  nude  mice  by  suppressing  angiogenesis  and  invasion  providing  direct 
involvement of NFκB in the regulation of angiogenesis and metastasis of prostate cancer 
cells (198).   
Numerous reports have demonstrated that in prostate cancer as well as other tumour types 
that the metastatic potential of tumour cells directly correlates with the expression level 
of several angiogenic genes, including vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (Bfgf), interleukin 8 (IL 8) and matrix metalloproteases MMP 2 
and MMP 9 (16). Expression of MMPs is associated with poor prognosis in a variety of 
cancers including prostate. An increase in MMP 2 and MMP 9 is associated with tumour 
progression but how the constitutive expression of these genes is regulated in prostate 
cancer is at present unclear. It is known however that NFκB binds the MMP 9 promoter 
(13). In this study MMP 9 expression was significantly associated with the presence of 
metastasis at relapse and was also significantly associated with shorter time to death from 
relapse  (Figure  4.5  &  Figure  4.9).    An  increase  in  MMP 9  expression  was  also 
significantly associated with a shorter overall survival (Table 4.5), again this was only 
observed in a few patients and the data is not shown. This study provides evidence that 163 
NFκB signallingis an important event in the progression of castrate resistant prostate 
cancer and metastasis in a subset of patients.  
In prostate cancer cells androgen depravation induces cell cycle arrest and apoptotic cell 
death. NFκB mediates cell cycle progression through direct binding of the Cyclin D1 
promoter at multiple sites and regulates progression through G1 S cell cycle check point 
(238).  The  expression  of  Cyclin  D1  was  investigated  in  another  study  done  in  our 
Laboratory  using the current patient  cohort. Therefore the association between  NFκB 
pathway members and Cyclin D1 expression was calculated using the Spearman’s Rank 
Correlation Test. In the hormone naïve tumours a positive correlation between nuclear 
p65 ser 
276 and nuclear Cyclin D1 was observed p=0.040 r
2 =4.32. Moreover a positive 
correlation between nuclear pIқBα
32/36 and Cyclin D1 expression p=0.020 r
2 =.516 was 
observed in the castrate resistant cohort. NFκB has also been shown to inhibit apoptosis 
by directly binding the promoter and inducing genes encoding BCL 2 homologue BCL 
XL and survivin (239). Therefore inhibition of p65 is an important strategy to inhibit 
prostate  cancer  tumourgenesis.  Due  to  the  diverge  ranges  of  upstream  activators  of 
NFκB, the effect of inhibiting NFκB activity directly was investigated.  In the current 
study  it  was  demonstrated  using  two  novel  NFκB  inhibitors  that  these  drugs  can 
significantly inhibit proliferation and stimulate apoptosis in both LNCaP and LNCaP CR 
cells.  These observations support the hypothesis that NFκB could offer a therapeutic 
target  for  treatment  of  castrate  resistant  prostate  cancer.  Additionally,  the  suggested 
biomarker for prediction of patient response for these novel therapies would be nuclear 
localization of p65 and not phosphorylation of the sites investigated in the current study.  164 
In summary, it was hypothesised that NFκB expression could be increased via activation 
of the Akt cascade however no positive correlation was observed between activated Akt 
and  activated  NFκB.  However  these  findings  suggest  that  activation  of  the  NFκB 
pathway  is  sufficient  to  maintain  androgen  independent  growth  of  prostate  cancer. 
Inhibition  of  NFκB  activity  leads  to  a  decrease  in  cellular  proliferation  and  induced 
apoptosis. Thus the NFκB pathway may be a potential target for therapy in a subset of 
patients with castrate resistant disease.  
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5. The relationship between Akt and the Androgen receptor 
 
5.1 Introduction 
The mechanisms driving the development of castrate resistance are not fully understood 
and there are several hypotheses. As discussed in chapter 1, the AR can be activated in a 
ligand dependent manner, via androgen or in a ligand independent manner via signal 
transduction cascades. During the progression of prostate cancer from hormone naïve to 
castrate resistant disease prostate cancer cells retain AR expression which suggests that 
AR plays a critical role in the development and progression of prostate cancer. Research 
suggest that activation of the PI3K/Akt cascade contributes to the development of castrate 
resistant disease through phosphorylating and activating the AR. Results from chapter 3 
suggested  that  low  levels  of  PTEN,  increased  levels  of  PI3K,  and  activated  Akt  are 
associated  with  reduced  time  to  relapse  and  patient  survival.  Inhibition  of  PI3K  also 
resulted in decreased Akt activation and decreased cellular proliferation. As mentioned in 
chapter 1, Akt specifically binds to AR and phosphorylates serines 213 and 791, thereby 
activating AR. Blocking the Akt cascade by a dominant – negative Akt or an inhibitor of 
Akt inhibits HER2 induced AR signalling. Thus, these results suggest  that Akt is an 
activator of AR signalling. The interaction between Akt and the AR is well documented 
however the consequence of AR phosphorylation by Akt on patient survival has not been 
investigated in clinical samples. 
This  study  investigates  whether  phosphorylation  of  AR  by  Akt  influences  clinical 
outcome  and  the  progression  to  castrate  resistant  disease.  Matched  patients  samples 
(hormone  naïve  and  castrate  resistant)  were  analysed  for  AR,  AR  phosphorylated  at 
serine 213 (Akt consensus site) and AR phosphorylated at serine 81 expression (which 166 
has  previously  been  shown  to  be  phosphorylated  in  response  to  androgens).  In  vitro 
models  were  employed  to  investigate  the  effect  of  PI3K  inhibition  on  AR 
phosphorylation and PI3K expression was knocked down using small interfering RNA 
specific  to  the  p85  regulatory  subunit  of  PI3K,  and  the  consequences  of  this  on  AR 
phosphorylation were investigated by Immunofluoresence. 
 
5.2 Patients 
 
Sixty two patients with matched hormone naïve and castrate resistant tumour pairs were 
retrospectively selected for analysis (124 tumours in total) Clinical data, recorded for 
each  patient  included  age  (median  70,  inter  quartile  range  66 74),  PSA  at  diagnosis 
(median 31 ng/ml, inter quartile range 7.8 109), PSA at relapse (median 13.4 ng/ml, 
inter quartile range 4.5 31) and Gleason grade at diagnosis (median 8, range 6 9).  All 
patients  under  went  biochemical  relapse  (median  time  to  relapse  2.49  years,  inter 
quartile range 1.63 4.27 years) and median follow up was 6.7 (2.8 8.4) years.  Patients 
in this cohort were diagnosed with locally advanced (39) or metastatic prostate cancer 
(23)  and  subsequently  received  surgery  and  androgen  deprivation  therapy  (26  sub 
capsular bilateral orchidectomy, 43 GnRH analogue, 3 had both).  Forty four of the 62 
patients also received anti androgen therapy and this included all those who received 
GnRH analogues. Forty patients (64%) had metastases at relapse.  Fifty nine patients 
(95%) died during follow up and median survival for these patients was 4.73 (3.75 
6.74).  Clinical parameters associated with time to biochemical relapse, time to death 
from biochemical relapse and disease specific survival are shown in table 5.1. 
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  Time to relapse  Time to death 
from relapse 
Disease specific 
survival 
Age 
 
0.210  0.247  0.246 
Gleason 
 
0.031  0.002  0.001 
Metastasis at 
diagnosis 
 
0.007  0.016  <0.001 
PSA at diagnosis 
 
0.025  0.471  0.141 
Metastasis at 
relapse 
 
NA  0.001  0.006 
PSA at relapse  NA  0.146  <0.001 
 
Table 5.1: Patient Characteristics 
An  overview  of  the  cohort’s  characteristics  where  each  clinical  parameter,  were 
appropriate has been correlated with time to relapse, time to death from relapse and 
disease specific survival (p values).  
 
5.3 Immunohistochemistry 
Before IHC commenced antibody specificity was confirmed by western blotting (Figure 
5.1). Information on all antibodies employed are displayed in table 5.2 and examples of 
immunohistochemical staining for each are displayed in figure 5.2 . I am grateful to Dr 
Yin Rue Lim for carrying out the AR IHC. 
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A.Androgen receptor 
(110kDa). Western blot of 
LNCaP, LNCaP CR and 
casodex resistant LNCaP cell 
extracts grown in full medium. 
 
B. Androgen receptor p serine 
81(110kDa).  Western blot of LNCaP cell 
extracts grown in full medium untreated 
and  treated with 10nm DHT.  
 
 
 
 
 
 
 
 
 
C. Androgen receptor p serine 
213 (110kDa). Western blot of LNCaP, LNCaP 
CR, and casodex resistant LNCaP cell extracts grown in full medium. 
 
Figure 5.1: Antibody specificity 
Western blotting was performed to confirm the specificity of all antibodies used in this 
study 
 169 
 
Protein  Antibody  Antigen 
Retrieval 
Antibody 
concentration 
Incubation 
temperature 
and time 
AR 
AR 
Mouse Monoclonal 
IgG1 Ab 
Dako (A/S) 
TE Buffer  1ug/ml  Overnight at 
4ºC 
AR 
AR p serine 81 
Rabbit Polyclonal 
IgG1 Ab 
Upstate 
TE Buffer  10ug/ml  Overnight at 
4ºC 
AR 
AR  p serine 213 
Rabbit Polyclonal 
IgG1 Ab 
Imgenex 
TE Buffer  50ug/ml  One hour at 
25ºC 
 
Table 5.2: Antibody Information 
Details  of  the  antibodies  used  to  detect  AR,  pAR  serine  81  and    pAR  serine 
213.Information  regarding  the  source;  antigen  retrieval  method,  concentation  and 
incubation are all recorded.  
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Figure 5.2: Immunohistochemistry 
Prostate tumours displaying immunohistochemical staining magnification x400 
 
5.3.1 Protein expression patterns 
 
Protein expression of AR, pAR serine 
213 and pAR serine 
81 was observed in the cell 
cytoplasm  and  nucleus.  Expression  of  all  proteins  investigated  was  non  parametric, 
median values  and inter quartile ranges for each protein at each  cellular location  are 
provided in table 5.3 for both hormone naïve and castrate resistant tumours. All IHC 
Androgen Receptor        Phosphorylated AR serine 81 
Phosphorylated AR serine 213 171 
statistical  analysis  was  carried  out  as  previously  described  in  Materials  and  methods 
(Chapter 2.9.1&2.9.2).  
Both  cytoplasmic  and  nuclear  AR  expression  increased  significantly  with  the 
development of castrate resistant disease. Nuclear pAR ser 
213 increased significantly with 
the development of castrate resistant disease and cytoplasmic pAR ser 
81 significantly 
decreased with the development of castrate resistant disease (Table 5.3).  
 
  HNPC 
(IQR) 
CRPC 
(IQR) 
P value  ICCC  Histoscore 
units 
AR, c 
AR, n 
0 
65.0  
( 36.7 90.7) 
5 (0 30)  
120.0  
(78.8 147.5) 
P=<0.0001 
P=<0.0001 
 
0.89 
0.81 
50 
48 
AR p ser 
81 c 
AR p ser 
81n 
90(50 115) 
100(50 135) 
60(30 95) 
90(50 120) 
P=0.001 
P=0.816 
0.75 
0.77 
73 
108 
AR p ser 
213n  35(0 85)  103(50 169)  P=<0.0001  0.93  52 
Table 5.3. Protein expression patterns 
The  median  histoscore  and  interquartile  range  (IQR)  for  hormone  naive  tumours 
(HNPC)  and  castrate  resistant  tumours  (CRPC)  and  the  p  value  of  these  values 
compared using a Wilcoxon sign rank test.  ICCC= interclass correlation coefficient.  
The mean difference in observer scores plus 2 standard deviations is also shown as the 
number of histoscore units that is defined as a change in protein expression. c and n 
relates to protein cellular location, c= cytoplasm and n = nucleus. P before a protein 
indicates that the antibody detects phosphorylated protein and the number following the 
protein represents the site of phosphorylation. 
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5.3.2 Protein expression in the Hormone Naïve cohort 
 
As done in the previous chapters, protein expression levels were analysed for association 
with clinical outcome by dividing into high (above median values) and low expression 
(below median values)  and Kaplan Meier  graphs were plotted to determine if protein 
expression  was  linked  to  patient  outcome.  None  of  the  protein  investigated  were 
associated time to biochemical relapse or patient survival. 
5.3.3 Protein expression in Castrate resistant tumours 
 
When expression levels of each protein investigated in the castrate resistant tumours were 
divided into to high or low expression, nuclear AR expression was associated with a 
quicker time to death from relapse (Figure 5.3). Patients with high AR expression had a 
median survival from time from relapse of 1.34 yrs (0.80 1.88) compared to 3.0 years 
(1.68 4.32) for those with low AR expression (p=0.038 HR 1.98 (1.03 3.82)) however, 
this was not significant on Cox Regression multivariate analysis. High expression of pAR 
ser 
213 was associated with quicker time to death from relapse (figure 5.4(a), p=0.003 HR 
2.85 (1.38 5.87)) and shorter disease specific survival (figure5.4 (b), p=0.0136, HR 2.33 
(1.16 4.66).  Median survival from time from relapse for those patients with tumours that 
expressed low levels of pAR ser 
213 was 3.42 (2.82 4.02) years compared to 1.40 (0.85 
1.95) for those who had tumours that expressed high levels of pAR ser 
213 . The median 
disease specific survival for those patients with tumours that expressed low levels of pAR 
ser 
213  was  8.57  (5.41 11.73)  years  compared  to  5.82  (3.18 8.46)  for  those  who  had 
tumours that expressed high levels of pAR ser 
213.  This represents a survival difference of 
almost 3 years for patients expressing high levels of pAR ser 
213 in their castrate resistant 
tumour.  Additionally,  correlations  between  clinical  parameters  and  protein  expression 173 
revealed  high  expression  of  AR  and  pAR  ser 
213  was  associated  with  presence  of 
metastases at relapse figure 5.5 (p=0.018 and p=0.046, respectively). The phosphorylation  
of AR ser 
81 was not associated with patient survival. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Nuclear AR expression 
Kaplan Meier plot demonstrates that those patients whose castrate resistant tumour has 
high AR nuclear expression (bottom line) have shorter time to disease specific death from 
time of biochemical relapse than those patients whose castrate resistant tumour have low 
AR nuclear expression (top line)(p=0.038). 
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Figure 5.4(a): Nuclear pAR ser 
213 expression 
Kaplan Meier plot demonstrates that those patients whose castrate resistant tumour has 
high pAR nuclear ser 
213  expression (broken line) have shorter time to disease specific 
death  from  time  of  biochemical  relapse  than  those  patients  whose  castrate  resistant 
tumour have low pAR nuclear ser 
213  expression (solid line)(p=0.003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4(b): Nuclear pAR ser 
213 expression and disease specific survival 
Kaplan Meier plot demonstrates that those patients whose castrate resistant tumour has 
high pAR nuclear ser 
213  expression (broken line) have shorter time to disease specific 175 
death than those patients whose castrate resistant tumour have low pAR nuclear ser 
213  
expression (solid line)(p=0.0136). 
 
 
 
 
 
 
 
 
Figure 5.5: AR & pAR ser 
213 expression and metastasis at relapse 
Box plot demonstrating difference in expression of total AR expression (left), and pAR ser 
213 expression (right) between metastatic and non metastatic patients at relapse. 
 
5.3.4 Changes in Protein Expression  
 
As with the previous two chapters changes in protein expression levels in the transition 
from hormone naive to  castrate resistant disease were used to investigate a link  with 
clinical outcome.  In the current cohort, castrate resistant tumours express significantly 
higher levels of pAR ser 
213 compared to hormone naïve tumours, approximately 42% of 
patients have an increase in pAR ser 
213 expression, (Figure 5.6). An increase in pAR ser 
213 expression (figure 5.7(a), p<0.0001, HR 4.18 (1.99 8.74)) was significantly associated 176 
with quicker time to death from relapse, the median survival from biochemical relapse for 
those patients whose tumours had a decrease or no change in pAR ser 
213 expression was 
3.46  (1.39 5.53)  years  compared  to  1.25  (0.83 1.67)  years  for  those  patients  whose 
tumours had an increase in pAR ser 
213 expression.  Additionally an increase in pAR ser 
213 (figure 5.7 (b) p=0.0015, HR 2.86 (1.45 5.67)) was associated with a shorter disease 
specific survival. The median survival from diagnosis for those patients whose tumours 
had  a  decrease  or  no  change  in  pAR  ser 
213  expression  was  6.95  (4.07 9.83)  years 
compared to 4.36 (1.67 7.10) years for those patients whose tumours had an increase in 
pAR ser 
213 expression. 
Figure 5.6: Change in pAR ser 213 expression 
Displays the number of patients who had an increase in pAR ser 
213 protein expression. 
IHC staining of a patient who had an actual increase of 150 histoscore units in the 177 
transition  tcastrate  resistant  disease.  Brown  nuclear  staining  denotes  pAR  ser 
213expression.  Magnification x400. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7(a): Increased pAR ser 213 and time to death from relapse 
Kaplan Meier plot demonstrates that those patients whose tumours exhibit a increase in 
pAR
213 expression (broken line) have shorter time to disease specific death from time of 
biochemical relapse than those patients whose tumours exhibit no change or a fall in 
pAR
213 expression (solid line). 
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Figure 5.7(b): Increased pAR ser 213 and disease specific death 
Kaplan Meier plot demonstrates that those patients whose tumours exhibit a increase in 
pAR
213 expression (broken line) have shorter time to disease specific death than those 
patients whose tumours exhibit no change or a fall in pAR
213 expression (solid line). 
 
 
 
5.3.5 Correlations between active members of the PI3K/Akt cascade 
 
Protein expression was also correlated with members of the PI3K cascade. In hormone 
naïve tumours expression levels of the phosphorylated proteins did not correlate, however 
in  the  castrate  resistant  tumours  pAkt  ser 
473  correlated  with  pAR  ser 
213  (rs=0.711, 
p<0.001) and pmTOR2
448 (rs.=0.489, p=0.003). 
5.3.6 Association between AR gene amplification and protein expression 
Data  for  AR  gene  amplification  from  the  same  cohort  of  patients  was  available  for 
analysis to determine if AR amplification was associated with an increase in expression 
of AR. Those patients who exhibited AR amplification, (Figure 5.8) (AR: X ratio >1.5) in 179 
castrate resistant tumours had a significantly shorter time to death from relapse compared 
to patients who had no AR amplification (p=0.0002) (102). 
 
Figure 5.8: AR gene amplification 
 Hormone  sensitive  tumour  with  normal  AR:X  chromosome  ratio  (left)  and  castrate 
resistant tumour with AR amplification; ratio of orange to green signal of > 1.5 
 
AR amplification was correlated with AR expression level, and a significant correlation 
was observed (p=0.033, correlation coefficient=0.25).  By dividing AR expression into 
tumours with or without AR amplification, tumours with amplification had significantly 
higher AR expression compared to those without amplification (p=0.005) (Figure 5.9(a)). 
Median AR expression for castrate resistant tumours without amplification is 125 (IQR 
73 156) histoscore units compared to 181 (IQR, 126 219) histoscore units for tumours 
with amplification. In addition, AR amplification significantly correlated with pAR ser 
213 expression (p=0.007, CC=0.315). Castrate resistant tumours with gene amplification 
have  significantly  higher  pAR  ser
213  expression  levels  (p=0.004).  Median  pAR
213 
expression  for  castrate  resistant  tumours  without  amplification  is  90  (IQR,  23 130) 180 
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histoscore units compared to 165 (IQR, 83 193) histoscore units, for tumours that do 
have amplification (Figure 5.9(b). Expression of pAR ser 
81 did not correlate significantly 
with AR amplification p=0.705.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9(a): AR amplification and AR protein expression 
 Box plot demonstrating difference in expression of total AR expression between AR 
amplified and Non amplified tumours. 
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Figure 5.9 (b): AR amplification and pAR ser 
213 protein expression 
 Boxplot demonstrating differences in expression of pAR ser 
213 between AR amplified 
and non AR amplified tumours. 
 
 
 
5.4 Cell line 
5.4.1 The phosphorylation of AR  
Work carried out previously in our laboratory confirmed the LNCaP cell lines used in this 
study to be a good in vitro model of hormone naïve and castrate resistant prostate cancers 
(2505). Hormone naïve LNCaP cells response to DHT was measured by phosphorylation 
of the AR at serine 
81 (Figure 5.10). Here it was observed that DHT stimulates AR ser 
81 
phosphorylation within five minutes while levels of AR remain constant.  
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Figure 5.10: DHT stimulation of LNCaP cells 
Western blot was performed on 50ug of extracts from LNCaP cells and probed for AR & 
pAR ser 81 (110kDa). Lane 1 unstimulated LNCaP. Lanes 2 6 treated with 10nM DHT 
for 5,15,30,60,180 minutes (respectively) Tubulin (50kd) was used as a loading control. 
 
5.4.2 Effect of PI3K inhibition on AR phosphorylation. 
 
As shown in chapter 3 the PI3K inhibitor LY294002 inhibits pAkt ser 
473 in LNCaP
 cells, 
(Figure 3.5). It was therefore deemed appropriate to determine whether this inhibition of 
Akt also results in down regulation of pAR at the Akt consensus site serine 213. The 
tissue results above indicate that phosphorylation of the AR at serine 213 is associated 
with the progression of castrate resistant disease it was therefore necessary to investigate 
the consequences of PI3K inhibition in LNCaP CR to mirror the tissue expression study. 
Therefore to determine whether PI3K/Akt cascade plays a role in the phosphorylation of 
AR serine 213 LNCaP CR cells were treated with LY294002 and with or without the 
stimulation  with  IGF 1  (chapter  2.1.6).  Expression  of  pAR  ser
213  was  determined  by 
western  blotting.  Here  it  is  observed  that  the  expression  of  pAR  ser
213  is  markedly 
reduced  in  the  castrate  resistant  cell  lines  (Figure  5.11).  This  indicates  that  a  kinase 183 
activated by the PI3K cascade, likely Akt is involved in phosphorylation of AR at serine 
213. 
 
 
Figure 5.11: LY294002 inhibition of pAR ser 
213 
 Western blot was performed on 50ug of extracts from LNCaP &LNCaP CR cells and 
probed for pAR ser
213 (110kDa). Lane 1&2 unstimulated LNCaP &LNCaP CR , Lane 
3&4  LNCaP  &LNCaP  CR  treated  with  LY294002  20uM  for  30  minutes  Lanes  5&6 
LNCaP  &LNCaP  CR  with  10ng  IGF 1  for  1  hour,  lanes  7&8  LNCaP  &LNCaP  CR 
treated with LY294002 20uM for 30 minutes then with 10ng IGF 1 for 1 hour.  Bands at 
110kD respresent full length AR, 80kD represent AR V 7 and 60kD represent AR V 
3.Extra bands in lane 1 are shadow from the protein ladder. 
 
 
 
 
5.4.3 Effect of siRNA knockdown of PI3K on AR phosphorylation 
 
PI3K was silenced in LNCaP CR cells and to visualize the effects of this silencing on 
down stream targets of PI3K an Immunofluorescent (IF) study was designed.  As shown 
in Figure 5.12 successful knockdown of PI3K was achieved. PI3K expression is observed 
in  the  non  silenced  control  cells  and  barely  expressed  in  the  PI3K  siRNA  cells.  The 
expression  of  downstream  targets  of  PI3K  was  also  observed  to  be  markedly  lower. 
Phosphorylation of both Akt ser 
473 and AR ser 
213 are also reduced in the PI3K siRNA 184 
cells  compared  with  the  controls.  Additionally  as  expected,  silencing  PI3K  has  no 
apparent effect on AR or phosphorylated AR at ser 
81 expression.  
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Figure 5.12: PI3Kp85 silencing in LNCaP cells 186 
5.5 Discussion 
 
It  has  been  well  documented  that  in  addition  to  protecting  and  stabilizing  AR, 
phosphorylation of specific serine residues can influence a ligand independent induction 
of transcription by the AR (92;240).
 The AR exists as a phosphorylated protein in cells 
even  in  the  absence  of  ligand binding  (94;241).  Ligand free  AR  is  unstable  and 
undergoes  degradation.  Upon  binding  of  androgens,  the  AR  undergoes  additional 
phosphorylation  predominantly  at  serine  residues  (94;242).  Translating  the  in  vitro 
evidence into the clinical scenario, this study established that phosphorylation at specific 
serine residues on the AR are involved in the development of castrate resistant disease. 
The current study investigated phosphorylation of the AR at serine residues 81 and 213 
with the aim of identifying if phosphorylation of AR is of clinical importance and to 
establish  if  phosphorylation  at  a  specific  site  played  a  key  role  in  castrate  resistant 
disease.    The  phosphorylation  at  serine  81  is  located  in  the  N terminus  between  the 
polyglutamine stretch and AF 1(243). In response to androgen binding, Serine 81 is the 
most  frequently  phosphorylated  site  on  the  AR,  giving  the  highest  stoichometric 
phosphorylation  yield in  LNCaP cells treated with androgens (94).Phosphorylation of 
Serine 81 is associated with AR stability and transcriptional activity (95) and prostate 
cancer cell growth in cell line studies (96).Cell lines studies investigating mutagenesis at 
serine 81 signify that phosphorylation at this site alone does not drive AR transcriptional 
activity or stabilization, which suggests multiple sites may be involved.  
In the current study expression of pAR ser 
81 significantly decreased with the progression 
to castrate resistant disease (Table 5.3).  These results indicate that AR phosphorylation 
at  serine  81  decreases  with  the  development  of  castrate  resistant  disease.  This  is  in 187 
agreement  with  reports  in  the  literature  stating  that  serine  81  occurs  in  response  to 
androgen binding. As androgen levels are higher in hormone naïve prostate cancers, a 
decrease in pAR ser 
81 expression would be expected in castrate resistant prostate cancer 
due to hormone depravation therapy which all patients in the cohort received. In LNCaP 
cells pAR ser 
81 expression was induced by DHT stimulation (Figure 5.9) and was barely 
detectable  without  the  addition  of  ligand.  Interestingly,  the  expression  of  pAR  ser 
81 
returns to barely detectable levels between 15 and 30 minutes whereas the expression of 
total  AR  remains  unchanged.  This  result  is  similar  to  that  published  by  Chen  et  al, 
however there are slight experimental difference with the conditions of Cell culturing and 
DHT exposure (244). Therefore the data gained from this study is in agreement with 
previous reports suggesting that multiple site of AR phosphorylation are involved in the 
transcriptional activity of the AR and thus the progression to castrate resistant disease. 
AR expression (above the median) was associated with a quicker time to death from 
relapse (Figure 5.3) and was also observed to be significantly higher in patients who 
acquired metastatic disease at relapse (Figure 5.5), this result suggests AR involvement in 
the progression of castrate resistant disease and metastases despite patients undergoing 
hormone  depravation  therapy  which  has  been  well  documented  in  the  literature. 
Interestingly  phosphorylation  of  the  AR  at  serine  213  was  shown  to  be  significantly 
associated with castrate resistant disease. A high protein expression (above the median) 
of pAR ser 
213 in castrate resistant tumours was observed to be significantly associated 
with  a  shorter  time  to  disease  specific  death  from  biochemical  relapse  and  a  shorter 
overall  survival,  (Figures  5.4  a&b),  in  addition  expression  of  pAR  ser 
213  was  also 
observed to be significantly higher in patients who acquired metastatic disease at relapse 188 
(Figure 5.5). Furthermore, castrate resistant tumours express significantly higher levels of 
pAR ser 
213 compared to hormone naïve tumours, (Table 5.3).   It was observed that 
approximately 42% of  patients have an increase in pAR ser 
213 expression and these 
patients have a significantly shorter survival period from time of relapse and a shorter 
disease specific death than those with no increase in expression (Figures 5.7 a & b).The 
expression levels of pAR ser 
213 were correlated with members of the PI3K cascade and it 
was  established  that    pAR  ser 
213  and  pAkt  ser 
473  expression  levels  correlated 
significantly  in  the  castrate  resistant  tumours  only,  suggesting  that  it  is  only  when 
androgen levels are low that this signallingcascade is activated. 
 Moreover,  these  results  confirmed  previous  findings  in  the  literature  that  AR 
amplification and protein over expression may be involved in castrate resistant disease
. 
Using  the  AR  gene  amplification  data  from  this  cohort  it  was  possible  to  determine 
whether AR amplification resulted in increased protein expression and it was observed 
that both AR and pAR ser 
213 expression was significantly higher in castrate resistant 
patients with AR gene amplification, (Figure 5.9 a& b). These results confirmed previous 
findings  in  the  literature  that  AR  amplification  and  protein  over expression  may  be 
involved in CRPC development (101 103). However, AR amplification and/or increase in 
AR expression are too low to wholly explain castrate resistant disease development. 
This  study  was  also  investigated  the  hypothesis  that  targeted  depletion  of  PI3K  will 
inhibit AR activation in prostate cancer cells. The AR remains the most important nuclear 
receptor in prostate cancer therefore this study used two prostate cancer cell lines which 
represent  prostate  cancers  cells  in  vivo  which  express  the  AR.  The  PI3K  inhibitor 
LY294002 targets the p110 catalytic site of PI3K. The use of this inhibitor in LNCaP cell 189 
lines  has  indicated  a  role  for  PI3K  in  the  phosphorylation  of  AR  at  serine  213.Both 
LNCaP and LNCaP CR cells were observed to have a markedly reduced expression of 
pAR ser 
213 when treated with LY294002 (Figure 5.11). Interestingly the castrate resistant 
LNCaP cells appear to be more sensitive. This may be due to the fact that in hormone 
naïve cells phosphorylation of serine 213 occurs in the presence of androgens suggesting 
that ligand binding induces a conformational change in the N terminus that reveals the 
serine  213  site  to  cellular  kinases  (245)  whereas  in  castrate  resistant  cell  lines  AR 
phosphorylation at serine 213 is ligand independent.   However as the PI3K catalytic 
subunit  is  highly  conserved  amoung  the  PI3K  family  members  LY294002  does  not 
discriminate amoung the various isoforms of PI3K and therefore affects many cellular 
processes (246). Therefore an alternative and  more selective approach is to block the 
phosphotyrosine  binding  of  the  p85  SH2  domains  thus  averting  the  recruitment  and 
activation of class 1a PI3K by growth factor tyrosine kinases (247). As shown in Figure 
5.12 siRNA silencing of PI3K results in reduced expression of PI3K, pAkt ser 
473 and also 
pAR ser 
213  without altering AR or pAR ser 
81 expression levels. The results show that it 
is possible to inhibit the phosphorylation of AR through targeted silencing of the p85 
subunit of PI3K in prostate cancer cells and may therefore be therapeutic approach to the 
treatment of prostate cancer patients who display higher levels of p AR at serine 213.  The 
functional consequences of siRNA silencing of PI3K remains to be investigated however 
it  is  expected  that  depletion  of  PI3K  should  result  in  a  significant  decrease  in  cell 
proliferation and induction of apoptosis as this cascade serves to inhibit many tumour 
suppressor like proteins that negatively regulate cell survival, proliferation and growth. 
Thus blocking this pathway could therefore inhibit the proliferation of tumour cells, (as 190 
discussed in chapter 3.2.1) and sensitize them to apoptosis.  A similar study in breast 
cancer  cell  lines,  reported  that  targeted  depletion  of  PI3K  resulted  in  a  significant 
decrease in cell viability and induction of apoptosis irrespective of their ER or HER 2 
status and resulted in a significant G1 phase cell cycle arrest in ER positive breast cancer 
cell lines (247). 
These  results  provide  additional  evidence  that  the  PI3K/Akt  cascade  is  up regulated 
during development of castrate resistant disease, resulting in phosphorylation of the AR 
and sensitisation to circulating adrenal androgens.  Cell line studies demonstrate that this 
occurs in vitro, however the current data demonstrates for the first time that this may be 
one possible mechanism allowing development of castrate resistant disease in the clinical 
setting and targeting PI3K cascade is a possible means of therapeutic intervention. 
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6. General Discussion 
 
One  of  the  many  challenges  in  the  effective  management  of  prostate  cancer  is  the 
identification of molecular markers capable of predicting disease progression. Castrate 
resistant disease represents the lethal phenotype of prostate cancer. The main aim of this 
study  was  to  investigate  the  role  of  the  PI3K/Akt  cascade  in  the  development  and 
progression of prostate cancer and to determine if it influenced patient outcome.  Key 
functions  of  the  PI3K/Akt  cascade  are  mediating  cell  survival,  as  well  as  cell  cycle 
progression and neoplastic transformation (159). The outcome of this study suggested 
that the PI3K/Akt cascade is in part accountable for mediating patient outcome.  
Aberrant signallingof the PI3K/Akt cascade  can occur through  a variety  of processes 
including gain of function oncogenic mutations of PI3KCA, which has been reported in 
Breast, Ovarian and Colorectal cancer (187), amplification or mutation of Akt isoforms 
and loss of function PTEN, (248;249). Loss of function of PTEN can occur through gene 
deletion,  mutation,  microRNA  expression  or  epigenetic  silencing  (182;183;249;250). 
Patients in the current study were analysed for modifications of PIK3CA, PTEN, AKT1 3 
and mTOR at the genetic level using FISH. As outlined in chapter 3, very  few  gene 
amplifications  were  detected  for  PI3K  and  AKT1  to  warrant  analysis  and  no  gene 
amplifications were detected for mTOR, AKT2 and AKT 3. However, PTEN deletions 
were detected in 23% of hormone naive tumours, which increased significantly to 52% in 
castrate  resistant  tumours  (p=0.044).    Loss  of  one  copy  of  PTEN  was  commonly 
observed, and this was heterogeneous in nature, being frequently observed in only one 
area of tumour. Immunohistochemistry indicated that low levels of both cytoplasmic and 192 
nuclear PTEN protein expression in hormone naïve tumours have a significantly quicker 
time to relapse and this also translates into shorter overall survival. Negative regulation of 
the  PI3K  pathway  is  primarily  accomplished  through  the  action  of  PTEN.  This 
mechanism may therefore provide prostate cancer with the ability to  evade apoptosis 
induced by hormone depravation therapy and hence the progression to castrate resistant 
disease. Loss of PTEN function in prostate cancer is quite common and results in an 
abundance of lipid second messengers (PtdIns (3, 4, 5) P3), which can cause constitutive 
activation of PH domain containing proteins including Akt. This is a likely reason why 
Akt is found to be highly activated in advanced prostate cancers. In the current study low 
levels of PTEN were associated with high levels of activated Akt. However, additional 
factors such as PI3K overexpression may also contribute to Akt activation and disease 
progression.  
Consequently,  it  would  stand  to  reason  that  loss  of  PTEN  would  initiate  heightened 
activation of this cascade, which could then enable the cell to adopt a number of cancer 
like properties. A recent study by Zhu et al reported that gene expression analysis of 
clinical specimens showed that both PI3Kp85α and PI3Kp110β were highly expressed in 
malignant  prostate  tissues  compared  to  the  nonmalignant  compartments,  and  their 
expression levels correlated significantly with disease progression (251). However, in this 
study expression of PI3Kp110 α was investigated and it was observed that in a sub cohort 
of patients increased levels of PI3Kp110α, pAkt thr 
308 and
 pAkt ser 
473 expression were 
observed  to  be  significantly  associated  with  shorter  time  to  biochemical  relapse  and 
shorter disease specific survival moreover, the increase in pAkt ser 
473 expression predicts 
disease specific survival independent of Gleason grade and presence of metastases. Taken 193 
together  these  results  suggest  that  the  PI3K  cascade  is  functionally  active  in  castrate 
resistant disease.  
The most widely used in vitro model of prostate cancer is the
 LNCaP cell line (252) 
LNCaP contains a frameshift mutation
 in the PTEN gene (253). Consistent with LNCaP 
having defective PTEN,
 this study observed that Akt is constitutively phosphorylated
 in 
LNCaP cells after 24 hours of culture in serum free media and treatment of LNCaP with 
PI3K  inhibitor  LY294002  diminishes  the  phosphorylation
  of  Akt  and  also  results  in 
inhibition of proliferation. Abrogation of PI3K/Akt activity by PI3K inhibitors has also 
been  shown  to  stimulate  apoptosis  in  LNCaP  cells  (254;255).  These  findings  are  in 
agreement with the concept that it is the constitutive
 activation of the PI3K/Akt pathway 
that  renders  these
  cells  capable  of  surviving  without  exogenous  growth  and  survival
 
factors.  
Akt is able to target a number of proteins known to affect cell survival including caspase 
9, BAD, and glycogen synthase kinase 3β (GSK 3β) (256 258). Phosphorylation of these 
proteins by Akt may result in either their activation or inactivation but the end result is to 
promote survival of the cell. Once activated, Akt is able to translocate to the nucleus 
where it affects the activity of a number of transcriptional regulators (259). Cyclic AMP 
response element binding protein (CREB), E2F, NFκB, Forkhead transcription factors 
(FOXO)  and  the  AR  are  all  either  direct  or  indirect  substrates  of  Akt  and  each  can 
promote  either  cellular  proliferation  or  survival  (98;191;260 262).  Aberrant  Akt 
activation is able to elicit the pro survival properties observed in prostate cancer cells 194 
through a number of mechanisms, hence inhibiting Akt or restoring PTEN activities are 
potential therapeutic targets in prostate cancer.  
This study is unique as it examines multiple components of the PI3K/Akt cascade, and 
also because it investigates PI3K/Akt interaction with down stream signallingcascades 
and links these with progression to castrate resistant prostate cancer. Given that NFκB 
signalling has been reported to play an important role in castrate resistant disease this 
study investigated if Akt signalling in prostate cancer involves the NFκB cascade. There 
is accumulating evidence associating NFκB in prostate cancer progression and metastasis 
(263).  The  NFκB  pathway  has  been  implicated  as  a  downstream  target  of  PI3K 
signalling(227). Akt is believed not to directly phosphorylate NFκB, but to activate it 
indirectly  through  IKKα  phosphorylation.  Although  this  study  did  not  observe  any 
correlations  between  Akt  and  NFκB  it  provided  further  evidence  that      NFκB 
signallingplays  a  role  in  progression  of  castrate  resistant  disease  and  metastases.  As 
discussed in chapter 4, increased levels of NFκBp65, pIкβα ser 
32/36  and MMP 9 were 
significantly associated with disease progression and patient survival. MMP 9 and pIкβα 
ser 
32/36  expression  were  also  significantly  associated  with  metastases.  NFκB  is  an 
important regulator of cell proliferation through its direct role in cell cycle progression 
(238)  Studies have shown prognostic significance of Cyclin D1 in prostate cancer and in 
the  development  of  castrate  resistant  disease  (264;265).  Interestingly  this  study  has 
shown a positive correlation between Cyclin D1 and NFκBp65 expression in hormone 
naïve prostate cancer and also a positive correlation between cyclin D1 and pIкβα ser 
32/36  
in  castrate  resistant  disease  suggesting  NFκB  signallingto  be  involved  in  cell  cycle 
progression  in  prostate  cancer.  A  significant  reduction  in  cellular  proliferation  and 195 
stimulation  of  apoptosis  was  observed  in  both  hormone  naïve  and  castrate  resistant 
LNCaP  cells  using  two  novel  NFκB  inhibitors.  Interestingly,  reports  in  the  literature 
suggest that NFκB can directly interact with the AR. Like Akt and AR the relationship 
between NFκB and AR remains controversial. However it is reported that there are NFκB 
binding sites on the AR promoter (2309). Elevated expression of NFκBp65 has been 
shown to repress AR mediated transactivation in a dose dependent manner (266). Yet, it 
has been reported by Lee et al that IL 4 induced NFκB is required for AR transactivation 
(267).  The  transcriptional  activation  of  genes  associated  with  cell  proliferation, 
angiogenesis, metastasis and suppression of apoptosis appears to lie at the heart of the 
ability of NFκB to promote prostate cancer and castrate resistant disease progression. 
Supporting these findings this study, performed in vivo and in vitro investigations, which 
implicate NFκB inhibition as an important approach for the treatment of castrate resistant 
prostate cancer. A study using the anticarcinogen 3,3′ Diindolylmethane (DIM) which 
induces
 cell cycle arrest and apoptosis, through unknown mechanisms has reported that 
B DIM (a formulated derivative with greater bioavailibility) significantly inhibited Akt 
activation, NFκB DNA binding activity, AR phosphorylation and the expression of both 
AR and PSA suggesting cross talk between Akt, AR and NFκB. Induction of apoptosis 
was  also  observed  in  both  hormone  naïve  and  castrate  resistant  prostate  cancer  cells 
(268).  Interestingly, five cancer treatment trials of DIM have been registered in the USA. 
Four of these trials have been completed or are not currently recruiting and formal results 
are awaited. The fifth trial in prostate cancer is ongoing and recruiting subjects. This trial 
is stated “To measure the level of diindolylmethane in prostate tissue after treatment with 196 
diindolylmethane (DIM) in patients with stage I or II adenocarcinoma of the prostate 
undergoing radical prostatectomy” (269).  
Evidence  strongly  suggests  that  interactions  of  PI3K/Akt  and  AR  signallingpathways 
provide prostatic epithelium with the necessary signallingevents to escape the apoptotic 
response associated with androgen withdrawal. Lin et al have previously shown that in 
low passage number LNCaP cells the PI3K/Akt signallingcascade suppresses AR activity 
and induces AR ubiquitylation and degradation by the 26S proteasome when PTEN is 
active (270).  Additionally they observed that PTEN also suppresses AR activity in low 
passage  LNCaP  cells  independently  of  PI3K/Akt  signalling.  PTEN  was  observed  to 
directly  interact with AR and induce caspase 3 activation.  It is hypothesized that the 
interaction between PTEN and AR may lead to AR to expose the active site for caspase 3 
recognition, resulting in AR degradation (271). However, in high passage number LNCaP 
cells  PI3K/Akt  signallingwas  reported  to  enhance  AR  activity  via  an  unknown 
mechanism and PTEN was shown to suppress AR activity via PI3K/Akt signalling. The 
relationship between PI3K/Akt cascade and AR has been well documented as discussed 
in chapter 5. In the current study increased levels of AR and phosphorylated AR at the 
Akt consensus site serine 213 was significantly higher in castrate resistant disease, with 
42% of patients showing an increase in AR ser 
213 expression. This also leads to a shorter 
time to relapse and a shorter disease specific survival time in castrate resistant prostate 
cancer tumours.  In addition, AR ser 
213 expression was further increased in patients who 
acquired AR amplification in the transition to castrate resistant disease.  Also patients 
who presented with metastases at relapse had significantly higher AR and AR ser 
213 
expression. This data is in keeping with PI3K signallinginducing continued AR gain of 197 
function despite reduced androgen levels (272). In vitro studies were also carried out to 
investigate the effect of PI3K inhibition and knockdown on AR phosphorylation. There 
were  several  key  findings  from  these  studies.  The  first  confirmed  that  AR 
phosphorylation by Akt could be reduced in LNCaP CR cells  by treating cells with the 
PI3K inhibitor LY294002
 and that inhibition of PI3K activity was sufficient to reduce 
phosphorylation of AR in LNCaP CR cells stimulated with IGF I. PI3Kp85 knockdown 
resulted in reduced levels of p85, pAkt ser 
473 and pAR ser 
213 expression while levels of 
AR and pAR ser 
81 remained unchanged in LNCaP CR cells,
 supporting the evaluation of 
PI3K  inhibitors  in  prostate  cancer  treatment.  Reports  suggest  an  important  role  for 
PI3Kp110β in prostate cancer. Both PI3Kp85α and PI3Kp110β appear to be essential for 
androgen induced AR transactivation because they are required for cell proliferation and 
tumour growth (2569). It has been demonstrated that PI3K inhibitors are unable to block 
AR nuclear translocation but can suppress AR mediated gene expression indicating that a 
PI3K dependent mechanism is involved in AR–DNA binding, or the assembly of AR 
mediated  transcription  complex  (273).  Zhu  et  al  reported  that  that  PI3K  inhibitor 
abolished  androgen induced  AR–DNA  binding  and  knocking  down  p110β  expression 
also resulted in loss of AR–DNA binding (251). Conditional knock out mice studies have 
evaluated the impact of deletion of p110β in the presence of PTEN loss in Prostatic 
epithelium.  Here  it  was  reported  that  the  epithelium  had  normal  appearance  in  the 
absence of p110β only. However, in the absence of PTEN alone high grade PIN was 
detected in the anterior lobe by 12 weeks therefore it seems ablation of p110β prevented 
tumourigenesis  caused  by  PTEN  loss  (2571).  PTEN  loss  led  to  increased  Akt 
phosphorylation in the prostate and ablation of p110β diminished Akt phosphorylation. 198 
These changes were shown to be p110β specific as p110α knockout did not abrogate 
tumour formation of Akt phosphorylation (274).  
The PI3K/Akt and NFκB signallingcascades has been considered promising targets for 
anticancer therapies. The research presented here further highlights the importance of 
these  proteins  as  possible  therapeutic  targets.  Potent  and  isoform  selective  PI3K 
inhibitors  are  now  entering  clinical  trials  (157).  PI  103  inhibits  the  PI3K  cascade  at 
multiple sites including all class 1A isoforms as well as mTOR C1 and mTOR C2. This 
dual PI3K/mTOR inhibitor has been shown to have significant anti tumour activity in 
xenografts tumour models (275). Phase 1 studies of the oral PI3K pathway inhibitors 
XL147  (Exelixis),  BEZ235  (Novartis)  and  GDC 0941  (Genetech)  are  currently  in 
progress (276;277). Formal published results of the clinical trial are awaited. Furthermore 
there  are  several  classes  of  Akt  inhibitors  currently  in  development.  These  include 
isoform  selective  Akt  catalytic domain  inhibitors  and  inhibitors  of  the  PH  domain. 
Alkylphospholipid,  perifosine  an  inhibitor  of  the  PH  domain  has  undergone  phase  II 
clinical trials in patients with castrate resistant disease however it has shown no evidence 
of significant activity (181). Targeting both Akt 1 and Akt 2 has been reported to be 
superior  to  the  inhibition  of  a  single  isozyme  for  induction  of  caspase   3  activity  in 
tumour cells. This suggests that pan Akt inhibitors such as the ATP competitive inhibitor 
GSK690639 (GlaxoSmithKline) are likely to be more effective although toxicity may be 
a potential issue (278). A number of other small molecule Akt inhibitors are in early 
clinical trials including  MK2206 (Merck,  Inc)  (279) and  formal published results are 
awaited. Additionally mTOR inhibitors have also been developed. mTOR is the target of 
the antibiotic Rapamycin, an immunosuppressive macrolide which  inhibits metastatic 199 
prostate tumor growth and angiogenesis in in vivo mouse models (280). At present there 
are several  rampamycin analogues in development including: Temsirolimus (CCI 779), 
Everolimus  (  RAD001)  and  Deforolimus  (AP23573)  however  prelimary  results  for 
studies  using  these  analogues  as  single  agents  in  the  treatment  of    castrate  resistant 
disease  have  been  disappointing  (281).    A  phase  II trial  using  CC1 779  has  recently 
finished however no results are available at present (282). 
It  is  evident  that  multiple  signal  transduction  cascades  are  critical  to  prostate  cancer 
progression and resistance to therapy. The data accumulated in this study provides the 
clinical evidence to support the hypothesis that the PI3K/Akt and NFқB cascades are 
functional  in  castrate  resistant  disease.  Both  play  a  role  in  promoting  disease 
development  and  progression  as  their  expression  significantly  impacts  on  time  to 
biochemical relapse and overall survival in a sub cohort of patients where in vitro studies 
showed that targeting both cascades can result in reduction of cellular proliferation and 
induction of apoptosis. Increasing our understanding of the biology of this disease has 
lead to the hope that novel inhibitors of these cascades will result in therapeutic benefit. 
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